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Chapter 1
Diabetes
According to World Health Organization, about 220 million people around the
world suffer from Diabetes. Surveys conducted by American Diabetes Association,
showed about 8.3% of Americans, including children and adults, suffer from diabetes
[data from 2011 National Diabetes Fact Sheet]. In US, diabetes ranks 7th as a leading
cause of death either as a contributing factor or the underlying cause for morbidity.
Diabetes mellitus is a metabolic disorder characterized by abnormally high blood sugar
levels. The high sugar in blood leads to classical symptoms of polyuria (frequent
urination), polydipsia (increased thirst) and polyphagia (increased hunger). There are
three types of diabetes:
•

Type 1 diabetes [T1DM]: Earlier known as juvenile diabetes or insulindependent diabetes, is a chronic condition where the body’s immune system
attacks insulin-producing beta cells. Various factors contribute to T1DM from
genetics to viruses. It is typically seen developing at adolescence.

•

Type 2 diabetes [T2DM]: A heterogeneous disorder characterized by impaired
secretion of insulin and insulin resistance. The disease progresses from a
stage of prediabetes to overt T2DM. Essentially there is progressive
dysfunction of islet during the course of the disease where insulin secretion is
gradually blunted. Along with impairment in insulin secretion, there is
evidence for reduction in beta cell mass.
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•

Gestational diabetes: Develops in pregnant women which might precede the
development of T2DM.

Pathogenesis of T2DM
T2DM is marked by a substantial beta-cell failure which starts at an early stage in
disease progression and after which deterioration accelerates precipitously. A study
conducted in the UK demonstrates a 50% loss in beta-cell secretory capacity by the
time fasting hyperglycemia was diagnosed [1]. In support of this, genome-wide studies
linked chromosomal loci for T2DM to genes associated with pancreatic beta-cell
development and survival and in the control of insulin secretion [2]. Under normal
conditions, the beta-cell balances changes in insulin sensitivity with proportionate
changes in beta-cell function, demonstrating a hyperbolic relationship between
sensitivity to and secretion of insulin. However, in persons with beta-cells predisposed
to T2DM, an imperfect compensatory mechanism, dysregulated glycemic levels and
abnormal beta-cell function are the triggers. Persons who progressed to T2DM as a
result of abnormal beta-cell function were termed as “progressors” and exhibited betacell dysfunction even before reaching impaired glucose tolerance [IGT]. With
progressing dysfunction, insulin secretion is reduced by ~80% accompanied by a 14%
decrease in sensitivity to insulin [3]. Whereas in nonprogressors, an 11% decrease in
insulin sensitivity was compensated by 30% increase in insulin secretion. This was
indicative of a transitory mechanism from normoglycemia to IGT to diabetes that
resulted from ineffective beta-cell compensatory effort for constant insulin resistance in
progressors [4].
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Figure 1-1. Proposed scheme for progression of T2DM [5].
Both genetic and acquired factors contribute to progressive beta-cell failure.
While genes encoding proteins responsible for glucose metabolism and insulin signaling
maybe compromised, acquired factors like glucotoxicity, lipotoxicity, inflammatory
cytokines and islet amyloid polypeptide [IAPP] deposition also contribute to beta-cell
failure [6, 7]. Numerous studies have demonstrated the functional, qualitative and
anatomic manifestations of beta-cell failure associated with T2DM. A qualitative defect
in release of insulin is marked by disrupted pulsatile secretion and processing of the
precursor proinsulin to fully active insulin [8, 9]. This is consistent with the loss of firstphase insulin secretion in both insulin dependent and non-insulin dependent diabetes.
The above facts indicate the importance of studying the mechanisms that regulate and
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control beta-cell physiology. Understanding beta-cell function may pave the way for a
better understanding of the pathophysiology of beta-cell dysfunction and aid in
discovering new therapeutic agents to protect beta-cells from defects.
Islet of Langerhans

Figure 1-2. Photo of an islet of Langerhans under microscope (Courtesy: web diabetes
Leeds Yorkshire)
Islet of Langerhans named after famous pathologist, Paul Langerhans, is a
critical organ that is divided into million other units embedded in the pancreas. Islets are
an ellipsoid cluster of cells with a diameter of ~50-250 µm. Islets come of different size
with medium sized islets contributing to total islet volume. But islets found in diabetes
can get very large ~350 µm due to oedema and amyloid accumulation [10]. The number
of islets in pancreas depends on the age, BMI, and size of pancreas.
The term “islet” was derived from their appearance as an island of cells in close
proximity to capillaries. Each islet is made of 100-1000 cells and is a mix of α-, β- and δcells scattered throughout. Pancreatic islets are highly-vascularized micro-organs
composed of diverse cell types. About ~64% in the human islet is made of insulinsecreting β-cells and remaining are 26% glucagon-secreting α-cells, 8% δ-cells which
secrete somatostatin [11]. Human islets represent a unique cytoarchitecture [12] as
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compared to rodent islets. In humans, the various cells are dispersed with no particular
arrangement as opposed to rodent islets which contain a core of insulin-secreting betacells. Such arrangement of cells in the islet suggests paracrine effect among the various
types of endocrine cells.

Figure 1-3. Above is a representation of islets showing interspecies differences. Panels
A-D represents confocal micrographs of immunostained islets from human [A], monkey
[B], mouse [C] and pig [D]. Insulin was immunostained red, Glucagon stained green and
somatostatin stained blue [12].
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Pancreatic beta-cells are the sole source of insulin, the major regulator of blood
glucose levels. Under physiological and pathological conditions, beta-cells coordinate
between increased insulin secretory granule [SG] biogenesis and insulin resistance
[13]. In conditions of high metabolic demands, beta-cells upregulate their insulin
synthesis and secretion. Glucose promotes the release of insulin from beta-cells while
increasing insulin production in order to replenish its stores. This is made effective by a
concomitant increase in biosynthesis of luminal and membrane proteins that facilitate
assembly and function of SGs. Secretory granules in beta cells are 300-350 nm in
diameter and are found polarized in the cell facing blood capillaries. Structural
separation does not stop the islet cells from communicating with each other. Each beta
cell communicates with the other through paracrine actions. Electrophysiological studies
also reveal beta cells to electrically synchronize with each other via gap junctions.
Insulin secretion
Over the years, pancreatic beta-cells have represented a well-characterized
endocrine system for regulated secretion of insulin hormone from large dense core
granules. Insulin secretion involves an intricate process, coupling various stimuli hormones, neurotransmitters and nutrients. Signal transduction systems co-ordinate the
multiple stimuli and aid in regulating secretion of insulin. Type 2 diabetes, the most
prevalent form, is characterized by insulin resistance and beta-cell dysfunction. Gradual
intolerance to glucose develops into diabetes where compensatory secretion of insulin
is lost. Thus a fundamental understanding of molecular mechanisms governing
stimulus-coupled secretion of insulin is necessary.
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Overview of insulin secretion
It is widely published that glucose is a primary stimulus for secretion of insulin
from pancreatic beta cells. Metabolism of glucose provides the necessary signal to
activate signal transduction system within the beta cell. This pathway is nutrientstimulated secretion which is distinct from other pathways acting via heterotrimeric Gproteins. Increase in extracellular concentration of glucose in blood creates an inflow of
glucose into pancreatic beta-cell. Beta-cells are equipped with glucose-metabolizing
enzymes. One such enzyme is glucokinase, which phosphorylates and increases the
Km for glucose. This increases the metabolic rate of glucose for a physiological range of
glucose concentrations.
Currently the well-understood mechanism for glucose-stimulated insulin secretion
[GSIS] is outlined below [14]:
•

Beta-cell acts as a glucose sensor, engulfing excess glucose from the blood.

•

Glucose metabolism increases ATP/ADP ratio, which in turn closes ATPsensitive K+ channels.

•

Closure of K+ channels depolarizes the membrane and results in opening of
voltage-sensitive Ca2+ channels.

•

Intracellular concentration of Ca2+ increases which sensitizes insulin-laden
vesicles for fusion and release.
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Figure 1-4. Insulin secretion in beta cells is triggered by rising blood glucose levels.
Starting with the uptake of glucose by the GLUT2 transporter, the glycolytic
phosphorylation of glucose causes a rise in the ATP:ADP ratio. This rise inactivates the
potassium channel that depolarizes the membrane, causing the calcium channel to
open up allowing calcium ions to flow inward. The ensuing rise in levels of calcium leads
to the exocytotic release of insulin from their storage granules [Taken from Beta Cell
Biology Consortium].
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However, in recent years it has become apparent that factors other than ATP and
Ca2+ [15] play a regulatory role in secretion of insulin. Not only nutrients, but also
neurotransmitters and hormones regulate the secretory process. Non-nutrient
stimulants, like acetylcholine, potentiate insulin secretion via release of Ca2+ from
intracellular stores by activating phospholipase C [PLC] [16, 17] and generating second
messengers like DAG and IP3, whereas neuromodulators like GLP-1 [18, 19] promote
insulin release via interaction with specific cell-surface receptors.

Hormones like

somatostatin inhibit insulin secretion by lowering second messengers such as cAMP
and indirectly modulating Ca2+ channels [20, 21]. Thus a balanced interplay between
various regulatory factors helps to maintain glucose homeostasis.
Sequential events of exocytosis
Insulin is a peptide hormone packaged into large dense core vesicle [secretory
granules] and released via exocytosis from pancreatic beta-cell. Exocytotic processes
are mediated by protein components of secretory machinery which are activated in
response to a stimulus. Exocytosis is marked by fusion of secretory vesicles with
plasma membrane and emptying out its contents, i.e. insulin, out into the extracellular
space to reach target organs [22, 23]. Apart from transporting insulin, secretory
granules act as a ‘warehouse’ for insulin, releasing it as and when required. Only a
small proportion of insulin is released on stimulation, the remaining being recycled back
into the cell. Thus to comprehend insulin secretion beyond metabolism of glucose, the
molecular pathway must be dissected involving exocytotic machinery and its modulatory
factors.
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Formation of Insulin Granules
Secretory vesicles are of two types: synaptic vesicles and large dense core vesicles
[LDCV]. Neurotransmitters are packed into synaptic vesicles which are subjected to
rapid exo-endocytosis, refilling and a subsequent round of fusion. On the other hand,
peptide hormones like insulin are packed into large dense core vesicles [LDCV]. LDCVs
are not exactly synthesized de novo but gradually “bud off” from the golgi bodies as they
are appropriately filled with biosynthetic cargo, proinsulin [24, 25]. Characteristic of
LDCVs, proinsulin undergoes a series of maturation steps where the C-peptide is
cleaved and insulin is released from proinsulin. Pancreatic beta-cell is abundant with
insulin-laden vesicles but even at maximally-stimulating conditions, only a small
proportion of insulin is released. This clearly reflects importance of regulation of
secretion than on the biosynthetic rate.
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Figure 1-5. Insulin granule: Electron micrograph [Left] of beta-cell. Contains thousands
of small membrane-bound vesicles loaded with insulin [Right]. These granules contain
many proteins, small molecules and ions in the lumen as well as transmembrane
proteins, channels and membrane-associated proteins. Insulin [INS], amylin [IAPP],
insulin-like growth factor [IGF] [25].
Towards Plasma Membrane
Chromaffin cells stand as a comparable system to study exocytosis of LDCVs.
Secretion of insulin granules from beta-cells mimic analogously exocytotic process in
chromaffin cells [26, 27]. In resting conditions, cortical actin forms a network and acts
as a barrier for the movement of insulin granules to the plasma membrane. It has been
shown with the help of clostridium toxin and other pharmacologic agents that disruption
of actin barrier is important for the movement of granules to access the plasma
membrane [28]. Liberation of Ca2+ from intracellular stores aids in cytoskeletal
remodeling. On the other hand, there has been evidence for involvement of molecular
motors, myosin-actin system, for which ATP serves as energy sponsor activating
myosin and kinases like myosin-light chain kinases [29]. With recent advances in
microscopy, ultrastructural visualization has revealed vesicles docking in proximity to
plasma membrane in insulin secreting beta-cells.

At the Plasma Membrane
In neuroendocrine cells, where Ca2+ regulated secretion has been extensively
studied insertion of vesicles into plasma membrane can be divided into two distinct
biochemical events: priming and fusion. Both events seem to require distinct factors.
“Priming” event requires the absolute necessity for ATP, sub-micro concentrations of
Ca2+ and alterations in lipids by phosphatidyl transfer protein I [PTP I] and
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phosphatidylinositol-4-phosphate-5-kinase

[PI4P5K]

[30,

31].

“Fusion”

step

is

characterized by the requirement of Ca2+. Since then the importance of PI4P5K in
secretion of insulin has been emphasized.
Biphasic Insulin Secretion
Priming and fusion are functional events which underlie a biphasic secretion as
observed in many cell types. Like many other cells, beta-cells also display an initial
rapid phase of secretion [priming] followed by more a sustainable phase [fusion]. In type
II diabetes, a complete loss of first phase accompanied by reduction in second phase is
observed [31]. Several studies over the past years have demonstrated the availability of
a readily releasable pool [RRP] of insulin granules that are immediately available for
release upon stimulation of beta-cells. The RRP is believed to be a subset of already
docked granules. ATP- and time-dependent priming of newly supplied granules
constitutes the second phase of secretion. The rate limiting step controlling the rate of
release in the second phase is the continued recruitment and priming of new granules
for release.
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Figure 1-6. Schematic representing Reserve, Docked and Readily releasable granule
pools in mouse pancreatic beta-cell [35].

As per Lang, the terms docking, priming and readily releasable pool are
functional terms designed to indicate their working description [36]. Docked vesicles
indicate a morphological description, primed vesicles are biochemically defined for their
ability to respond to Ca2+ and ATP and readily releasable pool was defined as an
electrophysiological description. Though each term was defined for operational purpose,
relation between them is yet to be established.
Modern theory: Kiss and run
For years, the mechanism by which insulin-laden dense core SGs approach and fuse
with plasma membrane have gained interest. The defects in these processes maybe
one of the contributing factors to T2DM. The release of insulin through exocytosis
follows similar steps as that of other peptide hormones and neurotransmitters, each
involving Ca2+-regulated fusion of secretory vesicles at plasma membrane. But there
are several aspects which are unique to GSIS. What happens to the dense-core vesicle
at the plasma membrane? Seminal work by Rothman and many others have identified a
“minimal machinery” for exocytosis [37]. It comprises of soluble NH2-ethylmaleimidesensitive fusion protein attachment protein receptors [SNAREs].
SNARE
Initial studies, identified SNARE proteins in neurons and was assumed they were
neuron-specific. But studies done in pancreatic beta-cells found SNARE proteins to be
generally associated with exocytotic processes. Later studies characterized many of the
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SNARE proteins like v-SNAREs [synaptobrevin/VAMP-2] on the vesicles and t-SNAREs
[syntaxin, SNAP25] on the plasma membrane in beta-cells [38]. They play an essential
role in Ca2+ regulated secretion. In addition to these proteins, there are Munc18 and
NSF that aid in Ca2+ regulated exocytosis. Interaction of these proteins to form a
“SNARE TUBE” serves to provide membrane selectivity and thermodynamic driving
force for membrane fusion. Earlier studies by Yang and Gillis [39] in INS-1 cells
demonstrated the existence of two pools of vesicles. One pool was sensitive to high
Ca2+ and may respond only to large increases in Ca2+ and which are situated adjacent
to Ca2+ channels at plasma membrane while the other pool of vesicles are remotely
located and are able to fuse with the membrane at lower Ca2+ levels.
Vesicle docking
The process whereby remotely located vesicles finally interact with the plasma
membrane with varying dependency on MgATP and phospholipids including
phosphatidylinositol 4, 5 bisphosphate [PIP2] is termed as “docking”. The recent
emergence of the involvement of “exocyst” complex in docking of secretory granules in
neurons seems to hold true in beta-cells also [40]. The approach of vesicles to the
plasma membrane requires formation of Sec6-Sec8 (exocyst) complex which is denoted
as DOCKING in the figure [41]. Fusion of docked vesicles requires the elevation of Ca2+
sensors such as synaptotagmins. This fusion leads to a partial release of vesicle’s
content [insulin] which is released as dimers with Zn2+ through a ~4 nm fusion pore. In
the meanwhile, low molecular weight molecules such as ATP and lipid components of
vesicle membrane rapidly associate with lipids of plasma membrane. This event where
the membrane is captured is termed as “cavicapture” [42]. A large GTPase dynamin-1
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terminates this cavicapture by pinching the vesicle membrane away from the plasma
membrane. This marks the endocytic phase of vesicle trafficking. Electron microscopy
in the past implied that the cargo from vesicles was emptied via an expanding pore that
eventually flattened itself into the membrane [43]. Such mechanism is a result of strong
stimulation as seen during repetitive membrane depolarizations measured using patch
clamp technique [44]. While one set of studies suggest granule membrane to undergo
complete fusion with the plasma membrane, [45-48] alternative studies suggest for a
transient fusion pore opening through which cargo diffuse out followed by recycling of
vesicles. This process is termed as “kiss-and-run” where the granule membrane content
mix or stay separate from the plasma membrane [49-51].

Figure 1-7. An exocytotic-endocytotic process in beta-cells [40].
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Apart from SNAREs, other important regulators of granule trafficking include
guanine nucleotides, small G-proteins of Rab, Arf and Rho family and dynamin
GTPases.
Guanine Nucleotides
In many systems like chromaffin cell, mast cells and pancreatic beta-cells,
exocytosis can be triggered independent of Ca2+. The induction of exocytosis was
carried out by intracellular application of GTPγS, a non-hydrolyzable analog of GTP.
Gomperts review gave rise to the term GE, G-protein for exocytosis, which affected
exocytosis without any involvement of second messengers [52]. Wollheim’s group
investigated the effects of guanine nucleotides on insulin-secreting RINm5F cells and
islets and demonstrated a GTP-induced, Ca2+ independent secretion of insulin. GTPγS
stimulated a slow but persistent release of insulin and its effect was not additive with
Ca2+, it did not require activation of PLC or PKC or the involvement of SNARE proteins.
Since both Ca2+- and GTPγS-induced exocytosis requires ATP and metabolism of
glucose regulates cellular levels of both ATP and GTP, a link was established between
glucose metabolism and insulin secretion [54, 55]. Kinetic studies were performed to
understand the sequential events behind Ca2+ and GTPγS induction of secretion and
understood that these two stimuli act at different phases of fusion of a same pool of
vesicles. This made clear that Ca2+ and GTPγS followed a common but distinct step in
the fusion process [56].
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GTP-binding proteins
The vectorial movement of proteins coupling exocytosis and endocytosis in eukaryotes
is mediated by a multitude of protein families. The first ever evidence that G-proteins
play an important role in hormone action was proven in early ‘70s in a work done by
Rodbell to show that cAMP generation by glucagon stimulation required GTP [57]. Two
toxins, pertussis and cholera, have been instrumental in identifying nine G-proteins and
their action. It soon became apparent that G-proteins not only worked as stimulators
but also inhibited secretion of hormones according to subunit activated [58, 59]. Metz
SA, in their JBC article, 1992, emphasized the necessity for GTP in exocytosis of insulin
from intact rat islets using selective inhibitors of GTP synthesis [60]. Ever since
functional roles for G-proteins in insulin secretion have been scrutinized. GTP
essentially activated either heterotrimeric G-proteins or small molecular-weight Gproteins by binding to them [58, 61].
Heterotrimeric G-proteins
Heterotrimeric G-proteins have been shown to effectively link signal recognition
elements, receptors, to the signal generators, effectors. Emerging evidence indicates a
role for heterotrimeric G-proteins in insulin secretion. Heterotrimeric GTPases are
composed of three subunits: α-subunit and βγ-dimer. α-subunit is activated by replacing
GDP with GTP which allows for dissociation of βγ-dimer. Both αGTP and βγ-dimer affect
a variety of effectors from ion channels to kinases. Activity of heterotrimeric GTPases is
regulated by GTPase activity intrinsic to α-subunit and also by Regulator of G-protein
Signaling proteins [RGS] as described by Gilman [62, 63]. The heterogeneity offered by
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the possible combinations of multiple isoforms of α, β and γ makes it difficult to
understand their functional parts. In beta-cells, activators of Gαi and Gαo inhibit release
of insulin via the inhibition of adenylate cyclase

Reduced cAMP levels and PKA

activation [64]. Whereas activators of isoform Gαq influence insulin secretion via PLC
activation leading to generation of IP3 and DAG. These second messengers further
release Ca2+ from intracellular stores and activate PKC respectively. Another set of
activators stimulate adenylate cyclase and activate PKA through generated cAMP [65,
66]. Of the three subunits, α-subunit was dissected with respect to insulin secretion but
later studies justified the presence of βγ-subunits in both Ca2+ and GTPS stimulated
insulin release [67].

Figure 1-8. Effect of regulator of G protein signaling (RGS) proteins on the classical G
protein cycle at the plasma membrane. A G protein–coupled receptor (GPCR) serves as
a guanine nucleotide exchange factor (GEF) that activates the G protein by enhancing
GDP dissociation from the Gα subunit. Gα and Gβγ dissociate and stimulate their
respective effectors. RGS proteins serve as GTPase activating proteins that accelerate
GTP hydrolysis and thereby return the Gα subunit to its inactivated GDP-bound form,
followed by reassembly of the heterotrimer [68].
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Role of small monomeric G-proteins
In the classic 2-compartment model of insulin secretion, the link between small
GTP-binding proteins and the KATP channel-dependent and –independent pathways
always remains unclear. And for the reason that guanine nucleotides have an effect on
secretion of insulin the role for small G-proteins was determined. Small G-proteins have
proven to play role in pairing t-SNARE with v-SNARE in Ca2+-induced exocytosis. And
also these proteins initiate and maintain transition of beta granules from reserve pool to
readily releasable pool thus maintaining the biphasic insulin response.
Small GTP-binding proteins are fondly called as “molecular switches” for their
tendency to alternate between active and inactive conformational states. GTPases of
varying diversity control and modulate different cellular activities from growth to cell
death. They participate in membrane traffic controlling formation, targeting and fusion of
secretory vesicles. Small G-proteins are otherwise termed as Ras-like proteins with Ras
being a prototype. They are essentially grouped into six major families: Ras, Rho, Rab,
Arf, Sar1 and Ran family of proteins. The last four members regulate intracellular
vesicle trafficking, the Ras family regulate cellular growth and the Rho family regulate
cytoskeletal remodeling [69].
They all share a common sequence motif for guanine nucleotide binding which is
a hallmark for all GTPases. Outside the GTP-binding motif, members of different family
are related by varying degrees of functional sequences which specify a particular
upstream/downstream effector. As expected with structural diversity, GTPases exhibit
diverse range of functions. Members of the Arf and Sar1 family coordinate the
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Figure 1-9. Schematic to represent both common and unique structural features of GTPases.
Blackbars-guanine nucleotide binding and GTP hydrolysis; a-aliphatic residue; F-farnesyl
chain; GG-geranylgeranyl chains; M-myristoyl chain; PH-pleckstrin homology

biochemical machinery for vesicle budding, and the Rab, boasting of the largest family,
controls protein-protein interactions during vesicle fusion.
Small G-proteins contain an amino and carboxy terminal, which directs the
protein to a specific location and an effector domain, for binding to effector proteins [70].
Another characteristic feature of small G-proteins is the presence of accessory factors.
Major accessory factors include guanine nucleotide exchange factors and GTPase
activating proteins. Another accessory protein is the GDP dissociating inhibitor [GDI]
which sequesters inactive protein. Some of the GEFs and GAPs are protein-specific
whereas others are same for a class of proteins.
Mammalian Rho GTPases comprise of nearly 20 members among which only
three are well characterized for cytoskeletal remodeling: Rho, Rac1 and Cdc42. Rho
GTPases are governed by GEFs which catalyze exchange of GDP for GTP, by GAPs
which activate the GTPase function and by GDIs which control the access of GTPases
to GEFs and GAPs and also their access to membranes where active effectors reside
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[71]. In early 90s, two Rho G-proteins Cdc42 and Rac1 were discovered to play key
roles in GSIS and colocalized to insulin granule [72-75]. The activation kinetics of
Cdc42 and Rac1 made clear that former was activated by glucose at an early time-point
[76, 77]. Rho GTPases have also been shown to bind and be responsible for
translocation of PI4P5Kinase and it has been shown that this kinase is important for
preparing vesicles for fusion at the plasma membrane [78, 79].

From Kowluru A, Endocr Rev. 2010 Feb; 31(1): 52-78

Figure 1-10. Modulatory roles of various classes of small G proteins and their
accessory proteins in insulin secretion. Small G proteins, such as Rac1, Cdc42, and
ARF-6 (and potentially Rho) regulate cytoskeletal reorgainzation and vesicular fusion in
the pancreatic islet. Rab3A, Rab27A, and Rap1 play an essential role in docking and
priming of secretory vesicles at the exocytotic sites. Glucose-mediated activation of
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these signaling proteins is under the fine control of various regulatory proteins including
GDIs (e.g., Rho GDI and Cav-1) and GEFs (Tiam1, ARNO, and Epac2).
Rab GTPases have been reported to regulate different membrane trafficking
pathways thorught their interaction with various effectors. Rab proteins are wellconserved vesicle tetherers to target membranes. Sec4 is a Rab GTPase that was
implicated to play a role in secretory process [80]. Among the Rab proteins, Rab3A [81]
and Rab27A have been associated with pancreatic beta cells located on insulin
granules [82, 83].

Kasai et al delineated the role for Rab in glucose signaling by

studying intact and Rab-defective beta cells. They quantitated insulin secretion in ashen
mice [mutated for Rab27a] which are known for defects in pigment granule transport.
These animals were characterized by impeded GSIS, reduced number of docked
granules and abnormal glucose-induced replenishment of granules in RRP [84].
Granuphilin, an effector of Rab, showed diminished interaction with syntaxin-1a in
ashen islets. This suggests an impaired SNARE complex formation, the reason for
abnormal granule trafficking [84].

Figure 1-11. Schematic representation of various small G-proteins that regulate vesicle
transport as highlighted [85].
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Two other members of Ras-like GTPases, Rap1 and RalA, have been closely
studied in beta cells with Rap1 being the first to be identified. Leiser showed that
stimulus-induced carboxylmethylation of Rap1 synced well with increased insulin
secretion [86]. A GEF identified for Rap1 is Epac2 which mediates activation of Rap1 by
cAMP in beta-cells. It is well-known that cAMP is a potentiator of GSIS and studies from
islets of Epac2-/- mice proved that Epac2 is a selective agonist of cAMP-mediated fusion
events. Another similar protein is RalA which mediates interaction with exocyst complex
and thus aids in granule tethering and docking at plasma membrane [87]. Knockdown
of RalA from INS-1 beta cells caused a reduction in depolarization-induced secretion of
insulin and also a reduction in size of RRP.
Arfs [ADP-ribosylation factors] have been widely implicated in vesicular
organization. Arf was originally discovered as a cofactor for ADP-ribosylation of
heterotrimeric G protein Gs [88]. Arf family is a highly conserved family from yeast to
humans consisting of six members: Arf 1-6. Members of the family are classified into
three classes based on sequence homology: Class I, Arf1-3; Class 2, Arf 4-5; Class 3,
Arf6 [89]. They differ from other members of Ras superfamily by the absence of a
carboxyl-terminal prenylation motif. Arfs are posttranslationally modified by the addition
of myristoyl moiety on the amino-terminal glycine residue, which is essential for
membrane association and function [90-21]. Arf proteins undergo similar GTP/GDP
cycling with GTP-bound form conferring activity. GTP/GDP cycling is regulated by GEFs
and GAPs as Arfs seems to have negligible GTPase activity [93]. With the help of X-ray
crystallography, molecular structures for mammalian Arf1 and Arf6 were determined. In
Arfs, GTP binds to regions called “switch” regions which as its name implies aids in
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switching Arf from inactive to active conformation. Substrate specificity for Arf1 and Arf6
is differentiated by the GTP-bound switch region. Compartment localization also
determines the Arf that is activated. Genetic studies performed in yeast revealed a role
for Arf in vesicular transport [94]. Their participation in membrane trafficking events
depends on recruitment of coat proteins, activation of lipid-modifying enzymes. Arf
proteins localize to golgi apparatus and secretory granules, two organelles in-charge of
organizing vesicles. Arf has been best characterized as an essential part of COP-coated
vesicles which mediate intra-golgi traffic. Apparently Arf function is as necessary for
transport to ER as it is for intra-Golgi transport.

Figure 1-12. Schematic representation of typical Arf and Rab G proteins on a
membrane. For the Rabs the extended hypervariable region (yellow) connecting the G
protein to the lipid anchor allows bound effectors to move further from the bilayer than is
the case for the Arfs [95].
Most studied Arf members are Arf1 and Arf6 which regulate Golgi-associated and
granule associated functions respectively. Arf1 in the active conformation binds to Golgi
membranes. A mutant of Arf1 deficient of GTP-hydrolysis causes accumulation of ER-
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to-Golgi carrier vesicles in vivo. This indicates as much as GTP-binding is important,
hydrolysis of bound GTP is equally necessary.
Arf6, on the other hand serves to maintain both exo- and endocytosis in
secretory cells. It governs these above processes by translocating to the plasma
membrane from where it can regulate vesicle traffic, cytokinesis and actin
reorganization. Constitutively active mutants of Arf6 also cause accumulation of proteins
in internal structures. Thus Arf6 plays an important role in spatio-temporal organization
of proteins which is essential for activity.
Some of the effects are due to regulation of PLD and PIP5K. Activation of PLD
generates phosphatidic acid [PA] which in turn activates PIP5K. This results in
production of PI-4,5-P2 which contribute to membrane trafficking events. There have
been controversial reports implicating Arf6 in clathrin-dependent and –independent
pathways [96, 97].
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Figure 1-13. Image from D’souza-Schorey depicting a model for involvement of Arfdependent and –independent pathways [97].
In addition to membrane traffic, Arf6 also plays an important role in actin
remodeling required for ruffle formation, cell migration, cell spreading and phagocytosis.
Arf6 regulates actin remodeling through the activation of Rac1 and lipid metabolism.
Modular GEFs for Arf
Small G-proteins are active in the GTP-bound form, which are catalyzed by the
GEFs. In case of Arf proteins, the displacement of GDP by GTP causes displacement of
N-terminal amphipathic helix and leads to interaction with membrane. From molecular
analysis of various members of Arf-GEFs, it was found that they all share a catalytic
domain, Sec7 domain [98]. Brefeldin A was initially used as target against Sec7 but was
later found not to be effective against all Sec7 domains, especially for cytohesin family.
Sec7 domain proteins also share high conservation from yeast to mammals. Along with
GEF, Sec7 domain requires the presence of phospholipids to aid in guanine nucleotide
exchange. How do phospholipids aid in this reaction? They serve to expose the Nterminal helix which then allows the GEF to interact with Arf protein to add on a GTP.
Sec7-domain containing proteins are represented by four subfamilies: Gea/GBF
[golgi-specific brefeldin A-rsistance factor], BIG [Brefeldin A-inhibited GEF], Cytohesin
and EFA6. Of particular interest is the cytohesin family, which seems to play a role in
activation of Arf6 for membrane trafficking events. Cytohesins gained further attention
for the ability of their PH domains to bind specifically to PI(3,4,5)P3 and recruited to
plasma membrane [99]. Cytohesins are again comprised of four members: cytohesin-1,
ARNO, ARNO 3/GRP1 and cytohesin-4. The C-terminus of these proteins contains a
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polybasic region which allows for phosphorylation by PKC. Phosphorylation of ARNO by
PKC has shown to aid in cytoskeletal remodeling [100]. What then is a substrate for
cytohesin? In an in vitro setting, cytohesins favor Arf1 as a substrate than Arf6 but in
vivo, Arf6 is favored as a substrate [101, 102]. Overexpression of ARNO in HeLa cells
induced changes in actin cytoskeletal structure as seen by the activation of Arf6 [103].
Apart from the GEF activity, cytohesins have been found to play major roles in
regulating cellular gene expression in response to extracellular signals and thus
pathogens exploit this to alter cellular program. Most commonly reported signaling, is
the involvement of cytohesin 1 and ARNO in the signaling of ERK1/2 [104-106]. In
activation of T-cell, cytohesin-1 has been found to play a role in ERK1/2 activation since
a dominant-negative cytohesin-1 abolished ERK1/2 activation. In a recent report
demonstrated in liver cells, insulin resistance resulted from an inhibition of cytohesins by
secinH3. Blockade of cytohesin in secinH3-fed mice showed increased expression of
gluconeogenic genes, reduced glycolytic and fatty acid metabolic genes and a
compensatory increase in plasma insulin [107].
Dyanmins: a new league of GTPases
Dynamins [108] belong to a novel group of GTPases comprising of three
members: dynamin 1-3 [109-111]. As a family they share sequence homology in an
amino-terminal GTPase domain responsible for guanine nucleotide binding and GTP
hydrolysis. They differ strikingly from Ras GTPases by their higher intrinsic rates of
GTP-hydrolysis. While the amino terminal is responsible for GTP-binding and
subsequent hydrolysis, the presence of a proline-rich region is essential for effector
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binding. Each of these domains carries some significance with regards to function [112].
First evidence for dynamin in recycling of vesicles was seen in Drosophila where
temperature-sensitive alleles exhibited rapid paralysis. This was related to the aberrant
recycling of synaptic vesicles from nerve terminals [113]. In recent observations, an
identical neuronal protein to dynamin, dephosphin was found to aid in stimulusdependent dephosphorylation in nerve terminals. Dynamin is now a substrate for
kinases, especially protein kinase C and casein kinase [114]. The phosphorylation cycle
of dynamin is essential to regulate its GTPase activity for rapid endocytosis in nerve
terminals.
This was verified in vivo in mammalian cells, using dynamin mutated for GTP
binding and subsequent hydrolysis. Another mutant, with a completely truncated
GTPase domain also inhibits endocytosis [115]. It also has an effector-binding domain.
Thus dynamin plays an essential role in endocytosis [116], whether it plays a role in
exocytosis is yet to be determined.
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Chapter 2
Materials and Methods
2.1 Materials
SecinH3 was from Tocris Biosciences [Ellisville, MO]. siRNA-Arf6 consisting of
pools of three to five target-specific 19-25 nt siRNAs were from Santa Cruz
Biotechnology [Santa Cruz, CA]. siRNA-ARNO was from Dharmacon [Lafayette, IL].
Antisera directed against Arf6, ARNO, ICMT, phospho- and total dynamin 1 were from
Santa Cruz Biotechnology [Santa Cruz, CA]. Cdc42 and Rac1 antisera were from BD
Biosciences [San Jose, CA]. Cdc42 and Rac1 activation kits were from Cytoskeleton
Inc., [Denver, CO].

Phospho- and total antibodies for ERK1/2 and cofilin were

purchased from cell signaling. Arf6 activation assay kit and the Classic Co-IP kit were
from PIERCE [Rockford, IL]. siRNA-ICMT [43907710] and scrambled siRNA [negative
control; 4390843] were from Ambion. AFC was from Cayman Chemical [63270]. ECL
reagent was from GE Healthcare [RPN2132]. HiPerFect transfection reagent was
obtained from Qiagen [301705]. The rat insulin ELISA kit was from American Laboratory
Products [80-INSRTH-E01]. DCHFDA [35845], thapsigargin [T9033] and etoposide
[E1383] were from Sigma Aldrich. Alexa-fluor 488 anti-rabbit secondary antibody
[A11008], PLD assay kit [A12219] and Hoechst dye [3570] was from Invitrogen
molecular probes. Cell proliferation kit [MTT, 11465007001] was purchased from Roche
diagnostics. All other reagents used in these studies were from Sigma Aldrich Co. [St.
Louis, MO] unless stated otherwise.
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2.2 Insulin-secreting INS 832/13 cells, rat islets and human islets

INS 832/13 cells were kindly provided by Dr. Chris Newgard (Duke University
Medical Center, Durham, NC). The cells were cultured in RPMI 1640 medium containing
10% heat-inactivated fetal bovine serum supplemented with 100 IU/ml penicillin and 100
IU/ml streptomycin, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol, 11 mM glucose,
and 10 mM HEPES (pH 7.4). Islets were isolated from pancreas of male SpragueDawley rats (Harlan Laboratories, Oxford, MI), using collagenase digestion and a ficoll
gradient as we described previously [117]. All experiments were reviewed and approved
by the Wayne State University Institutional Animal Care and Use Committee. Human
pancreatic islet lysates were kindly provided by Dr. Karl Olson [Michigan State
University, Lansing, MI].

Male [9-11 wks] ZDF and Zucker Lean control [ZLC] rats were procured from
Charles River laboratories [Wilmington, MA] and maintained in a 12-h light/dark cycle
with free access to water and food [Purina Diet no. 5008; Charles River Laboratories].
All animal protocols were reviewed and approved by the Wayne State University
Institutional Animal Care and Use Committee. Hyperglycemia in diabetic rats was
confirmed prior to sacrifice by tail vein puncture using Glucometer Elite from Bayer
[Leverkusen, Germany]. Body weight of ZLC and ZDF rats were 300 ± 6 g and 396 ± 12
g respectively [n=11; p <0.05]. Islets were isolated by collagenase digestion method
[117].
Human islets from normal and T2DM donors were obtained from Prodo
Laboratories, Inc. [Irvine, CA]. Control islets [from a 54 year old male donor; 85-90%
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purity] and diabetic islets [from a 45 year old male donor; ~60% purity] were
homogenized with Tris-HCl buffer [50 mM, pH 7.4] containing sucrose [250 mM], EDTA
[1 mM], DTT [1 mM], and protease inhibitor cocktail. Lysate proteins were resolved on
12% SDS-PAGE, and used for Western blot analysis.
2.3 Isolation of total particulate and soluble fractions from INS 832/13 cells and rat
islets
INS 832/13 cells were homogenized in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1%
NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1mM EDTA, 1mM PMSF, 1mM
Na3VO4, 1mM NaF and protease inhibitor cocktail) and were centrifuged at 105000 x g
for 1 h to separate total particulate and soluble fractions. Proteins from individual
fraction were resolved by SDS-PAGE and transferred to a nitrocellulose membrane.
The blots were then probed with antibody raised against Arf6 [1:1000] or ARNO
[1:1000] or ICMT [1:500 dilution] and probed with appropriate secondary antibody
conjugated to horseradish peroxidase. Immune complexes were then detected using
the enhanced chemiluminescence kit.
2.4 Hydrophilic and hydrophobic phase partitioning method using triton X-114
Total hydrophobic and hydrophilic phases of lysates derived from INS 832/13
cells and pancreatic islets were separated using triton X-114 according to method
described earlier by us [Veluthakal]. Briefly, about 400 µg of cell [INS 832/13 cell or
islet] homogenate protein, prepared in 400 µl of buffer (20 mM Tris-HCl, pH 7.5, 0.5 mM
EGTA, 2 mM MgCl2, 10 µg/ml leupeptin, and 2 µg/ml aprotinin), supplemented with 1 %
(w/v) Triton X-114 was overlaid on 400 µl sucrose cushion 6 % (w/v) prepared in 20 mM
Tris-HCl buffer (pH 7.4) containing 0.06 % (w/v) triton X-114. Following brief incubation
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at 30 °C, samples were centrifuged at 300 x g for 3 min and the aqueous phase was
mixed with 0.5 % (w/v) fresh triton X-114 at 4 °C. F ollowing dissolution, the mixture was
again overlaid on the same sucrose cushion, incubated for 3 min at 30 °C and
centrifuged at 300 x g for 3 min. The lower hydrophobic phase was diluted to a final
volume of 400 µl with homogenization buffer, while the aqueous phase was transferred
into a separate tube supplemented with 2 % fresh triton X-114, incubated for 3 min at 30
°C, and centrifuged at 300 x g without sucrose cushion. The supernatant obtained
thereof served as total hydrophilic phase. The relative abundance of ARNO in
hydrophilic and hydrophobic phases were determined by Western blotting.
2.5 Transfection of Arf6 or ARNO mutants and siRNAs
INS 832/13 cells were subcultured at 50-60% confluency and transfected using
Effectene [Qiagen, Valencia, CA], with 0.2 µg of plasmid DNA constructs against either
dominant-negative of Arf6 [T27N] or ARNO [E156K] per well of a 24-well plate.
Endogenous Arf6 or ARNO or ICMT expression was depleted by transfecting cells using
small interfering RNA [siRNA; 100 nM] using HiPerfect transfection reagent [Qiagen,
Valencia, CA]. Efficiency of mutant expression or protein knockdown was determined by
Western blotting.
2.6 Insulin release studies
Arf6 or ARNO mutant or siRNA-transfected or secinH3 inhibitor-treated cells
were cultured overnight in low serum and low glucose containing medium and then
stimulated either with high glucose, KCl or arginine in Krebs-Ringer bicarbonate buffer
[KRB, pH 7.4] for different time intervals as indicated in the text. In studies involving
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KCl-induced insulin secretion, we noticed that INS 832/13 cells were not responsive to
40 mM KCl in releasing insulin. However, higher KCl concentrations [60 mM] were
found to elicit robust insulin release. Therefore, in KCl-stimulated insulin secretion
[KSIS] studies, cells were incubated with 60 mM KCl in an osmolarity-balanced KRB
medium [79]. For arginine [L-Arg]-stimulated insulin release, a stock solution was
prepared in Tris.HCl [pH 7.4], and diluted to desired concentration with KRB. The insulin
released into the medium was quantitated by ELISA [117].
2.7 Quantitation of Arf6.GTP in pancreatic β-cells
Active Arf6 was quantitated by a pull-down assay. Briefly, the incubation medium
was aspirated and cells were washed with ice-cold PBS. Cells were lysed with 500 µl
lysis buffer and the lysate was clarified by centrifugation at 16,000 x g at 4 °C for 15 min
and incubated ~400 µg protein with 100 µl of glutathione resin and 100 µg of GSTGGA3-PBD beads at 4 °C for 1 hr with gentle rocking, following which the reaction
mixture was spun at 6,000 x g for 30 sec. The GST-tagged beads were washed [3x] and
proteins were separated by SDS-PAGE and activated Arf6 was identified by Western
blotting.
2.8 Quantitation of Cdc42 and Rac1 activation
Relative degree of activated Cdc42 and Rac1 [i.e., GTP-bound form] were
determined by p21-activated kinase-p21-binding domain pull-down assay as described
in [117]. Briefly, INS 832/13 cells treated with either diluent or secinH3 [50 µM] or cells
were either mock-transfected or transfected with ARNO-siRNA were cultured overnight
in low serum-low glucose media. Cells were stimulated with either low [2.5 mM] or high
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[20 mM] glucose for 3 or 30 min at 37 °C in the conti nued presence of either diluent or
secinH3 with respect to inhibitor studies. The GTP-bound forms of Cdc42 and Rac1 in
the pull-down samples were quantitated by Western blotting and densitometry.
2.9 Co-immunoprecipitation studies
Immunoprecipitation studies were performed using the Classic Co-IP kit as
suggested by the manufacturer [118]. Briefly, β-cell lysates [500 µg protein] were
incubated with anti-ARNO for 2 hr at 4 °C followed b y incubation with agarose resin for
an additional 1 hr at 4 °C. Beads were washed; eluted using sample buffer and proteins
were resolved by SDS page to quantify Arf6.
2.10 Immunofluorescence studies
INS 832/13 cells were plated onto coverslips and incubated with [2.5 or 20 mM]
glucose for 30 or 60 min at 37 °C as indicated in text, followed by washing in PBS and
fixed with 4% paraformaldehyde solution for 15 min at room temperature. They were
then permeabilized with 0.2% Triton X-100 for 15 min at room temperature. After
blocking with 1% BSA for 1 hr, the cells were further incubated with primary antibodies
[Arf6 [1:150], ARNO [1:150], ICMT [1:150] and p-dynamin-1 [1:150] in 0.1% BSA
solution for 1 hr. After extensive washes, the cells were further incubated with
secondary antibodies Alexa-fluor 488 anti-mouse [1:1000], Alexa-fluor anti-goat 546
[1:1000], Alexa-fluor anti-rabbit [1:1000] or Alexa-fluor anti-sheep 546 [1:1000] in 0.1%
BSA solution for 1 hr at 37 °C. Hoechst dye was used to stain for nuclei. The coverslips
were then mounted on glass slides containing mounting media [DAKO corporation,
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Carpinteria, CA] and visualized under a confocal LSM 510 microscope in the midplane
using a 63X oil-immersion lens [118].
2.11 Quantitation of PLD activity
The Amplex Red phospholipase D [PLD] assay kit provides for a sensitive
method of measuring PLD activity in vitro. An enzyme-coupled assay, PLD activity is
measured by using Amplex Red reagent. First, PLD cleaves phosphatidyl choline [PC]
to choline and PA. The choline generated is oxidized by choline oxidase to hydrogen
peroxide. Finally, hydrogen peroxide along with horseradish peroxidase present in the
reagent mix reacts with Amplex Red and generates highly fluorescent resorufin. We
used the protocol for PLD enzyme activity at near neutral pH 8. Essentially treated cells
were collected and lysate prepared in buffer [Tris 50 mM, pH 8.0]. Cells were broken by
three freeze-thawing cycles and clarified to remove debris [unbroken cells]. Supernatant
was used for protein estimation. 100 µg of lysate was made to 100 µL total volume and
to which 100 µL of the prescribed reagent mix was added and incubated for 30 min at
37 ºC. Fluorescence was measured in a microplate reader [Synergy Biotek instrument]
at Ex 530 nm and Em 590 nm.
2.12 Quantitation of ROS generation
INS 832/13 cells or rat islets were treated with secinH3 and stimulated with
glucose for 60 min. Following incubation, medium was removed, and cells were further
incubated with DCHFDA [10 µM] at 37 ºC for 30 min in PBS. DCHFDA is a non-polar
compound, diffuses rapidly into the cells and hydrolyzes cellular esterases into polar
compound, 2’, 7’-dichlorofluorescein. In the presence of ROS, 2’, 7’-dichlorofluorescein
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oxidizes readily to form fluorescent compound dichlorofluorescein. After 30 min, cells
were washed with ice-cold PBS and harvested. Protein estimation was done and equal
amounts of protein were added into 96-well black bottomed plates. Fluorescence was
measured at Em 485 nm and Ex at 535 nm using luminescence spectrophotometer
[Perkin Elmer].
2.13 Preparation of cell lysates for phosphoprotein analysis
INS 832/13 cells or isolated islets were lysed in 50 mM Tris buffer pH 8.0
containing 10 mM NaCl, 1% NP-40, 5% deoxycholic acid, 0.1% SDS, 1mM EDTA, 1mM
PMSF, 10 µg/mL leupeptin, 10 µg/mL aprotinin, 5 mM EGTA, 5 mM EDTA, 10 mM NaF
and 1 mM sodium orthovanadate. After incubation for 10 min in lysis buffer on ice,
samples were clarified to remove debris and supernatant collected. Protein estimation
was done using Pierce BCA 660 nm protein assay. Equal amounts of protein was
loaded and separated by SDS-PAGE. Resolved proteins were transferred onto
nitrocellulose membrane and probed for phosphoproteins as indicated in text.
2.14 Caspase-3 activity
Activation of caspase-3 was assessed in cells either transfected with ICMT
siRNA or in cells treated with AFC. Cells were harvested and homogenized in sample
buffer (0.5 % Nonidet P-40, 20 mM HEPES, pH 7.4, 100 mM NaCl and 20 mM DTT and
PIC). And ~30 µg of proteins were resolved by SDS-PAGE (12%) and immunoprobed
for caspase-3. Activation of caspase-3 is evidenced by the presence of a hydrolytic
product (~17 kDa). Etoposide (60 µM, 6 h) was used as a standard for apoptotic cell
death.
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2.15 Cell viability assay
INS 832/13 cells were either treated with AFC (100 µM, 1 h) or transfected with
ICMT -specific or scrambled siRNA as described above. Cell viability was determined
by incubating AFC treated or ICMT-siRNA transfected cells with 10 µL of stock MTT [4,
5-dimethylthiazol−2-yl) −2, 5-diphenyl tetrazolium bromide] for 4 h at 37˚C. Following
dissolution of formazan crystals in solubilization solution, the absorbance was measured
at 570 nm using ELISA plate reader.
2.16 ICMT expression profile
INS 832/13 cells were plated in six-well plates, grown to 70 % confluence and
treated with low glucose (2.5 mM), high glucose (50 mM), palmitic acid (300 µM),
palmitic acid plus high glucose for 48 h or thapsigargin (0.5 µM) for 9 h. Cells were then
harvested and centrifuged. The pellet was resuspended in buffer solution [0.5 %
Nonidet P-40, 20 mM HEPES, pH 7.4, 100 mM NaCl, 20 mM DTT and protease
inhibitor cocktail]. Equal amount of proteins were resolved by SDS-PAGE and
transferred to a nitrocellulose membrane. The blots were then probed with antibody
raised against ICMT [1:500 dilution] and with rabbit secondary antibody conjugated to
horseradish peroxidase. Immune complexes were then detected using the enhanced
chemiluminescence kit.
2.17 Statistical analyses
The statistical significance of the difference between the experimental conditions
was determined by Student’s t test unless mentioned otherwise. p values < 0.05 were
considered significant.
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CHAPTER 3
ARNO/Arf6 signaling cascade is involved in nutrient-induced insulin secretion
from the pancreatic beta cell.

•

Portions of this work have been published [copy of the published manuscript is
appended].

Jayaram B, Syed I, Kyathanahalli CN, Rhodes CJ, Kowluru A. Arf nucleotide binding
site opener [ARNO] promotes sequential activation of Arf6, Cdc42 and Rac1 and insulin
secretion in INS 832/13 β-cells and rat islets. Biochem Pharmacol. 2011 Apr 15;
81(8):1016-27. Epub 2011 Jan 26.
ARNO/Arf6 signaling cascade is involved in nutrient-induced insulin secretion
from the pancreatic beta cell
Homeostasis of blood glucose is a highly regulated process maintained by
various hormones, nutrients and neurotransmitters. Of significance is the contribution of
peptide hormone, insulin, which coordinates signals to effectively maintain blood
glucose. The primary pathway for secretion of insulin from within large dense core
granules involves coupling of glucose metabolism and other factors which lead to
depolarization of plasma membrane thus preparing it for fusion of granules. Influx of
Ca2+ has always been the fort for insulin secretion. Recent years of research have
identified many of the molecular players responsible for vesicular transport after influx of
Ca2+, but it never stops there. There are still many signaling molecules like
phospholipases, kinases, phophatases, actin-modifying agents and finally G-proteins.
Extensive studies in the area of small G-proteins have established a role in
regulating various cellular functions including proliferation, survival and demise. So far,
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four major classes of small G-proteins have been identified in the pancreatic β-cell.
These include the Ras, Rho, Rab and ADP-ribosylation factor [Arf] family of G-proteins
[69]. The Ras family is responsible for signal transduction in cellular differentiation and
proliferation, Rho family regulate actin cytoskeleton and Rab family aid in
priming/docking of secretory vesicles. For decades, the Arf family has been studied in
relation to cellular growth and secretion in several cell types. Yet its potential in the
pancreatic beta cell was untapped. Though originally identified as an ADP-ribosylator
for cholera toxin, Arf has gained much importance as a critical modulator of membrane
traffic in eukaryotic cells. Among the six members of the Arf family, Arf1 has been the
paradigm for intracellular vesicular trafficking by regulating budding via recruitment of
coat proteins. Initial evidence for involvement of Arf1 in secretory process came from
yeast genetic studies where a deletion of Arf gene led to a secretory defect in
Saccharomyces cerevisiae [119]. Another member, Arf6 is also a well documented
protein for its positive modulatory roles in trafficking of secretory granules to the plasma
membrane for exocytosis [120]. Regazzi and coworkers first described localization and
regulation of Arfs in insulin-secreting RINm5f cells [72, 73]. More recently, Lawrence
and Birnbaum have demonstrated regulatory roles for Arf6 in insulin secretion mediated
by glucose, GTPγS and membrane depolarization. They further demonstrated that Arf6
regulates insulin secretion by maintaining plasma membrane phosphatidylinositol 4, 5biphosphate [PIP2; Lawrence PNAS]. Existing evidence also supports a potential role for
PLD in physiological insulin secretion [121-123].
Arf6 cycles between the GDP-bound [inactive] and GTP-bound [active]
configurations; which are tightly regulated by two distinct classes of regulatory factors
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namely the GTPase activating proteins [GAP] and the GTP/GDP exchange factors
[GEF; 95; 124]. GAPs inactivate Arf6 by promoting its conversion to the inactive GDPbound form, while GEFs facilitate its activation. The GEF activity is a rate-defining step
and involves coordination of multiple intracellular signals. In this context, many GEFs
with distinct size and structure have been identified for Arf6 [102, 125, 126]. However,
in the majority of the signaling events, only one member belonging to the cytohesin
family has been closely linked to activate Arf6 [127, 128].
Arf6 and ARNO are present in pancreatic beta cells: subcellular view
Thus the first goal of this project was aimed at establishing a positive
involvement for Arf6 and its exchange factor ARNO in regulated insulin secretion. Galas
MC demonstrated a potential role for Arf6 associated with secretory granule in
chromaffin cells [120]. As an initial step, we immune-characterized Arf6/ARNO in
pancreatic beta cells: INS 832/13 cells, rat and human islets. Figure 3-1 A clearly
shows the presence of Arf6 and ARNO in the various pancreatic beta cells. It is wellreported that small G-proteins, including Rho family i.e Cdc42 and Rac1, are cytosolic in
distribution and translocate to membranous sites on activation [129]. Unlike most smgs,
Arf6 was predominantly localized to membranous fraction. Data in Figure 3-1 B
demonstrates cytosol/membrane abundance of Arf6 and ARNO in clonal pancreatic
beta cells and rat islets. As reported in other neuroendocrine cells, Arf6 was abundant in
membranous fraction and ARNO in cytosol.
As the total membrane fraction derived from the single step centrifugation
technique would comprise of membranes derived from various intracellular organelles
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[secretory granules, mitochondria, microsomes], we studied the intracellular distribution
of both Arf6 and ARNO via differential centrifugation. Subcellular fractionation in
cultured chromaffin cells revealed Arf6 to be bound to secretory granule membrane.
Figure 3-1 C indicates a similar pattern in INS 832/13 cells.
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Figure 3-1: Expression of ARNO in INS 832/13 cells, rat islets and human islets
Panel A: Lysates from rat islets, human islets and INS 832/13 cells were separated by
SDS-PAGE and probed for Arf6 [18 kDa] and ARNO [48 kDa].
Panel B: Lysates from rat islets and INS 832/13 cells were separated into cytosolic
[Cyt] and membranic [Mem] fraction by a single-step centrifugation. Proteins were
separated by SDS-PAGE and probed for Arf6 and ARNO.
Panel C: Lysates from INS 832/13 cells were differentially centrifuged into various
subcellular fractions: Cytosol [Cyt], mitochondria [Mito], secretory granules [SG] and
microsomes [Micro] and proteins were separated by SDS-PAGE. Blot was probed for
Arf6 and ARNO.
Panel D: INS 832/13 cells were serum-starved and further stimulated with low [2.5 mM]
glucose and high [20 mM] glucose for 30 min. Lysates were separated into cytosolic
and membranic fractions by single-step centrifugation and proteins were separated by
SDS-PAGE. Blot was probed for Arf6.
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Panel E: Hydrophilic [Aqueous] and hydrophobic [Lipid] phases of the homogenates
from rat islets and INS 832/13 cells were isolated using triton X-114 partition technique
[see Methods for additional details]. Proteins were separated by SDS-PAGE and probed
for Arf6 and ARNO. A representative blot from three independent experiments is shown
here.
Among the various cellular organelles, Arf6 is found to be predominantly
associated with secretory granule and ARNO in the cytosolic fraction. This adds to the
fact that Arf6 might regulate stimulated-insulin secretion through priming/docking of
granules. Even though Arf6 is abundant in membranous fraction, some amount of free
Arf6 is found in cytosol. Bands seen in cytosol/membrane fraction reveal the presence
of two bands for Arf6. This could be explained by a possible post-translational
modification of Arf6 protein which aids it to bind to granule membranes. And in evidence
to this in chromaffin cells, granule-bound Arf6 displayed two spots on a 2D gel
electrophoresis, the two spots different only in isoelectric points but of same molecular
weight [120]. Sucrose density gradient centrifugation performed in chromaffin cells to
separate plasma membrane and secretory granules clearly showed the translocation of
Arf6 from granule fraction to plasma membrane upon stimulation. INS 832/13 cells were
stimulated with insulinotropic concentrations of glucose and lysates were separated into
cytosol and membrane by single-step centrifugation. Data in Figure 3-1 D clearly
indicates an increased amount of Arf6 localized to membrane fraction upon glucose
stimulation as compared to control. In another approach, to determine whether Arf6 and
ARNO preferred the hydrophilic/hydrophobic compartment in a phase partitioning
assay, we used Triton X-114. As a characteristic property of nonionic detergents, Triton
X-114 is homogeneous at 0 ºC but separates into an aqueous and detergent phase at
greater than 20 ºC. The assay makes use of the principle that integral membrane
proteins interact directly with the lipid bilayer by a hydrophobic domain. Triton X-114
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essentially mimics the lipid bilayer thus causing integral membrane proteins to separate
into the hydrophobic phase. Phase partitioning experiment clearly indicates that both
Arf6 and ARNO are loosely-bound and not integral membrane proteins [Figure 3-1 E].
Expression of a dominant negative mutant of Arf6 and ARNO inhibits GSIS
Localization studies intrigued us to believe that Arf6 was an essential component
of catecholamine-secretion as demonstrated in chromaffin cells. Furthermore, a
synthetic myristoylated peptide of Arf6 blocked catecholamine secretion and PLD
activation. These blocking peptides demonstrated the fact that myristoylation, a posttranslational modification, was essential for regulated-secretion, but it does not exhibit
any functional evidence for involvement of GTP-bound Arf6 in secretion [120].
Therefore to verify the role for Arf6 in GSIS, we used the more conventional GTPbinding deficient mutant, Arf6-T27N. The dominant negative Arf6 [DN-Arf6] mutant lacks
the inherent ability to bind GTP which switches the protein to the active conformation.
Lawrence and Birnbaum have demonstrated earlier that DN-Arf6 blocks both
depolarization- and GTPˠS-induced secretion in MIN6 cells [79]. As a logical step to
validate our hypothesis, we tested the effect of DN-Arf6 or DN-ARNO in GSIS. Figure
3-2 A indicates expression levels of Arf6 or ARNO mutants in INS 832/13 cells either
mock-transfected

or

transfected

with

plasmid

mutants

as

indicated.

Cells

overexpressing either DN-Arf6 or DN-ARNO were assayed for insulin release in the
presence of 2.5 or 20 mM glucose. Data in Figure 3-2 B showed a marked reduction in
GSIS in cells expressing Arf6-T27N. Likewise, overexpression of ARNO-E156K, a
mutant lacking the GEF function, significantly inhibited GSIS in these cells [Figure 3-2
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C]. Together, these data suggested key roles for Arf6 and ARNO in signaling events
leading to GSIS.

A. Overexpression of dominant negative mutants of Arf6 or ARNO
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Figure 3-2: Overexpression of inactive mutants markedly inhibits glucoseinduced insulin secretion in INS 832/13 cells
Panel A: INS 832/13 cells were mock-transfected or with either dn Arf6/ARNO (see
Methods). Overexpression of Arf6/ARNO was verified by Western blotting. A
representative blot from three independent studies yielding similar results is provided
here.
Panel B: INS 832/13 cells were transfected with dominant negative Arf6 [T27N] at a
final concentration of 0.2 µg of DNA and cultured for 48 hr. Following this, cells were
stimulated with either low [2.5 mM] or high [20 mM] glucose in KRB for 30 min at 37°C.
Insulin released into the media was quantitated and expressed as ng/mL. Data are
mean ± SEM from three independent experiments. * represents p < 0.05 vs. mock low
glucose; **p < 0.05 vs. mock transfected cells treated with high glucose, and data points
with similar symbol did not differ significantly.
Panel C: INS 832/13 cells were transfected with dominant negative ARNO [E156K] at a
final concentration of 0.2 µg of DNA and cultured for 48 hr following which cells were
stimulated with either low [2.5 mM] or high [20 mM] glucose for 30 min at 37°C. Insulin
released into the medium was quantitated and expressed as ng/mL. Data are mean ±
SEM from three independent experiments. * represents p < 0.05 vs. mock transfected
low glucose and **p < 0.05 vs. mock transfected high glucose, and data points with
similar symbol do not differ significantly.
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Silencing of endogenous Arf6 or ARNO attenuates insulin release by various
insulin secretagogues in INS 832/13 cells
Next, we verified if knockdown of endogenous Arf6 and ARNO by using siRNA
affects insulin secretion elicited by high glucose. We observed 50-60% reduction in the
expression of Arf6 or ARNO by Western blotting analysis [Figure 3-3 A]. Under these
conditions, GSIS was significantly inhibited in Arf6- and ARNO-knocked-down cells
[Figure 3-3 B and C]. Together, data in Figure 3-2 and 3-3 implicated Arf6/ARNO
signaling axis in GSIS.
In order to test the possibility that inhibition of GSIS by deficient Arf6/ARNO
function is due to a block in coupling of glucose metabolism to secretion, we tested the
effect of siRNA-Arf6/-ARNO in depolarization-induced insulin secretion. Since work has
been done in MIN6 cells, demonstrating the involvement of Arf6 in depolarizationinduced secretion, we chose to study the effect of siRNA-ARNO in depolarization
induced by high K+. The next series of studies, essentially determined potential roles of
Arf6 or ARNO in insulin secretion elicited by a membrane-depolarizing concentration of
KCl or arginine. In case of arginine, depolarization is thought to result in some part
from the entry of the positively charged amino acid per se but with a clear
glucose dependency and not by closure of KATP channels [130]. To address this, INS
832/13 cells were transfected with either siRNA-Arf6 or siRNA-ARNO, and insulin
secretion in the presence of KCl [60 mM; Figure 3-3 D] or arginine [20 mM + 1 mM
glucose; Figure 3-3 E and F] was quantitated. Data depicted in Figure 3-3 [Panels DE] demonstrated that insulin secretion elicited by KCl or arginine was inhibited in cells in
which endogenous Arf6 or ARNO was knocked-down.
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A. Knockdown of endogenous expression of Arf6 or ARNO with siRNA
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Figure 3-3: siRNA-Arf6/-ARNO
secretion in INS 832/13 cells

markedly

inhibits

glucose-induced

insulin

Panel A: INS 832/13 cells were mock-transfected or transfected either with Arf6siRNA/ARNO siRNA as described in the Methods section. Expression of Arf6/ARNO
was verified by Western blotting. A representative blot from three independent studies
yielding similar results is provided here.
Panel B: INS 832/13 cells were either mock-transfected or transfected with Arf6-siRNA
at a final concentration of 100 nM. After 48 hr culture in regular medium, cells was
stimulated with low [2.5 mM] or high [20 mM] glucose for 30 min. Insulin released into
the medium was quantitated and expressed as ng/mL. Data are mean ± SEM from
three independent experiments. * represents p < 0.05 vs. mock low glucose; **p < 0.05
vs. mock transfected cells treated with high glucose, and data points with similar symbol
did not differ significantly.
Panel C: INS 832/13 cells were either mock-transfected or transfected with ARNOsiRNA at a final concentration of 100 nM. After 48 hr culture in regular medium, cells
were stimulated with low [2.5 mM] or high [20 mM] glucose for 30 min. Insulin released
into the medium was quantitated and expressed as ng/mL. Data are mean ± SEM from
five independent experiments. *represents p < 0.05 vs. mock transfected low glucose;
**p < 0.05 vs. mock transfected high glucose. Insulin release values between mock low
glucose or siRNA transfected low glucose did not differ significantly.
Panel D: INS 832/13 cells were either mock-transfected or transfected with ARNOsiRNA at a final concentration of 100 nM. After 48 hr culture in regular medium, cells
were stimulated with low [2.5 mM] or K+ [60 mM] for 60 min. Insulin released into the
medium was quantitated and expressed as ng/mL. Data are mean ± SEM from three
independent experiments. *represents p < 0.05 vs. mock-transfected low glucose; **p <
0.05 vs. mock transfected K+. Insulin release values between mock low glucose or
siRNA transfected low glucose did not differ significantly.
Panel E & F: INS 832/13 cells were mock-tranfected or transfected either with Arf6siRNA/ ARNO-siRNA at a final concentration of 100 nM. After 48 hr culture in regular
medium, cells were stimulated with 1 mM glucose [Glu] or 1 mM glucose + 20 mM Larginine [L-Arg] for 15 min. Insulin released into the medium was quantitated and
expressed as percent of control. Data are mean ± SEM from replicates. * represents p
< 0.05 vs. mock-transfected 1 mM glucose; **p < 0.05 vs. mock-transfected 1 mM Glu +
20 mM L-Arg. Insulin release values between mock 1 mM Glu or siRNA transfected 1
mM Glu did not differ significantly.
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Together, data described in Figure 3-3 implicate regulatory roles for ARNO/Arf6
in insulin secretion elicited by a variety of secretagogues.
Stimulation with secretagogues changes Arf6 to active state
Like every other small GTPases, the guanine nucleotide-bound state regulates
Arf6 function [131, 132]. With no exception, GTP-bound Arf6 confers “activity” and
enables it to interact with effectors. To further understand the role of Arf6 in stimuluscoupled secretion, we examined whether insulinotropic concentrations of glucose/K+
activates Arf6 in the β-cell. This was accomplished by using a recently developed GSTGGA3 pull-down assay, which utilizes GGA proteins to capture activated forms of Arf6
by interacting with the Arf-binding domain [133]. Efficiency and specificity of the
activation assay was confirmed by the ability of GTPγS to stimulate Arf6 activation in
broken cell preparations [Figure 3-4 A]. A time-course study for Arf6 activation by
glucose/K+ [Figure 3-4 B and C] suggested that glucose-induced activation was seen
as early as 1 min and reached optimum at 3 min time point. Even though, we noticed a
reduction in activated Arf6 at 5 min time point, Arf6 remained active [Arf6.GTP] above
basal till 30 min [additional data not shown]. Together, these data suggest that Arf6
activation might represent one of the early signaling steps leading to GSIS.
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Figure 3-4: Time-dependent activation of Arf6 by glucose in pancreatic β-cells
Panel A: Lysates from INS 832/13 cells were incubated with either GDP or GTPˠS.
Cell lysates were used for detecting activated Arf6 [Arf6.GTP] by GST-GGA3-PBD pull
down assay [see Methods]. Total Arf6 was used as the loading control and a
representative blot from three independent experiments is shown.
Panel B: INS 832/13 cells were incubated with KRB for 1 hr and either left unstimulated
[diluent] or stimulated with high glucose [20 mM] or K+ [60 mM] for different time points
as indicated. Cell lysates were used for detecting activated Arf6 [Arf6.GTP] by GSTGGA3-PBD pull down assay [see Methods]. Total Arf6 was used as the loading control
and a representative blot from three independent experiments is shown.
Panel C: Densitometric quantitation of Arf6 activation depicted in Panel B is shown
here. * represents p < 0.05 vs. diluent. Statistical analysis was performed using Oneway ANOVA, All pairwise multiple comparison method (Dunnetts’).

SecinH3 markedly attenuates GSIS in INS 832/13 cells and rat islets
Recently, Hafner et al., reported a small molecule inhibitor, secinH3, which
selectively blocks ARNO-mediated activation of Arf6 [107]. The inhibitor was tested for
its antagonistic potential against other members of Arf family and Rho GTPases [134].
SecinH3 showed a higher affinity towards ARNO and in particular inhibited the ARNOcatalyzed activation of Arf6. Previous studies have utilized secinH3 to determine the
regulatory roles for ARNO/Arf6 signaling in cellular signal transduction [135, 136]. As a
logical extension to the above studies, we evaluated the potential impact of
pharmacological inhibition of ARNO on GSIS in INS 832/13 cells and in normal rat
islets. It should be noted that inhibitory effects of secinH3 on GSIS [Figure 3-5] or Arf6
activation [Figure 3-6] were not due to its cytotoxic effects since we noticed no
significant effects of this inhibitor on the metabolic cell viability of β-cells under these
conditions [Figure 3-5 C]. Data in Fig 3-5 demonstrated complete inhibition of GSIS by
secinH3 in INS 832/13 cells [Panel A] and normal rat islets [Panel B]. Under these
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conditions secinH3 failed to increase basal secretion in either INS 832/13 cells or rat
islets [Figure 3-5 A and B]. Together, these pharmacological data confirm the above
molecular biological data to support our hypothesis that ARNO/Arf6 signaling cascade
plays a positive modulatory role in GSIS.
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Figure 3-5: SecinH3, a selective inhibitor of ARNO attenuates GSIS in INS 832/13
cells and normal rat islets
Panel A: INS 832/13 cells were incubated in low serum-low glucose overnight in the
continuous presence of 50 µM secinH3 or diluent and stimulated with either low [LG, 2.5
mM] or high glucose [HG, 20 mM] for 30 min in KRB. Insulin released into the medium
was quantitated by ELISA and expressed as ng/mL. Data are mean ± SEM from four
independent experiments.
* represents p < 0.05 vs. low glucose without secinH3; **p
< 0.05 vs. high glucose without secinH3 and data points with similar symbol do not differ
statistically.
Panel B: Normal rat islets were incubated in low serum-low glucose overnight in the
continuous presence of either 50 µM secinH3 or diluent and stimulated with either low
[LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min in KRB. Insulin released into the
medium was quantitated by ELISA. Data are expressed as ng/mL insulin released and
are mean ± SEM from four independent experiments. * represent p < 0.05 vs. low
glucose with secinH3 and without secinH3; and **p < 0.05 vs. high glucose without
secinH3. Data points with similar symbol do not differ significantly.
Panel C: INS 832/13 cells were incubated in the presence or absence of secinH3 [20 or
50 µM] for 15 hr. Metabolic cell viability was determined using MTT assay [methods].
The data indicated a modest inhibition of ~13% in cells treated with maximum
concentration of inhibitor. Data are expressed as percent of control [mean ± SEM].

ARNO activates Arf6 in pancreatic beta cells
The conversion of the GDP-bound inactive forms of G-proteins to their GTPbound active state is mediated by GEFs. ARNO is one of the four related proteins in the
cytohesin family of Arf-GEFS. They share a ~70% identity with one another. To
investigate the possibility that ARNO plays a role in glucose-mediated activation of Arf6,
we undertook the following two complementary methods. In the first, glucose-induced
activation of Arf6 was examined in cells in which ARNO expression was reduced by
siRNA-ARNO. Data in Figure 3-6 A and B indicated complete inhibition of glucoseinduced activation of Arf6 under these conditions. This was further verified by a second
approach involving pharmacological inhibition of ARNO/Arf6 signaling by secinH3 [107].
Data in Figure 3-6 C and D suggested a complete inhibition of glucose-induced
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activation of Arf6 by secinH3. Taken together, these data indicate that glucose-induced
activation of Arf6 requires the intermediacy of ARNO.
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Figure 3-6: Molecular biological or pharmacological inhibition of ARNO
attenuates glucose-induced activation of Arf6 in INS 832/13 pancreatic β-cells
Panel A: INS 832/13 cells were either mock-transfected or transfected with siRNAARNO and cultured for 48 h following which cells were stimulated in the presence of
either low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min at 37°C. The
relative amounts of activated Arf6 [i.e, Arf6.GTP] were determined by pull down assay.
Total Arf6 from cell lysates was used as the loading control and a representative blot
from three independent experiments is shown.
Panel B: Data shown in the panel A were analyzed densitometrically and expressed as
fold change in Arf6.GTP over basal and are mean ± SEM of three independent
experiments.
* represents p < 0.05 vs. mock transfected low glucose; **p < 0.05
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vs. mock transfected high glucose, and data points with similar symbol do not differ
statistically.
Panel C: INS 832/13 cells were incubated overnight in the presence or absence of
secinH3 [50 µM] and stimulated with either low glucose [LG, 2.5 mM] or high glucose
[HG, 20 mM] in the continuous presence or absence of secinH3 [50 µM] for 30 min.
Relative degrees of Arf6 activation was quantitated as described in Panel A. Total Arf6
from cell lysates was used as the loading control and a representative blot from three
independent experiments is shown.
Panel D: Data shown in the Panel C are analyzed densitometrically and expressed as
fold change in Arf6.GTP over basal. Data are mean ± SEM from three independent
experiments.
* and # represents p < 0.05 vs. low glucose without secinH3; and ** p <
0.05 vs. high glucose without secinH3.

Glucose promotes association between Arf6 and ARNO in pancreatic β-cells
Then, I examined the ability of ARNO to interact physically with Arf6 in response
to glucose. To investigate this interaction, I utilized co-immunoprecipitation and
immunofluorescence approaches on β-cells exposed to an insulinotropic concentration
of glucose. In our system, activation of ARNO was evidenced by a substantial increase
in the amount of Arf6 coupled to ARNO in pancreatic beta cells when stimulated with
glucose. Data shown in Figure 3-7 A indicate detectable levels of Arf6 in ARNO
immunoprecipitates suggesting that these two proteins stay complexed under basal
conditions. Moreover, incubation of these cells with stimulatory glucose resulted in a
significant increase [~2-fold] in the amount of Arf6 in the ARNO immunoprecipitates
[Figure 3-7 B]. Together, these data suggest that glucose promotes physical
association between ARNO and Arf6 in insulin-secreting cells. We verified these
findings via a complementary immunofluorescence approach. Data in Figure 3-7 C
suggested that both Arf6 [green] and ARNO [red] remain diffused throughout the cell
under basal conditions [2.5 mM glucose]. Merged images of subpanels a and b in
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Figure 3-7 C [i.e., subpanel c] further suggested that the two proteins remain localized
in the cytosolic compartment. However, exposure of these cells to a stimulatory
concentration of glucose [20 mM] led to a significant association of these proteins as
evidenced in the merged images of subpanels d and e of Figure 3-7 [i.e., sub-panel f].
Together, these findings [Figure 3-7] provide evidence for increased association of Arf6
and ARNO in the presence of glucose leading to the activation of ARNO/Arf6 signaling
pathway culminating in insulin secretion.
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Figure 3-7: Glucose promotes association between Arf6 and ARNO in INS 832/13
cells
Panel A: Coimmunoprecipitation studies: Herein, INS 832/13 cells were incubated in
the presence of low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min at
37°C. ARNO was immunoprecipitated in the lysates using a specific antibody as
described in Methods. The immunoprecipitates were separated by SDS-PAGE and
probed for Arf6. A representative blot from three studies is shown.
Panel B: Data from multiple studies shown in Panel A are analyzed densitometrically
and expressed as densitometric units and are mean ± SEM. * represents p <0.05 vs.
low glucose.
Panel C: Immunofluorescence studies using confocal microscopy: INS 832/13
cells were cultured on coverslips and cultured overnight prior to the incubation with
either 2.5 mM or 20 mM glucose for 30 min at 37°C. T he cells were fixed in 4%
paraformaldehyde solution in PBS for 15 min and permeabilized using 0.2% triton X-100
for 15 min. Fixed cells were examined for Arf6 [stained in green] and ARNO [stained in
red] as described under Methods.
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Chapter 4
Potential down-stream signaling events such as activation of effector proteins
involved in ARNO/Arf6 signaling and posttranslational modification of small Gproteins in pancreatic beta- cells
•

Portions of this work have been published, or have been submitted for
publication [copies of the published/submitted manuscripts are
appended].
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Active Arf6 regulates putative downstream effectors in the events leading to
insulin release
Arf6 GTPase has a dual role in cells, regulating membrane traffic and organizing
cortical actin. Many of its downstream effectors include lipid-modifying enzymes, actin
remodelers, kinases and also other small G-proteins. As such, I investigated a number
of potential effectors either using siRNA-ARNO or secinH3 inhibitor.
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Nm23H1 may act as local supplier of GTP for Arf6
In cancer biology, nm23H1 is termed as “tumor metastasis suppressor” and is an
important modulator of tumor invasion. An article by Palacios F in Nature Cell biology
demonstrated a cross-talk between Arf6 and nm23H1 in epithelial cells during adherens
junction disassembly caught our attention [137]. Second, there were intriguing
observations which suggested that NDP kinase can act as a local GEF, for GTPases
[138]. So I investigated whether nm23H1 had any effect on levels of Arf6-GTP as Arf6
seemed to be constitutively active for almost 30 min [Chapter 3]. I investigated this by
silencing nm23H1 using siRNA and studied the levels of Arf6-GTP upon glucose
stimulation by pull-down assay. Interestingly, cells transfected with nm23H1-siRNA (sinm23H1) showed a reduced level of Arf6-GTP [Figure 4-1]. This was consistent with
our hypothesis that nm23H1 might act as a localized GEF for Arf6, thus providing a
constant supply of GTP at the plasma membrane where active Arf6 is required to
regulate downstream effectors.
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Figure 4-1: Molecular biological inhibition of nm23H1 attenuates glucose-induced
activation of Arf6 in INS 832/13 pancreatic β-cells
Panel A: INS 832/13 cells were either mock-transfected or transfected with siRNAnm23H1 (i.e., si-nm23H1) and cultured for 48 h following which cells were stimulated in
the presence of either low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30
min at 37°C. The relative amounts of activated Arf6 [i.e., Arf6.GTP] were determined by
pull down assay. Total Arf6 from cell lysates was used as the loading control and a
representative blot from three independent experiments is shown.
Panel B: Data shown in the panel A were analyzed densitometrically and expressed as
fold change in Arf6.GTP over basal and are mean ± SD from two independent
experiments. * represents p < 0.05 vs. mock transfected low glucose; **p < 0.05 vs.
mock transfected high glucose.
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Arf6/ARNO affects the activation of Rho family of GTPases
Several recent studies, including our own, have implicated Rho subfamily of
small G-proteins [e.g., Cdc42 and Rac1] in cytoskeletal remodeling leading to the
translocation of insulin-laden secretory granules to the plasma membrane for fusion and
exocytotic secretion of insulin [139, 140]. In this context, recent evidence appears to
suggest a significant cross-talk between Arf6/ARNO and Rac1 in the regulation of cell
function in multiple cell types [141-146]. Therefore, I wondered if Arf6/ARNO signaling
axis regulates glucose-induced Rac1 activation in the pancreatic β-cell. We addressed
this question by quantitating glucose-induced Rac1 activation in INS 832/13 cells in
which ARNO function is compromised via pharmacological [e.g., secinH3] or molecular
biological [e.g., siRNA-ARNO] approaches. As expected, we noticed a significant Rac1
activation in control cells exposed to glucose [Figure 4-2 A]. Interestingly, siRNAmediated knockdown of ARNO increased Rac1 activation under basal glucose
conditions. However, glucose-induced activation of Rac1 was completely inhibited in
ARNO-depleted β-cells [Figure 4-2 A and B]. Likewise, pharmacological inhibition of
ARNO/Arf6 signaling axis with secinH3 abolished glucose-induced activation in these
cells [Figure 4-2 C and D] suggesting that ARNO/Arf6 signaling step might be regulate
Rac1 activation in the cascade of events leading to GSIS. These data, which are
compatible with our original proposal [117] also fit into the time-frame for glucoseinduced activation of these proteins. We noticed in this study that Arf6 activation is seen
as early as 1 min while glucose-induced activation of Rac1 is maximal at 15-20 min
[139, 140].
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Figure 4-2: Molecular biological or pharmacological inhibition of ARNO function
attenuates glucose-induced Rac1 in INS 832/13 cells
Panel A: INS 832/13 cells were either mock-transfected or transfected with siRNAARNO at a final concentration of 100 nM and after 48 hr culture, cells were stimulated
with either low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min at 37°C.
The relative amounts of activated Rac1 [i.e, Rac1.GTP] were quantitated by PAK-PBD
pull down [see Methods for additional details]. Total Rac1 from cell lysates was used as
the loading control. A representative blot from three independent experiments is shown
here.
Panel B: Data from Panel A were analyzed densitometrically and expressed as fold
change in Rac1.GTP over basal. Data are mean ± SEM of five independent
experiments. * and # represent p < 0.05 vs. low glucose without siRNA-ARNO; and **p <
0.05 vs. high glucose without siRNA-ARNO.
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Panel C: INS 832/13 cells were cultured overnight in the presence or absence of
secinH3
[50 µM] and further stimulated with low glucose [LG, 2.5 mM] and high
glucose [HG, 20 mM] for 30 min in the continuous presence or absence of secinH3. The
relative amounts of activated Rac1 [i.e, Rac1.GTP] were determined by PAK-PBD pull
down assay as described in Panel A. Total Rac1 from cell lysates was used as the
loading control.
Panel D: Data were analyzed densitometrically and expressed as fold change in
Rac1.GTP over basal and are mean ± SEM of three independent experiments. *
represents p <0.05 vs. low glucose without secinH3; ** p < 0.05 vs. high glucose without
secinH3, and data points with similar symbol do not differ statistically.
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Along these lines, earlier studies from our laboratory have suggested that the
carboxylmethylation of Cdc42 is stimulated by glucose within 1 min of exposure [75].
More recent and comprehensive investigations by Thurmond’s group [76, 139] have
reported glucose-induced activation of Cdc42 within 3 min of exposure. They also
demonstrated that Cdc42 activation is upstream to Rac1 activation in the cascade of
events leading to GSIS [139]. Therefore, we examined if inhibition of ARNO/Arf6
signaling step affects Cdc42 activation. Our findings suggested ~50% inhibition of
glucose-induced activation of Cdc42 in INS 832/13 cells following inhibition of
ARNO/Arf6 either by siRNA-ARNO or by secinH3 [Figure 4-3 A-D]. Together, our
findings are suggestive of sequential activation of Arf6, Cdc42 and Rac1 by ARNO in
glucose-stimulated β-cell culminating in insulin secretion.
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Figure 4-3: Molecular biological or pharmacological inhibition of ARNO function
attenuates glucose-induced Cdc42 activation in INS 832/13 cells
Panel A: INS 832/13 cells were either mock-transfected or transfected with siRNAARNO (i.e., si-ARNO) at a final concentration of 100 nM and after 48 hr culture, cells
were stimulated with either low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] for
30 min at 37°C. The relative amounts of activated Cdc42 [i.e, Cdc42.GTP] were
quantitated by PAK-PBD pull down [see Methods for additional details]. Total Cdc42
from cell lysates was used as the loading control. A representative blot from three
independent experiments is shown here.
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Panel B: Data from Panel A were analyzed densitometrically and expressed as fold
change in Cdc42.GTP over basal. Data are mean ± SEM of three independent
experiments. * and ** represent p < 0.05 vs. low glucose without si-ARNO; and ***p <
0.05 vs. high glucose without si-ARNO.
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Panel C: INS 832/13 cells were starved overnight in the presence or absence of
secinH3 [50 µM] and were stimulated with low glucose [LG, 2.5 mM] and high glucose
[HG, 20 mM] for 3 min in the continuous presence or absence of secinH3. The relative
amounts of activated Cdc42 [i.e, Cdc42.GTP] was determined by PAK-PBD pull down
assay. Total Cdc42 from cell lysates was used as the loading control.
Panel D: Data were densitometrically analyzed and is expressed as fold change in
Cdc42.GTP over basal and are mean ± SEM of three independent experiments yielding
similar results. * and ** represents p<0.05 vs. low glucose without secinH3 and # p <
0.05 vs. high glucose without secinH3.
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Phospholipase D is modulated by ARNO/Arf6
Phospholipase D [PLD] has been a key player in the regulation of golgi trafficking
as well as exo-endocytotic processes. Membrane trafficking involves the input of lipidmodifying enzymes which either help to form micro-domains or supply second
messengers. PLD catalyzes the breakdown of phosphatidyl choline to phosphatidic acid
[PA] and choline. A role for PLD in regulating vesicular traffic is particularly compelling
due its cellular location and its function as a lipid-modifier. It has been well-established
to play a regulatory role in release of insulin by secretagogues. Arf6, so far, has been a
well-known mediator of membrane reorganization.

Earlier work has shown the

interaction between Arf6 and PLD in MIN6 cells upon glucose stimulation [147]. They
also demonstrated the ability of Arf6 to regulate the PLD’s activity under stimulatory
conditions using brefeldin A [BFA] which inhibits the guanine nucleotide exchange on
the Arf6. Therefore we sought to assess if PLD activity was dependent on activation of
Arf6 via its GEF, ARNO. As seen in Figure 4-4, INS 832/13 cells show an increased
activity of PLD when stimulated with glucose, consistent with findings in chromaffin cells
[148]. But in cells challenged with secinH3, an inhibitor of ARNO, cellular activity of PLD
was reduced, notably more than 40% when stimulated with glucose. These data confirm
a close relationship between active Arf6 and PLD activity in pancreatic beta cells.
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Figure 4-4: SecinH3 inhibits glucose-induced activation of PLD
INS 832/13 cells were starved in low serum-low glucose overnight ± secinH3 [50 µM]
and stimulated with either low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] ±
secinH3 [50 µM] for 30 min. PLD activity was determined by Amplex red PLD assay kit.
50 µg protein was made upto 100 µL volume with 1x reaction buffer [kit]. 100 µL of
working reagent [kit components] was added and incubated for 30 min at 37 ºC.
Fluorescence was measured at 530/590 nm and hydrogen peroxide was used as a
positive control. Data shown above are expressed as fold change over basal and mean
± SEM from three independent experiments.
* represents p < 0.05 vs. low glucose
without secinH3; high glucose with secinH3 and low glucose with secinH3. Similar
symbols do not differ significantly.
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ERK1/2 activation requires active Arf6
Cationic events following glucose metabolism activates protein kinases. In
addition to calcium-dependent protein kinases, mitogen-activated protein kinases like
extracellular signal-regulated kinases [ERK1/2] have been characterized in the beta-cell
[149]. ERK1/2 are regulated in a manner to meet the secretory demands of the
pancreatic beta-cell, integrating long- and short-term fuel sensing information. Recently
published evidence from our laboratory demonstrated activation of ERK1/2 in GSIS.
Data using siRNA of ERK1/2 clearly indicated that ERK1/2 activation regulates the
activity of Rho GTPase, Rac1, leading to insulin release [150]. Added to this, my earlier
work has demonstrated Arf6 to be a potential upstream regulator of Rac1 in GSIS from
pancreatic beta-cells. Furtherance to earlier findings, I tested the effect of secinH3 on
activation of ERK1/2. Data described in Figure 4-5 A-B demonstrated that incubation of
INS 832/13 cells with a stimulatory concentration of glucose leads to a significant
increase in ERK1/2 phosphorylation whereas secinH3, a known inhibitor of ARNOmediated activation of Arf6, totally abrogated the effect of glucose on ERK1/2 activation.
This clearly indicates the role for ARNO/Arf6 in modulating the activity of ERK1/2 in the
events leading to insulin secretion.
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Figure 4-5: Pharmacological inhibition of ARNO function attenuates glucoseinduced ERK1/2 activation in INS 832/13 cells
Panel A: INS 832/13 cells were starved overnight in the presence or absence of
secinH3 [50 µM] and were stimulated with low glucose [LG, 2.5 mM] and high glucose
[HG, 20 mM] for 30 min in the continuous presence or absence of secinH3. Lysates
were prepared in RIPA lysis buffer substituted with appropriate phosphatase and
protease inhibitors. Quantitated amounts of proteins were loaded and probed for p-ERK
1/2 [p-44/42]. The blot was reprobed for total ERK 1/2.
Panel B: Data were densitometrically analyzed and is expressed as fold change in ratio
of p-ERK ½ over total ERK ½ and are mean ± SEM of three independent experiments
yielding similar results. * represents p<0.05 vs. low glucose without secinH3; ** p < 0.05
vs. high glucose without secinH3 and *** p < 0.05 vs. low glucose without secinH3.
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Arf6-mediated regulation of ROS
Reactive oxygen species [ROS] are involved in pathogenesis of diabetes [151],
cardiovascular [152] and neurodegenerative diseases [153]. But growing evidence has
suggested ROS to play an essential role in physiological processes such as insulin
secretion and signaling acting as second messengers [154]. Apart from being produced
by mitochondria, ROS is also generated by NADPH oxidase which also contributes to
GSIS in the pancreatic islets [155, 156]. Evidence from Collins’ and Pénicaud’s
laboratory [157] provided strong evidence in favor of ROS as a metabolic signal in
insulin secretion. Collin’s group demonstrated the following: i) glucose stimulates
production of ROS, ii) increased ROS stimulates insulin secretion and iii) use of
antioxidants that quenched ROS production inhibited secretion of insulin [154]. Recent
evidence from my lab demonstrated a role for prenylated Rac1 in glucose- and
mitochondrial fuel-induced Nox-dependent ROS generation in INS 832/13 cells and
rodent islets [158]. Apparently, the unidentified prenylated protein is required for
glucose-induced ERK1/2 phosphorylation, ROS generation and Rac1 activation. Along
this line of evidence, I wondered if Arf6 had any regulatory role over glucose-induced
ROS generation. With this in mind, using a pharmacological approach, I examined
whether activated Arf6 was necessary for ROS generation. Data in Figure 4-6
demonstrated a significant reduction in glucose-induced ROS generation in INS 832/13
cells [Panel A] and in rat islets [Panel B]. Together, these findings suggested
involvement of Arf6/ARNO in the signaling cascade leading to ROS generation by
glucose.
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Figure 4-6: SecinH3 inhibits glucose-induced generation of ROS
Panel A and B: INS 832/13 cells [A] or rat islets [B] were starved in low serum-low
glucose overnight ± secinH3 [50 µM] and stimulated with either low glucose [LG, 2.5
mM] or high glucose [HG, 20 mM] ± secinH3 [50 µM] for 60 min. At the end of
stimulation, cells were incubated with DCHFDA (10 µM; 30 min) and harvested for
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quantitation of DCF fluorescence. Data shown above are expressed as fold change
over basal and mean ± SEM from three independent experiments. In Panel A, *
represents p < 0.05 vs. low glucose without secinH3; high glucose with secinH3 and low
glucose with secinH3. Similar symbols do not differ significantly. Panel B, * represents p
< 0.05 vs. low glucose without secinH3; low glucose with secinH3 and high glucose with
secinH3. Similar symbols do not differ significantly.
Regulation of NADPH Oxidase by ARNO/Arf6
At the outset, I demonstrated that generation of ROS is regulated by ARNO/Arf6 upon
stimulation with glucose. ROS is generated by a family of Noxs in response to stimuli
that signal through Rho GTPases, Rac [159, 160]. Supportive evidence demonstrated
the localization and activation of Nox subunits in clonal beta-cells, rat islets and human
islets [161, 162]. Activated Rac1 is an essential component of Nox holoenzyme
complex and initiates the assembly of both cytosolic and membranic Nox subunits.
Activation of the Nox complex has been associated with phosphorylation of p47phox,
p67phox and p40phox and their subsequent translocation to plasma membrane [159].
Since ARNO/Arf6 has been shown to regulate both the activation of Rac1 and
generation of ROS, I wanted to determine if the regulatory pair modulated the assembly
of Nox by affecting the activation and translocation of p47phox, a cytosolic subunit of
Nox. Therefore, I monitored the impact of secinH3 on glucose-induced phosphorylation
of p47phox and its recruitment to membranes in INS 832/13 cells. Figure 4-7 A and B
shows that glucose stimulation increased the phosphorylation of p47phox which was
reduced in secinH3-treated cells to near basal levels. In Figure 4-8 A and B, secinH3
treated cells showed reduced translocation of p47phox to membrane compared to control
cells when stimulated with glucose. Collectively, the above evidence demonstrates
ARNO to regulate the activation and assembly of Nox enzyme complex in pancreatic
beta cells leading to insulin secretion.
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Figure 4-7: SecinH3 inhibits glucose-induced phosphorylation of p47phox
Panel A: INS 832/13 cells were starved in low serum-low glucose overnight ± secinH3
[50 µM] and stimulated with either low glucose [LG, 2.5 mM] or high glucose [HG, 20
mM] ± secinH3 [50 µM] for 60 min. Lysates were prepared in RIPA lysis buffer
substituted with appropriate phosphatase and protease inhibitors. Quantitated amounts
of proteins were loaded and probed for p-p47phox. The blot was reprobed for total
p47phox. A representative blot from three independent experiments is shown here.
Panel B: Data shown above are expressed as fold change over basal and mean ± SEM
from three independent experiments. In Panel A, * represents p < 0.05 vs. low glucose
without secinH3; high glucose with secinH3 and low glucose with secinH3. Similar
symbols do not differ significantly.

79

[A]

LG

HG

-

+

-

+

secinH3
p47phox

1.5

[B]
phox

Translocation of p47
[Fold change over basal]

*
1.0

**

**

-

+

**

0.5

0.0

LG

-

+ secinH3
HG

Figure 4-8: SecinH3 inhibits glucose-induced translocation of p47phox to
membrane
Panel A: INS 832/13 cells were starved in low serum-low glucose overnight ± secinH3
[50 µM] and stimulated with either low glucose [LG, 2.5 mM] or high glucose [HG, 20
mM] ± secinH3 [50 µM] for 60 min. At the end of stimulation, cells were lysed in
homogenization buffer. Lysates were then differentially centrifuged [methods] to
separate cytosol and membranic fractions. Total amount of proteins were quantitated in
membrane fractions and separated onto SDS-PAGE. Proteins transferred onto
nitrocellulose membrane were probed for p47phox. A representative blot from three
independent experiments is shown here.
Panel B: Data shown above are expressed as fold change over basal and mean ± SEM
from three independent experiments. In Panel A, * represents p < 0.05 vs. low glucose
without secinH3; high glucose with secinH3 and low glucose with secinH3. Similar
symbols do not differ significantly.
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Actin remodeling
Arf6/ARNO has demonstrated many roles in regulation of actin cytoskeleton
[163-166]. Particularly in neuroendocrine cells, cortical actin is shown to act as a barrier
to movement of preformed dense core granules [167]. Upon stimulation, the actin
network is dissolved thus allowing the granules to traverse the cell in order to access
the plasma membrane. In addition to prominent roles of ARNO/Arf6 in actin cytoskeletal
remodeling, cofilin is considered as a prototype of a family of actin-binding proteins that
modulate cytoskeleton organization [168]. Cofilin is a well-studied protein that can bind
and sever actin filaments and is involved in actin remodeling. Inactive cofilin is defined
by its phosphorylated state. Activation of a phosphatase in response to stimulus,
dephosphorylates cofilin and thus enabling it to bind actin [169, 170]. In order to study
modulation of cytoskeleton organization, I investigated the effect of ARNO/Arf6 on the
activation of cofilin. First, I determined the time-kinetics for the dephosphorylation or
phosphorylation cycle of cofilin upon glucose stimulation. When INS 832/13 cells were
stimulated with glucose for 0, 15, 30 and 60 min, cofilin was dephosphorylated
significantly after 30 min time-point. This is in line with second-phase of insulin secretion
where the reserve pool of granules needs to access the plasma membrane. To imply a
role for active Arf6 in actin remodeling we tested the effect of secinH3 on glucoseinduced dephosphorylation of cofilin. When activation of Arf6 is blocked using secinH3,
cofilin is no longer dephosphorylated [Figure 4-7 A and B]. This above data correlated
Arf6/ARNO to be an essential upstream regulator actin remodeling via the actinsevering agent, cofilin.
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Figure 4-9: Pharmacological inhibition of ARNO function attenuates glucoseinduced cofilin activation in INS 832/13 cells
Panel A: INS 832/13 cells were starved overnight in the presence or absence of
secinH3 [50 µM] and were stimulated with low glucose [LG, 2.5 mM] and high glucose
[HG, 20 mM] for 30 min in the continuous presence or absence of secinH3. Lysates
were prepared in RIPA lysis buffer substituted with appropriate phosphatase and
protease inhibitors. Quantitated amounts of proteins were loaded and probed for pcofilin [Ser 3]. The blot was reprobed for total cofilin.
Panel B: Data were densitometrically analyzed and is expressed as fold change in ratio
of p-cofilin over total cofilin and are mean ± SEM of three independent experiments
yielding similar results. * represents p<0.05 vs. low glucose without secinH3; ** p < 0.05
vs. low glucose without secinH3 and *** p < 0.05 vs. high glucose without secinH3.
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Active Arf6 regulates endocytosis
Dynamin-1, found in abundance in neuroendocrine cells, specifically regulates
recycling of secretory vesicles after exocytosis [171, 172]. Among the three domains,
the PRD domain plays a crucial role in mediating interaction with other proteins. The
phosphorylation cycle of dynamin regulates protein-protein interactions and protein-lipid
interactions [173, 174]. In a resting nerve terminal dynamin remains phosphorylated,
but on stimulation phosphatases like calcineurin is activated, which dephsophorylates
dynamin

[114].

Moreover,

it

is

directly

demonstrated

that

dynamin-1

is

dephosphorylated at Ser 774 after stimulation in neurons in vivo [175]. Dynamin-1
dephosphorylation in response to glucose stimulation is not yet investigated. This is an
essential determinant of stimulus-induced activity. I challenged pancreatic beta-cell
cultures with stimulatory concentrations of glucose at increasing time-point [0, 15 and
60 min]. Glucose challenge dephosphorylated dynamin 1 at Ser-774 with increasing
time. In INS 832/13 cells, we found dynamin-1 to be dephosphorylated [active] to the
maximum at 60 min upon glucose stimulation coinciding with endocytotic process
[Figure 4-9]. Arf6 is a potential regulator of membrane traffic. It seems to efficiently
control both exocytosis and endocytosis of vesicles as evident in many cell types. There
has been direct implication of active Arf6 recruiting dynamin to membrane for
endocytosis [137]. With this in regard, we tested whether active Arf6 functioned as an
upstream regulator in the activation of dynamin-1. Upon treatment with secinH3,
stimulation with glucose could not dephosphorylate dynamin-1 anymore [Fig 4-10]. This
is clear evidence for active Arf6 to regulate the endocytic limb of the secretory process.

83

[A]
0

15

60

Time, min
p-Dynamin1
(Ser774)
Total Dynamin1

[B]

Fold change in Dynamin I
dephosphorylation

1.2

20 mM Glu

0.9

*
0.6

0.3

0.0

0 min

15 min 60 min

84

[C]

Green- p-Dynamin 1
Blue - Nucleus

Figure 4-10: Glucose induces activation of dynamin-1 over time in INS 832/13
cells
Panel A: INS 832/13 cells were starved overnight and further stimulated with low
glucose [LG, 2.5 mM] and high glucose [HG, 20 mM] for indicated time-points. Lysates
were prepared in RIPA lysis buffer substituted with appropriate phosphatase and
protease inhibitors. Quantitated amounts of proteins were loaded and probed for p-pdynamin-1. The blot was reprobed for total dynamin-1.
Panel B: Data were densitometrically analyzed and is expressed as fold change in ratio
of p-dynamin-1 over total dynamin-1 and are mean ± SD of two independent
experiments yielding similar results. * represents p<0.05 vs. p-dynamin-1 at 0 and 15
min time point.
Panel C: INS 832/13 cells were starved overnight and further stimulated with low
glucose [LG, 2.5 mM] and high glucose [HG, 20 mM] for indicated time-points. Cells
were fixed and permeabilized and stained with p-Dynamin-1 antibody and Hoecsht
nuclear stain for immunofluorscence [Methods]. The signal intensity of p-dynamin-1 is
reduced in cells stimulated with glucose for 60 min as compared to 0 min. A
representative image from multiple cells on two sets of coverslips is shown here.
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Figure 4-11: SecinH3 attenuates glucose-induced dynamin-1 activation in INS
832/13 cells
Panel A: INS 832/13 cells were starved overnight in the presence or absence of
secinH3 [50 µM] and were stimulated with low glucose [LG, 2.5 mM] and high glucose
[HG, 20 mM] for 0, 15 and 60 min in the continuous presence or absence of secinH3.
Lysates were prepared in RIPA lysis buffer substituted with appropriate phosphatase
and protease inhibitors. Quantitated amounts of proteins were loaded and probed for pdynamin-1. The blot was reprobed for total dynamin-1.
Panel B: Data were densitometrically analyzed and is expressed as fold change in ratio
of p-dynamin-1 over total dynamin-1 and are mean ± SD of two independent
experiments yielding similar results. * represents p<0.05 vs. p-dynamin-1 at 0 and 15
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min time point with or without secinH3 and ** represents p<0.05 vs. p-dynamin-1 at 60
min stimulation without secinH3.
Role(s) of Posttranslational Modification of Small G-Proteins in GlucoseStimulated Insulin Secretion
For decades it is well known that small G-proteins undergo certain other
chemical modifications apart from the addition of GTP to confer functional activity [69,
176]. A growing body of evidence indicates that G-proteins undergo isoprenylation and
methylation.

These

chemical

modifications

are

termed

as

post-translational

modifications which enable small G-proteins to attach to plasma membrane. Recent
years have seen advances in elucidating these modifications that confer biological
activity upon small G-proteins. Ras family of G-proteins consist a CAAX motif [C,Cys; A,
Aliphatic amino acid and X, any amino acid] at the C-terminal end [120]. The processing
of

CAAX-containing

proteins

undergoes

prenylation

[farnesylation

or

geranylgeranylation] [177] followed by a prenyl-cysteine carboxylmethylation. The
enzymes that catalyze the above processes are of utmost interest for their therapeutic
potential as anti-cancer agents and have also been a valuable tool in evaluating the
importance of such modifications in stimulated insulin secretion. Prenylation process
involves the addition of prenyl intermediates that are generated from acetyl CoA and
acetoacetyl CoA in the cholesterol biosynthetic pathway at the CAAX motif. The
candidate protein is incorporated with either a farnesyl group [15-carbon derivative of
mevalonic acid] by farnesyltransferases [FTase] or a geranylgeranyl group [20 carbon
derivative of mevalonic acid] by geranylgeranyltransferases [GGTase] [178]. The major
farnesylated proteins include Ras, nuclear lamins and also gamma-subunits of trimeric

87

G-proteins whereas the geranylgeranylated proteins include Cdc42, Rac1 and Rho
[140].
Extensive evidence from our laboratory has shown the localization and
involvement of prenylation signaling event to be an essential step in GSIS from
pancreatic beta cells [150, 158, 179]. Earlier studies have also demonstrated a potential
regulatory role for prenylation in physiological insulin secretion with the use of
pharmacological inhibitors [177].

From Kowluru A, Endocr Rev. 2010

Figure 4-12. Image depicting a biosynthesis of farnesyl and geranyl pyrophosphates.
[140].
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Followed by the addition of a prenyl group to the C-terminal cysteine, the three amino
acids after the prenylated cysteine are cleaved by Ras-converting enzyme 1 [Rce 1],
thus exposing the carboxylate anion. A secondary step involves the methylation of
carboxylate site by isoprenylcysteine-O-carboxyl methyltransferase [ICMT] [180, 181]. It
is widely accepted that the two steps increase the hydrophobicity of the candidate
proteins for optimal targeting to their relevant membranous sites for the regulation of
effector proteins [181]. While a significant number of recent studies have focused on
putative roles of G-protein prenylation in glucose-stimulated insulin secretion (GSIS),
very little is known with regard to potential roles of carboxymethylation in islet function
[181]. Original studies from our laboratory have attempted to address the roles of
carboxymethylation in islet function, including insulin secretion [75, 77]. Therein, using
selective inhibitors of ICMT such as acetyl farnesyl cysteine (AFC) we have been able
to demonstrate that Cdc42 and Gγ subunits undergo carboxymethylation in response to
glucose in clonal β-cells, normal rat islets and human islets [75, 77]. Follow-up studies
by Li and coworkers characterized ICMT in insulin-secreting cells for its subcellular
localization and regulation by known second messengers of insulin secretion [182]. In
the current study, I have revisited this area of islet biology to precisely determine the
role of carboxymethylation and the identity of methylated proteins to further evaluate
their roles in the signaling events leading to insulin secretion.
Along these lines, emerging evidence implicates novel regulatory roles for
phagocyte-like NADPH oxidases (Nox) in physiological insulin secretion. For example,
using selective inhibitors (e.g., DPI or apocynin) and molecular biological tools (e.g.,
antisense and siRNAs for Nox subunits), several recent studies have demonstrated
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“second messenger” roles for Nox-derived reactive oxygen species

in glucose-

stimulated insulin secretion [183-185]. Some of these aspects, including downstream
targets for reactive oxygen species signals have been reviewed by Pi and Collins
recently [153]. Furthermore, recent studies from our laboratory have also demonstrated
a novel regulatory role for Rac1 in Nox-derived generation of reactive oxygen species,
thus suggesting that glucose-induced Rac1 activation step might be necessary for Noxmediated generation of reactive oxygen species and insulin secretion. For example,
using selective inhibitors of prenylation (e.g., GGTI-2147), we have demonstrated that
post-translational prenylation of Rac1 is important for its regulation of generation of
reactive oxygen species [158]. Therefore, based on the above evidence and as a
logical

extension

to

studies

to

suggest

obligatory

roles

of

ICMT-mediated

carboxymethylation of Rac1 function for its subcellular localization and function [186,
187], we undertook the current investigation to determine the regulatory roles of ICMT
in glucose-induced Rac1 activation, generation of reactive oxygen species and insulin
secretion in INS 832/13 cells.

We have accomplished this goal by two distinct

approaches to compromise the β-cell endogenous ICMT function, via siRNA-mediated
knockdown of ICMT expression and pharmacological inhibition of ICMT by AFC.
Indeed, data accrued from the current studies underscores the importance of
carboxymethylation of Rac1 in glucose-induced Nox activation and associated
generation of reactive oxygen species and insulin secretion.
ICMT is expressed in INS 832/13 cells
At the outset, I determined the immunological localization and subcellular distribution of
ICMT in INS 832/13 cells. For this, total particulate and soluble fractions were isolated
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from INS 832/13 cells by a single step centrifugation method and relative abundance of
ICMT was determined in these fractions by Western blotting.

Data in Figure 4-13

suggested a predominant membrane association of ICMT in these cells. It should be
also noted that we consistently observed a doublet for ICMT on Western blots, which
might represent a post-translationally modified form of this protein.

ICMT (32 kDa)
Cytosol

Membrane

Figure 4-13: Expression and subcellular distribution of ICMT in INS 832/13 cells
Total particulate and soluble fractions were isolated from INS 832/13 cells by a single
step centrifugation method described under Methods. ICMT expression was determined
in these fractions by Western blotting. A representative of three blots is shown here.
A

B

Figure 4-14: Localization of ICMT in INS 832/13 cells by immunofluorescence
under basal and glucose-stimulated conditions
INS 832/13 cells were plated on coverslips and cultured overnight in low serum low
glucose media prior to the incubation with either 2.5 mM (Panel A) or 20 mM glucose
(Panel B) for 45 min at 37°C. The cells were fixed in 4% par aformaldehyde solution in
PBS for 15 min and permeabilized using 0.2% triton X-100 for 15 min. Fixed cells were
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examined for ICMT (stained in green) and nuclei (stained in blue) as described under
Methods.
In the next series of studies we determined the distribution of ICMT in INS 832/13 cells
by immunofluorescence method. Data in Figure 4-14 suggested that ICMT [green]
remain diffused throughout the cell under basal (Panel A; LG; 2.5 mM glucose)
conditions. Further, we observed no clear effects of stimulatory glucose (Panel B; HG;
20 mM glucose) on ICMT distribution in these cells.
siRNA-mediated knockdown of ICMT attenuates glucose-, but not KCl-induced
insulin secretion in INS 832/13 cells
We next investigated potential regulatory roles of ICMT in glucose-induced insulin
secretion in these cells. To address this, we knocked down the endogenous expression
of ICMT by siRNA methodology. Data in Figure 4-15 A and B indicated more than ~70
% inhibition in the expression of ICMT following siRNA-ICMT transfection.

Data in

Figure 4-15 C suggested no significant effects of scrambled siRNA transfection either
on basal or glucose-induced insulin secretion (bars 1 vs. 3 and 2 vs 4). However,
transfection of siRNA-ICMT in these cells led to a modest increase in basal secretion
(bars 1 or 2 vs. bar 5), but insulin secretion elicited by stimulatory glucose was
significantly reduced in ICMT knocked down cells (bars 2 or 4 vs. 6). These data
suggested that activation of ICMT is necessary for glucose-stimulated insulin secretion
to occur.

We then determined potential requirement for ICMT in insulin secretion

elicited by a membrane depolarizing concentration of KCl. Data shown in Figure 4-15
D suggested no significant effects of ICMT knockdown on KCl-induced insulin secretion.
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Together, data in Figure 4-15 C and D suggest that glucose, but not KCl-evoked insulin
secretion is mediated via activation of ICMT.

[A]
ICMT

Actin
Mock

[B]

Scr ICMT- siRNA

Fold Change Over Basal

1.2

0.8

*
0.4

0.0

Mock

Scr ICMT-siRNA

Figure 4-15: Glucose-, but not KCl-stimulated insulin secretion, is attenuated in
INS 832/13 cells following siRNA-mediated knockdown of ICMT
INS 832/13 cells were either mock transfected or transfected with scrambled siRNA or
siRNA-ICMT at a final concentration of 100 nM and cultured for 24 h. Transfection
efficiency was determined by separating equal amounts of proteins on SDS-PAGE and
probing with ICMT antibody (Panel A; representative of three transfections is shown
here). Data in Panel A was densitometrically analyzed and expressed as fold change
over basal (Panel B). * represent p< 0.05 compared with mock or scrambled siRNA
transfected cells.
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Further, transfected cells were incubated either with low glucose (LG; 2.5 mM) or high
glucose (HG; 20 mM: Panel C) or a membrane depolarizing concentration of KCl (60
mM; osmolaity adjusted by lowering NaCl; Panel D) for 45 min at 37°C. Insulin released
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into the medium was quantitated by ELISA. Data are expressed as percentage of basal
and are mean ± SEM from three independent determinations. * p< 0.05 vs. respective
low glucose controls; ** p< 0.05 vs. mock transfected cells.

siRNA-mediated knockdown of ICMT attenuates glucose-induced Rac1 activation
in INS 832/13 cells
Published evidence from several laboratories, including our own have suggested that
activation of Rac1, a small G-protein, is a requisite step in the signaling events leading
to glucose-insulin secretion [139, 140, 188]. Furthermore, using inhibitors of posttranslational geranylgeranylation [e.g., GGTI-2147] or a dominant negative mutant of
the α-subunit of geranylgeranyl transferase, we have demonstrated a requirement for
post-translational geranylgeranylation in glucose-induced Rac1 activation and insulin
secretion [179]. Since Rac1 undergoes carboxymethylation, we investigated if silencing
of ICMT affects glucose-induced Rac1 activation. Data shown in Figure 4-16
demonstrated a significant increase in glucose-induced Rac1 activation (lane 1 vs. 3).
siRNA-mediated knockdown of ICMT failed to exert any clear effects on basal Rac1
activation (lane 1 vs. 2), but significantly attenuated glucose-induced Rac1 activation
(lane 3 vs. 4). Pooled data from multiple experiments are provided in Figure 4-16 B.
Together, these findings suggested a requirement for carboxymethylation for glucoseinduced activation of Rac1.
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Figure 4-16: Depletion of endogenous ICMT markedly attenuates glucose-induced
activation of Rac1 in INS 832/13 cells.
INS 832/13 cells were transfected with ICMT-siRNA or mock transfected and cultured
for 24 h. At confluence, cells were starved overnight and stimulated with either low (2.5
mM) or high (20 mM) glucose for 30 min. The extent of Rac1 activation in these cells
was quantitated by PAK-PBD pulldown assay. Total and activated (Rac1.GTP) were
determined by Western blotting (Panel A) and quantitated by densitometry (Panel B).
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Data are expressed as fold change in Rac1 activation and are mean ± SEM from three
independent determinations. * p< 0.05 vs. mock transfected low glucose; **p<0.05 vs.
mock transfected high glucose.

siRNA-mediated knockdown of ICMT markedly inhibits glucose-induced reactive
oxygen species generation in INS 832/13 cells
Emerging evidence from multiple laboratories appears to suggest novel second
messenger roles for reactive oxygen species in GSIS [153]. It has also been shown that
ROS generated via the activation of phagocyte-like NADPH oxidase (Nox) plays such
regulatory roles in GSIS since pharmacological (e.g., apocynin or DPI) or molecular
biological (e.g., siRNA or antisense for p47phox) inhibition of Nox led to inhibition of GSIS
[184, 185]. Since Rac1 represents one of the members of Nox holoenzyme [140, 159],
we investigated if siRNA-mediated knockdown of ICMT exerts any regulatory effects on
glucose-induced generation of reactive oxygen species in INS 832/13 cells. Data in
Figure 4-17 suggested no significant effects of ICMT knockdown on basal levels of
reactive oxygen species in these cells (bar 1 vs. 2). However, glucose-induced
generation of ROS was markedly attenuated in cells in which expression of ICMT was
knocked down (bar 3 vs. 4). Taken together, these data demonstrated that glucoseinduced Rac1 activation (Figure 4-16), generation of ROS (Figure 4-17) and insulin
secretion (Figure 4-15) are regulated by ICMT in INS 832/13 β-cells.

Fold change in DCF fluorescence
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Figure 4-17: Glucose-induced ROS generation was attenuated in INS 832/13 cells
following siRNA-mediated knockdown of ICMT
INS 832/13 cells transfected with ICMT-siRNA (or mock transfected) following which
cells were stimulated with low glucose (2.5 mM) or high glucose (20 mM) for 1 h and
were incubated with DCHFDA (10 µM; 30 min) and harvested for quantitation of DCF
fluorescence. Data expressed as DCF fluorescence and are mean ± SEM from three
independent determinations.* p< 0.05 vs. respective low glucose; ** p< 0.05 vs. high
glucose in mock transfected cells.
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Acetyl farnesyl cysteine (AFC), a selective inhibitor of ICMT, attenuates glucoseinduced generation of reactive oxygen species and insulin secretion in INS 832/13
cells
We next confirmed the above data accrued through the use of siRNA-ICMT by a
pharmacological approach. In the following studies, we determined the effects of acetyl
farnesyl cysteine (AFC), a selective inhibitor of ICMT [74, 77], on glucose-induced
generation of reactive oxygen species and insulin secretion. Data shown in Figure 4-18
A indicated a modest, but significant inhibition in basal level of reactive oxygen species
in these cells following exposure to AFC (Figure 4-18; bar 1 vs. 2). However, increase
in the level of reactive oxygen species seen in the presence of stimulatory glucose was
significantly inhibited by AFC (Figure 4-18; bar 3 vs. 4). Furthermore, insulin secretion
elicited by stimulatory (Figure 4-18; Panel B; bar 3 vs. 4), but not basal glucose (Figure
4-18; Panel B; bar 1 vs. 2), was markedly attenuated by AFC. In addition, in a manner
akin to siRNA-ICMT effects, we observed no significant effects of AFC on KCl-induced
insulin secretion (Figure 4-18; Panel C). Together, our above described findings confirm
that glucose-, but not KCl-mediated effects on insulin secretion require activation of
ICMT. Furthermore, along these lines, we also noticed a significant inhibition of glucoseinduced activation of Rac1 by AFC under the conditions it inhibited glucose-induced
generation of reactive oxygen species (~ 41 ± 10% inhibition by AFC; mean ± SEM from
three pull down assays; p <0.05 vs. diluent) and insulin secretion (additional data not
shown). Together, these data further confirm our siRNA-ICMT findings and support our
hypothesis that ICMT-mediated carboxymethylation of specific proteins (e.g., Rac1)

99

plays a positive modulatory role in the cascade of events leading to glucose-induced

[A]

Fold change in DCF fluorescence

generation of reactive oxygen species and insulin secretion in INS 832/13 cells.
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Figure 4-18: AFC, a competitive inhibitor of ICMT, attenuates glucose-induced
ROS generation and insulin secretion in INS 832/13 cells
INS 832/13 cells were cultured overnight with low-glucose and low-serum medium and
then incubated in KRB in the presence of diluent or AFC (100 µM; 1 h) as indicated in
the figure. Cells were further stimulated with either low glucose (LG; 2.5 mM) or high
glucose (HG; 20 mM) for 1 h in continuous presence or absence of diluent or inhibitor.
At the end of stimulation, ROS generation was determined by quantitating DCF
fluorescence (Panel A) as described in Figure 4-16.
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In a separate set of studies glucose- and KCl-stimulated insulin secretion was
quantitated (Panel B and C) under conditions described in Methods section. Data in
Panel B are mean ± SEM from three independent determinations.* p< 0.05 vs. low
glucose without AFC; ** p< 0.05 vs. high glucose without AFC whereas data in Panel C
are mean ± SEM from 12 determinations in each case. * p< 0.05 vs. low glucose without
AFC and low glucose with AFC.
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Inhibition of ICMT does not affect cell viability
We next investigated potential cytotoxic effects of ICMT knockdown (via siRNA-ICMT)
or inhibition of ICMT activity (by AFC) on INS 832/13 cells. We asked this question to be
sure that either inhibition in Rac1 activation, reactive oxygen species generation or
insulin secretion seen under these conditions are not due to potential loss in cell viability
or cell demise following inhibition of ICMT expression and/or activity. We addressed this
by two independent experimental approaches. In the first, we quantitated activation of
caspase-3, a hallmark of cellular apoptosis, in both siRNA-ICMT transfected cells and
AFC-treated cells. In the second approach, we quantitated the metabolic viability of
siRNA-ICMT transfected or AFC-treated cells using the MTT assay. Data shown in
Figure 4-19 A and B indicated no caspase 3 activation following siRNA-ICMT
transfection or AFC treatment. However, a significant activation of caspase 3 was seen
in INS 832/13 cells treated with etoposide, which causes apoptosis in cells via caspase
3 activation. Together, these data in Figure 4-19 A and B suggest no cell death in INS
832/13 cells following inhibition of expression and activity of ICMT. In addition, we
observed only a modest inhibition in cell viability as assessed by the MTT in cells
following ICMT knockdown via siRNA-ICMT (Figure 4-19 C) or AFC treatment [Figure
4-19 D].

Together, these findings suggest that the observed inhibition of glucose-

induced Rac1 activation, generation of reactive oxygen species and insulin secretion
following inactivation of ICMT are specific and do not involve cytotoxic mechanisms.

102

Caspase-3
37 kDa
Hydrolytic product
17 kDa
Actin

Mock

Scr ICMT-siRNA

Control

100

*

75
50
25
0

Mock

Scr ICMT-siRNA

Cell viability
[Percent change over control]

Cell Viability
[Percent change over control]

125

AFC

Etoposide

125
100

*
75
50
25
0

Ctrl

AFC

Figure 4-19: ICMT inhibition does not affect cell viability.
Panel A INS 832/13 cells treated with AFC [100 µM, 1h] were incubated with MTT [5
mg/mL, 4h] as described in Materials and Methods. Cell viability was determined by
quantitating reduction of MTT by metabolically active cells at 570 nm. Data are means ±
SEM from two independent experiments yielding identical results with n: >12 in each
group and expressed as percent change over control. * represents p< 0.05 compared
with control. In Panel B, INS 832/13 cells were mock transfected or transfected either
with ICMT siRNA or scrambled siRNA (100 nmol, 24h). Cell viability in transfected cells
was determined by MTT reduction method as described above. Data are means ± SEM
from two independent experiments yielding identical results with n: >12 in each group
and expressed as percent change over control. * represents p< 0.05 compared with
mock or scrambled siRNA transfected cells.
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Alterations in ICMT expression in in vitro models of gluco-, lipo-, glucolipotoxicity
and endoplasmic reticulum stress
A growing body of evidence implicates that long-term exposure of β-cells to
saturated fatty acids [i.e., lipotoxicity], glucose [i.e., glucotoxicity] or both [i.e.,
glucolipotoxicity] leads to severe metabolic dysfunction and eventual demise of the βcell [189] Furthermore, exposure of these cells to thapsigargin, leads to endoplasmic
reticular stress via depletion of calcium pools culminating in cellular dysfunction [190,
191]. Therefore, in the last series of these studies we investigated potential alterations
in the expression of ICMT in INS 832/13 cells following exposure to palmitate, glucose
or thapsigargin. Data shown in Figure 4-20 indicated a significant increase in the
expression of ICMT in cells exposed to gluco-, lipo- or glucolipotoxic conditions.
However, no detectable changes were seen in the expression of ICMT protein in
thapsigargin-treated cells.

ICMT

Actin
LG

HG

PA

TH

HG+PA

Figure 4-20: Expression of ICMT in lysates of INS 832/13 cells under the duress of
gluco-, lipo-, glucolipotoxicity and endoplasmic stress
INS 832/13 cells were plated in six-well plates, grown to 70 % confluence and treated
with low glucose (LG, 2.5 mM, 48 h), high glucose (HG, 50 mM, 48 h), palmitic acid (PA,
300 µM; 48 h), HG plus PA (48 h) and thapsigargin (TH, 0.5 µM, 9 h). ICMT expression
was determined by Western blotting. A representative of two blots is shown here. Actin
was used as a loading control.
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Chapter 5
Functional status of the ARNO/Arf6 signaling cascade and its down-stream
metabolic steps in models of impaired insulin secretion and type 2 diabetes.
Type 2 diabetes [T2D] is characterized by a progressive loss of beta-cell function
throughout the course of the disease. Investigators have established the course of the
disease starting with an initial loss in early or first phase insulin secretion, which is
followed by a decreasing maximal capacity of glucose to potentiate all non-glucose
signals. Apart from these, disproportionate hyperinsulinemia and impaired basal or
steady-state insulin-secretion [192] add to the symptoms. The disease in clinical
settings is defined at the end stage of this process and demonstrates all the above
symptoms. But the remarkable finding is that impaired glucose potentiation and secondphase defect are compensated by hyperglycemia, at the intermediate stages of final
beta-cell failure such that even non-glucose secretagogues stimulate release of insulin
[193-195]. T2D has been shown to develop mainly in subjects that are unable to sustain
the beta cell compensatory response. Longitudinal studies in T2D, which involved a
continued observation of variables in a set of subjects over time, indicated a rise in
levels of insulin in normoglycemic and prediabetic phases that maintain normal blood
glucose levels inspite of insulin resistance. It was later followed by a decline in insulin
levels when fasting glycemia surpassed the upper limit of basal [5.5 mM] due to betacell failure.
Hyperglycemia is one of the major determinants in the development of diabetic
complications. Many biochemical and molecular events of high concentration of blood
glucose underlie the pathogenesis of complications but the exact mechanism is still
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unclear. With significant advances in tight glucose control, by blood-glucose monitoring
and therapeutics, debilitating complications still remain the same. It is found that as
early as the ‘80s, the concept of a “metabolic memory” has been prevalent, that is
diabetic complications like vascular stress and retinopathy persist even after glucose
normalization. This memory phenomenon has been supported by experimental
evidence seen in both diabetic animals and isolated cells exposed to high glucose,
followed by normalization to physiological concentrations of glucose and in early 2000,
in results from clinical trials [196]. Furthermore, researchers have implicated
nonenzymatic glycation of cellular proteins along with excessive ROS/RNS maintain the
stress signaling even after tight glucose control thus contributing to metabolic memory.
Various evidences implicate a role for epigenetic modulation as a factor
contributing to maintenance of stress levels even after normalization of blood glucose
levels [197-199]. The idea that early glycemic environment is remembered in target
organs of diabetic complications [i.e. eye, heart, kidney and extremities] [200-202], I
wanted to study whether islet beta cells maintained the same metabolic memory. It is
clearly evident that both Arf6 and Rac1 are essential modulatory factors mediating GSIS
from pancreatic beta cells. Evidences also indicate a disruption in insulin secretion in
T2DM. Thus, I was curious to investigate the above phenomenon with respect to
signaling events associated with insulin secretion, we incubated INS 832/13 cells with
either 5 or 30 mM glucose for 24 hr followed by normalization and stimulating with 20
mM glucose for time periods appropriate to activation of Arf6 and Rac1.

When

compared to control incubated in 11.1 mM, the activation of Arf6 and Rac1 was reduced
in cells exposed to glucotoxic conditions [Figure 5-1 & 5-2]. Under physiological
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glucose concentrations [20 mM], both Arf6 and Rac1 demonstrated an increase in fold
activation which was lost under glucotoxic conditions. But there was no apparent
change in total protein expression of Arf6 or Rac1. The probable dysfunction of the
proteins might be due to a possibility of some chemical modification of the proteins like
glycation which has not been reported yet. This is a clear indication that the beta cell is
also conditioned to memory process which seems to be irreversible.
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Figure 5-1: Effect of glucotoxicity on Arf6 activation to stimulatory concentrations
of glucose
Panel A: INS 832/13 cells were exposed to either 11.1 (control) or 5 or 30 mM glucose
for 24 hr. Thereafter, both control and glucotoxic cells were starved overnight in low
serum-low glucose. Cells were then stimulated with either 2.5 or 20 mM glucose in KRB
for 3 min. Lysates were collected and used for the detection of Arf6.GTP. Total Arf6 was
used a loading control. Expression of ARNO under these conditions was also analyzed.
Panel B: Amount of activated Arf6 was quantitated densitometrically and expressed as
percent change over control. The values obtained are mean ± SEM three independent
experiments. * and *** indicates p < 0.05 vs. control 2.5 mM glucose, ** vs. control 20
mM glucose.
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Figure 5-2: Effect of glucotoxicity
concentrations of glucose

on

Rac1

activation

to

stimulatory

Panel A: INS 832/13 cells were exposed to either 11.1 (control) or 5 or 30 mM glucose
for 24 hr. Thereafter, both control and glucotoxic cells were starved overnight in low
serum-low glucose. Cells were then stimulated with either 2.5 or 20 mM glucose in KRB
for 20 min. Lysates were collected and used for the detection of Rac1.GTP. Total Rac1
was used a loading control.
Panel B: Amount of activated Rac1 was quantitated densitometrically and expressed as
percent change over control. The values obtained are mean ± SEM four independent
experiments and three out of four experiments followed a similar trend as shown. * and
*** indicates p < 0.05 vs. control 2.5 mM glucose, ** vs. control 20 mM glucose.
Table 5-1: Characteristics and islet histopathology of various rodent models of
TTDM [203].
Plasma glucose

Model (14+ weeks)

Normoglycemic
Wistar rats

ZF rats

ZDF rats

Goto-Kakizaki rats

P. obesus

HIP rats

12+ hours
fasting, 0 min
into OGTT (mM)

41

53

115

71

60 min
Typical fasting
into
OGTT plasma insulin
(pM)
(mM)

51

133

225

161

25.16 (nonfasted)

177

841

18503

2414

1241

53006(nonfasted)

—
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Typical fasting
plasma
triglyceride (mM)

Islet pathology

0.382

Well delineated islets
with central β cells
surrounded by α- and δcell mantle

55.94

Hypertrophied islets
with β-cell proliferation.
Reduced insulin
granulation. Some
degenerate islets.

17.34

Most islets are poorly
delineated, showing
extensive fibrosis and a
severe reduction in β
cells. Remaining β cells
show reduced insulin
granulation.

592

“Starfish shaped” islets
where previously
hypertrophied islets
have atrophied and
fibrotic projections
remain.

26.96 (nonfasted)

β-Cell vacuolation and
reduced insulin
granulation.

—

Progressive amyloidosis
with a high frequency of
β-cell apoptosis
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Plasma glucose

Model (14+ weeks)

STZ with high-fat
diet diabetes in Rats
Partially
Pancreatectomized
Rats

•

12+ hours
fasting, 0 min
into OGTT (mM)

6.98

5.59

60 min
into
Typical fasting
OGTT plasma insulin
(mM)
(pM)

228

229

1868

849

Typical fasting
plasma
triglyceride (mM)

7.58

—

Islet pathology
Irregular islets, β-cell
vacuolation and
apoptosis. Reduced
insulin granulation.
Islet hypertrophy with
some fibrosis and
occasional inflammatory
infiltration of islets.

Note: TTDM, type 2 diabetes mellitus; OGTT, oral glucose tolerance test; ZF,
Zucker fatty; ZDF, Zucker diabetic fatty.

Table 1 elucidates the various rodent models available in market that were
generated by spontaneously mutated genes and induced to develop T2DM. The ZDF
rat is a rodent model of NIDDM which shows a predictable progression of the disease
from prediabetic to diabetic state. The ZDF rat carries a mutation in the gene coding
leptin receptor (fa/fa) in addition to a mutation that leads to spontaneous hyperglycemia
at 7 to 10 weeks of age in males [204]. Female rats tend to become hyperglycemic only
when fed a diabetogenic diet, with this additional mutation still unidentified [205]. Rats
expressing fa/- genotype are lean and do not develop hyperglycemia. Leptin is a
hormone that controls feeding behavior and a mutation in the leptin receptor results in
obesity.
I used the male ZDF model to assess some of the key signaling events in the
regulation of insulin secretion and thus may provide an understanding in the
pathogenesis of diabetes characterized by defective insulin secretion. Changes in
protein expression were also evident in islets from diabetic ZDF rats compared with
age-matched lean control animals. Following the onset of diabetes, insulin secretion is
severely reduced. The islets appear hypertrophic and show degenerative changes. By

110

14 weeks, the islet faces severe degenerative changes leading to defective insulin
secretion, as the islet has to meet an increased secretory demand added to insulin
resistance, in response to sustained, raised glucose levels. And there is also a loss in
reserve pool due to inadequate repletion [206, 207].
Expression profile of membrane trafficking proteins under diabetic conditions
In another study, we quantitated protein expression of Arf6, ARNO, PLD1 and
actin in islets of both ZDF and diabetic human [Figure 5-3]. The expression levels of
the indicated proteins were significantly increased compared to the normal phenotype.
A study from Rutter’s laboratory published evidence for a functional and gene profiling
analysis of proteins that might be responsible for defective GSIS from ZDF rat islets
[208]. Microarray analyses of several “glucose-sensing” and exocytotic genes were
significantly altered in ZDF islets. They also saw marked changes in expression of
proteins involved in regulation of vesicle traffic and exocytosis. Another set of key
players, notably the actin remodelers like gelsolin, actin and scinderin were upregulated
in ZDF islets [208].

Lean
Ctrl 1

Lean
Ctrl 2

ZDF 1

ZDF 2
ARNO
PLD1
Actin
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Actin

Figure 5-3: Increased expression of membrane trafficking proteins in ZDF rat and
T2D islets compared to respective control
Islets from ZLC or ZDF rats were lysed using RIPA buffer. Equal amount of lysate
proteins were resolved by SDS-PAGE. Expression of phosphorylated and total cofilin
was determined by Western blotting. A representative blot is provided in Figure 5-3 A
and B for ZDF and TDM islets.
In line with these studies and our own findings on cofilin, a marker used for actin
remodeling, we investigated the activation of cofilin in ZDF and diabetic human islets.
Apart from a significant increase in expression levels of both actin and cofilin under
diabetic conditions, the phosphorylation of cofilin was upregulated [Figure 5-4]. This
indicated that actin remodeling might be impaired under beta-cell dysfunction
contributing to impaired insulin secretion.
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Figure 5-4: Increased expression and phosphorylation of cofilin in ZDF rat and
T2D islets compared to respective control
Islets from ZLC or ZDF rats were lysed using RIPA buffer. Equal amount of lysate
proteins were resolved by SDS-PAGE. Expression of phosphorylated and total cofilin
was determined by Western blotting. A representative blot is provided in Figure 5-4 A
and B for ZDF and TDM islets.
Thus, emerging evidence that hyperglycemia leaves an imprint to the
development of future complications has potential therapeutic applications. All these
evidences suggest that ‘glucotoxic memory’ persists even after good glycemic control is
achieved. This evidently calls for early therapeutic treatment of hyperglycemia from
diabetes, a strategy that may benefit T1DM with concerns of early insulin use in T2DM
subjects.
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Chapter 6
DISCUSSION
Metabolic coupling factors generated by glucose and hormones play a regulatory
role in insulin exocytosis. A rise in intracellular calcium followed by an increase in
ATP/ADP ratio is an important trigger for exocytosis. Ca2+ mediated action is mediated
via calcium sensors like synaptotagmins and exocytosis takes place at proximity to
voltage-dependent Ca2+ channels. SNARE complex formation aided by its chaperones
NSF and CSP is essential for exocytosis. Insulin exocytosis is also sensitive to GTP and
major exploratory work has been done to understand the organization of its reputed
targets, small monomeric and heterotrimeric G-proteins. In this study, I have described
a role for Arf6/ARNO in stimulated secretion of insulin from pancreatic beta cells. As
stated in the Introduction, small G-protein Arf6 and its exchange factor ARNO play a key
regulatory in stimulated-insulin secretion. This cascade involves Rho family proteins,
lipid-modifying enzymes and actin-severing protein.
One of the main objectives of my doctoral work was to elucidate a role for
Arf6/ARNO in GSIS and identify putative effectors for the pair in the cascade leading to
insulin secretion. These studies were based on the overall hypothesis that ARNOmediated activation of Arf6 is necessary to activate downstream effectors in the
signaling cascade that primes insulin granules and remodels actin cytoskeleton. To
address this, I have used clonal pancreatic beta cells [INS 832/13 cells] and rat islets. I
have quantitated several indices both biochemical and molecular biological aspects to
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validate the above hypothesis. The use of pharmacological tools aided in validating the
hypothesis.
In over the years, Arf family of G-proteins has been traditionally portrayed to play
key regulatory roles in membrane trafficking [95]. From among a family of six, only Arf1
and Arf6 are well-explored and have been implicated to regulate several cellular events
including cell motility, vesicular transport, and cortical actin rearrangements [97, 127,
143]. Arf1, is best characterized as a recruiter from cytosol to Golgi complex. At the
Golgi it mediates binding of coat proteins and adaptins to Golgi membranes. But recent
work has shown Arf6 to play distinct functions in eukaryotes. In contrast to Arf1 which is
restricted to Golgi, Arf6 is majorly associated with secretory granules and plasma
membrane. Apart from playing a role in granule translocation, Arf6 also serves to
modulate actin cytoskeleton. In view of early investigations to test functions of Arf family
in regulated-exocytosis, Arf6 is the most-famed participant. Our localization studies
remain on par with findings described in chromaffin cell, a model neuroendocrine cell for
regulated-secretion [120].
On examining localization data of Arf6, it was predominantly associated with
membrane fraction and on further separation into various cellular compartments, Arf6
was majorly associated with secretory granules. In chromaffin cells, secretory granulebound Arf6 was found to associate with plasma membrane on stimulation. And this
substantiates the involvement of the protein in intracellular vesicle trafficking.
Key to our understanding of Arf6 function in insulin exocytosis will be regulatory
factors that activate the protein. One important regulatory factor for Arf6 is the GEF,
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ARNO. In our study we report the presence of ARNO, predominantly localized in the
cytosol. To show that they are hydrophilic proteins we performed phase partitioning
experiment with Triton-X 114 as integral membrane proteins separate out in the
hydrophobic detergent phase. In the present study we demonstrated that ARNO might
subserve the function of a GEF for Arf6 in the islet β-cell. There are enough reports for
the involvement of this small G-protein in regulated secretion in chromaffin cells as well
as in MIN6, another clonal pancreatic beta cell.
To confirm their involvement in GSIS, dominant negative mutants [inactive
conformations] of these proteins were overexpressed and its effect on GSIS was
quantitated. To add more weightage to the above data, endogenous expression of both
Arf6/ARNO was silenced and GSIS was quantitated. Data accrued from insulin
secretion studies, indicated a positive modulatory for Arf6/ARNO in GSIS. We further
wanted to test if Arf6/ARNO modulated K+-stimulated insulin secretion. We transfected
cells with siRNA-ARNO and found that K+-stimulated insulin secretion was reduced by
~60%. Though glucose is a major insulin secretagogue, there are other nutrients like
amino acids which potentiate GSIS. A detailed study on the dose- and glucosedependent effects of amino acids on insulin secretion made us to question if Arf6/ARNO
played a role in amino-acid potentiated GSIS. We tested this hypothesis using siRNAs
of both Arf6 and ARNO and found that they attenuated L-arginine potentiated GSIS. All
the above evidence corroborated the involvement of Arf6/ARNO in regulated-insulin
secretion.
The next step in the project was only apt to determine the time-course
dependence of glucose-stimulated activation of Arf6. With recent advances in molecular
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biology, we were able to study the time kinetics of Arf6 activation in pancreatic beta
cells. We employed GST-GGA3 beads in a pull-down assay, which essentially
recognizes only active form of Arf6 [Arf6-GTP]. Glucose stimulation at multiple timepoints starting from 0-30 min indicated a constitutive activation of Arf6. Surprisingly, K+
stimulation also activated the protein unlike other G-proteins.
We also demonstrated that ARNO is one of the regulatory factors for glucosemediated activation of Arf6 using pharmacological and gene-silencing tools.

Figure 6-1. Structural representation of secinH3 with binding element that binds to
cytohesin sec-7 domain [134].
Until very recently, only one small-molecule inhibitor, brefeldin A, an inhibitor of Arf
GDP/GTP exchange, was available. But it was found brefeldin A was not sensitive
towards cytohesins. The availability of secinH3, a novel small-molecule inhibitor of
cytohesins, made it easy to dissect the role of ARNO. Above is the chemical structure of
secinH3 designed by Famulok group [134]. SecinH3 gets its name for its high affinity to
the functional domain of cytohesins, sec7. When used in mice, flies and human liver
cells, it impaired Arf6/ARNO signaling pathway. In their paper describing synthesis and
application for secinH3, they tested the selectivity of the inhibitor and found it to be
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highly selective for cytohesin family with minimal or no effects against other Arf family of
GEFs or other GTPases [134]. Hafner utilized the compound to study the role of
Arf6/ARNO in insulin signaling pathway. It further substantiated the potential of secinH3
to inhbit ARNO-mediated activation of Arf6 [107].
We found that GTP-bound Arf6 upon glucose stimulation was significantly
reduced when functional role of ARNO was compromised.
Salient features of our study are:
I.

Arf6/ARNO is expressed in clonal β-cells, rodent islets and human islets

II.

Overexpression of inactive mutants of ARNO or Arf6 or siRNAs of Arf6 or ARNO
reduces insulin secretion elicited by glucose, arginine and KCl in insulin-secreting
cells

III.

SecinH3, a selective inhibitor of ARNO/Arf6 signaling pathway, also inhibits GSIS
in INS 832/13 cells and rodent islets

IV.

Insulinotropic concentration of glucose/KCl stimulates Arf6 activation

V.

Glucose-induced Arf6 activation is inhibited by secinH3 or siRNA-ARNO,
suggesting a critical involvement of ARNO/Arf6 in insulin secretion and

VI.

Glucose promotes association between ARNO and Arf6 as evidenced by coimmunoprecipitation and confocal microscopic studies.

These findings provide the first evidence to implicate novel roles for Arf6/ARNO in
insulin secretion.
2. What are the potential effectors of Arf6/ARNO signaling pathway?
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Over decades, research has progressed to understand signal transduction
involved with insulin secretion. And over the course, new proteins have been discovered
and many pathways have been built. So far, we had worked on establishing a role for
Arf6/ARNO in regulating stimulated-insulin secretion. Now we were interested in
identifying downstream effectors in this signaling cascade. We studied the effects of
compromised Arf6/ARNO on the activity of putative targets. Our first target was
nm23H1, a tumor suppressor, whose function is to provide a localized supply of GTP.
But its role as a regulator of heterotrimeric GTP-binding proteins gained much
importance [209]. In 1979, Kimura and Nagata showed that NDP kinase
transphospatidylated GDP to GTP thus aiding in hormonal activation of adenylyl cyclase
[210]. The GTP-supply of nm23H1 operated by NDP kinase serves to maintain maximal
activation of G-protein coupled signaling. The idea that nm23H1 could act as a localized
GEF for Arf6 was interesting. In support of this, Randazzo PA examined potential
substrates for NDP kinase activity. They examined the nucleotide exchange activity of
NDP kinase on purified Arf [211]. So I investigated if knockdown of Nm23H1 affected
the status of GTP-bound Arf6. Data obtained from this study indicated a positive role for
Nm23H1 in maintaining active form of Arf6.
Next in my line of targets were the famed Rho class of G-proteins, Cdc42 and
Rac1. Several laboratories have contributed the current understanding of Rho GTPases
in insulin secretion. In particular, Cdc42 and Rac1 have been characterized in insulinsecreting cells and their functional importances have been established. Time kinetics for
glucose-induced activation of both proteins has been demonstrated. It is a wellestablished fact that both Cdc42/Rac1 work together to cause insulin secretion upon
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glucose stimulation. A study from Thurmond’s laboratory serves as evidence to suggest
involvement of active Cdc42 in cytoskeletal rearrangement [139]. Using gene-silencing
methodology, they showed glucose-mediated sequential activation of Cdc42 to PAK1 to
Rac1 in insulin secretion. Using Clostridium difficle toxins, Kowluru et al., demonstrated
a potential role for Rac1 in GSIS [212]. Further on, several studies were documented to
define essential roles for Rac1. Both Cdc42 and Rac1 may be essential for regulating
actin dynamics in phase of secretion. There are many regulatory factors like GEFs and
GAPs. But what was the upstream signal that was required to activate these proteins?
Studies done in primary human fibroblast cells clearly indicated an enhancing role of
Arf6 on Rac1 in actin remodeling [213]. Soon, several other studies followed suit to
indicate a regulatory role for Arf6 on activation of Rac1. In HeLa and CHO cells, Arf6
influenced the redistribution of Rac1 from endosomes to cell periphery [213, 214]. An
Arf6-dependent was also shown to be essential for polarized recruitment and activation
of Cdc42 in astrocytes [215]. Another group demonstrated a role for active Arf1 to bind
GAP of Cdc42 thus enabling it be activated by its GEF [216]. All the above evidences
urged us to investigate if Arf6 had a regulatory hold on Cdc42/Rac1. Cells treated with
secinH3 or transfected with siRNA-ARNO showed a reduction in GTP-bound forms of
Cdc42/Rac1. These data indicated ARNO-activated Arf6 is an important upstream
signal for the activation of Cdc42/Rac1.
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Arf6/ARNO has been shown to activate several lipid-modifying enzymes like
PI4P-5K and PLD to generate fusogenic lipids. The generated lipids aid in activating
downstream effectors or in preparing the plasma membrane for fusion process [217,
218].

Figure 6-2: An illustration to represent Arf6/ARNO-regulated membrane trafficking and
actin rearrangement for secretion of vesicles in chromaffin cells [219].
Earlier observations also demonstrated potential involvement of PLD activation in the
signaling mechanisms leading to GSIS [220, 221]. More recent findings by Ma and
coworkers further implicated Arf6 in glucose-induced PLD activation in MIN6N8 cells,
which suggested binding of Arf6 to PLD. Furthermore, brefeldin A, a known inhibitor of
Arf6, decreased glucose-induced PLD activity and insulin secretion [147]. So when I
investigated the effect of secinH3 on PLD activity, we found its activity to be reduced.
A growing body of evidence pointed towards glucose-induced activation of
ERK1/2 mediated via G-protein activation. Evidence from my own lab established a
farnesylation-dependent signaling that leads to ERK1/2 activation in insulin secreting
cells. And also several reports suggesting an Arf6-regulated activation of ERK1/2 [144,
222] led us to investigate effect of secinH3 on activation of ERK1/2. SecinH3 was found
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to inhibit the phosphorylation of ERK1/2 via glucose stimulation. This placed ERK/12 as
a downstream effector of ARNO/Arf6 in the signaling cascade leading to insulin
secretion. Whether Arf6/ARNO is a direct mediator of ERK1/2 activation needs to be
investigated.
Investigation of prenylation roles in Nox activation suggested a role for Rac1GTP in generation of ROS. And to test if Arf6/ARNO played a role in Rac1-mediated
activation of Nox and generation of ROS, we used secinH3 and quantitated ROS
generation. My findings provided in this document suggest a clear role for Arf6/ARNO
mediated induction of ROS generation in both clonal pancreatic beta cells and rat islets.
Several published reports indicated a role for small G-proteins, lipid-modifying enzymes,
certain kinases and also ROS to bring about cytoskeletal remodeling in a stimulated
cell.

Figure 6-3: An illustration to represent regulatory factors that govern the activity of
cofilin [223].
Arf6/ARNO by itself has been reported to act as actin remodeling agents. It is
without doubt that breakdown of actin barrier is essential for insulin release. One among
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the several actin-binding proteins, cofilin, was investigated in this aspect. Cofilin severs
actin filaments by binding to F-actin and stabilizes the twisted filament [224].
Cofilin activity is regulated by dephosphorylation/phosphorylaton at Ser3 [225].
Phosphorylation of cofilin does not confer any changes in protein conformation rather
generates a charge repulsion that prohibits it from binding actin [226].

Figure 6-3: An illustration to represent activity of cofilin as an actin-severing agent,
promoting F-actin remodeling [223].

Phosphorylation of cofilin is regulated by LIMK, which lie downstream to RhoGTPases as seen in the illustration. Dephosphorylation is controlled by a phosphatase,
specific to cofilin, slingshot. Glucose-induced dephosphorylation of cofilin activated the
protein to severe actin filaments. Treatment of INS 832/13 cells with secinH3 attenuated
dephosphorylation of cofilin via glucose.
Having examined the exocytotic partners in insulin release, we tested if
Arf6/ARNO played any role in endocytotic pathway as implicated in other cell types. In
several cases, literature has demonstrated a large GTPase, dynamin, to be a major
mediator of endocytosis. Recurring evidence suggested active dynamin to aid in
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recycling of secretory vesicles after insulin release. A report published in Nature
depicted an Arf6-regulated role of dynamin in endocytosis. It is likely that active Arf6
regulated phosphorylation/dephosphorylation cycle of dynamin. This was confirmed with
the use of secinH3 which inhibited dephosphorylation of dynamin.
Several earlier studies have implicated activation of small G-proteins (e.g., Arf6,
Cdc42 and Rac1) in physiological insulin secretion. Such conclusions were drawn from
studies involving the use of Clostridial toxins, dominant negative mutants, siRNAs and
inhibitors of post-translational modifications, including prenylation, carboxymethylation
and palmitoylation [140]. To the best of our knowledge, the current study provides the
first evidence to implicate carboxymethylation of Rac1 in the signaling cascade leading
to glucose-induced ROS generation and insulin secretion. We have presented
supporting evidence via two distinct approaches, namely siRNA-mediated knockdown
or selective pharmacological inhibition of ICMT, which mediates the carboxymethylation
of these signaling proteins.
At least two distinct carboxylmethyl transferases have been identified in insulin
secreting cells. The first one is involved in methylating the carboxy terminal leucine
(Leu-309) of the catalytic subunit of protein phosphatase 2A; such a signaling step has
been implicated in subunit interaction and catalytic activation of the enzyme [227]. The
second enzyme, which is the focus of the current study, is the ICMT. In a previous
study, Li and associates characterized the ICMT in insulin-secreting cells and normal rat
islets [182]. Such an activity was monitored by quantitating the degree of methylation of
AFC by the islet ICMT in the presence of [3H] S-adenosylmethionine as the methyl
donor. Subcellular fraction assays revealed that this enzyme activity is enriched in the
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endoplasmic reticulum [182] Along these lines, using the pharmacological approaches,
we have demonstrated that glucose promotes the carboxymethylation of Cdc42,
another small G-protein involved in cytoskeletal remodeling and glucose-stimulated
insulin secretion [75]. It was also demonstrated that the Gγ-subunits also undergo
carboxymethylation in a glucose-sensitive manner in clonal β-cells, normal rat islets and
human islets [77]. Not much has been reported since then with regard to potential
functional consequences of carboxymethylation in islet function primarily due to lack of
experimental tools (e.g., siRNA) to selectively deplete the expression of ICMT in
isolated β-cells. Indeed, data from the current investigation further reinforce our original
hypothesis that in addition to prenylation, carboxymethylation of specific G-proteins
(e.g., Rac1) plays regulatory roles in physiological insulin secretion. Such regulatory
effects may, in part, be due to the ability of methylated Rac1 to increase the activation
of Nox and associated generation of reactive oxygen species.
Data accrued in the current studies implicate carboxymethylation as one of the
requisite signaling steps for glucose-induced activation by Rac1 in a stimulated β-cell.
Moreover, the carboxymethylation of Rac1 appears to be necessary for glucoseinduced Nox activation and generation of reactive oxygen species. In this context, using
reconstituted systems and the C-terminal Rac1 peptides, Kreck and coworkers have
provided experimental support to implicate participatory roles for Rac1 in cell-free
activation and assembly of NADPH-oxidase [228]. Compatible with these findings are
our recent data to implicate inhibition of glucose- or mitochondrial-fuel-induced Nox
activation and generation of reactive oxygen species in INS 832/13 cells and normal rat
islets by inhibitors of protein prenylation. These studies thus provided evidence for
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requisite roles for prenylation in the functional regulation of Nox in the islet β-cell [158].
Data from the current investigation indicate that in addition to prenylation, the
carboxymethylation of specific G-proteins may be necessary for optimal regulation of
Nox by

glucose.

More

importantly,

my

current

findings

also

suggest

that

carboxymethylation is necessary for glucose-induced activation of Rac1, since
pretreatment of isolated β-cells with AFC or selective depletion of ICMT by siRNA
markedly attenuated glucose-induced Rac1 activation. These findings are in agreement
with recent findings of Cushman and Casey demonstrating inhibition of EGF-induced
Rho A and Rac1 activation by cysmethynil, a selective inhibitor of ICMT, in MDA-MD231 cells [229]. Together, based on the above discussion it is concluded that both
prenylation and carboxymethylation of Rac1 are necessary for glucose-induced Noxmediated ROS generation and insulin secretion. It is important to note that
palmitoylation of cysteine residues upstream to prenylated and carboxylmethylated
Rac1 may not be involved in this signaling cascade at least based on recent studies
from Roberts and associates who reported no known consensus palmitoylation motifs
for Rac1 [230] although this remains to verified experimentally in the islet β-cell.
Emerging evidence appears to implicate a significant contributory role for Nox in
the generation of oxidative stress and the onset of mitochondrial dysfunction in multiple
cell types, including the islet β-cell. For example, it has been shown that chronic
exposure of isolated β-cells to high concentrations of saturated fatty acids (e.g.,
palmitate; lipotoxicity), glucose (i.e., glucotoxicity) or both (i.e., glucolipotoxicity) or a
mixture of cytokines (e.g., IL-1β, TNFα and IFNγ) culminates in increased oxidative
stress, mitochondrial dysfunction and apoptosis in these cells [231-233]. Inhibition of
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protein prenylation of Rac1 by pharmacological approaches (e.g., GGTI-2147) or Rac1
activation by Tiam1, a known guanine nucleotide exchange factor for Rac1 (using
NSC23766) markedly attenuated metabolic dysfunction of the β-cell [232, 233]. Along
these lines, data described herein suggest a significant increase in the expression of
ICMT under glucolipotoxic conditions. It remains to be verified if such an increase in the
expression translates into increased ICMT activity. Nonetheless, it may be likely that
use of selective inhibitors of carboxymethylation might prove to be valuable in
preventing oxidative stress induced under the duress of glucolipotoxicity and/or
cytokines.

These are being studied in our laboratory currently. Based on the data

accrued in the current studies we conclude that ICMT regulates glucose-induced Rac1
activation, generation of reactive oxygen species and insulin secretion in pancreatic βcells.
Synchronized with obesity epidemic, the incidence of T2DM is also increasing at
an alarming rate. T2DM results from a failure of endocrine pancreas to secrete sufficient
insulin to meet the metabolic demands due to acquired dysfunction of beta-cells along
with decreasing beta-cell mass. Whether or not insulin secretory dysfunction is a cause
for the dysfunction, beta-cell loss seems to play an important role in the pathogenesis of
T2DM. As seen in obese individuals who do not develop diabetes exhibit an increase in
beta-cell mass and a compensatory mechanism for the metabolic load. This very same
beta-cell adaptation seems to have failed in obese individuals who developed T2DM.
Several defects in insulin secretion are well documented in human T2DM; however the
role in the pathogenesis and the possible clinical relevance of high frequency rapid
pulsatile insulin secretion is still unclear. Chronic elevation of FFA and glucose has
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been implicated to cause beta-cell dysfunction. Whereas acute exposure of beta-cells to
FFA has been shown to stimulate insulin secretion, chronic exposure to FFA inhibits
insulin secretion. Chronic elevation of blood glucose concentration impairs beta-cell
function largely due to activation of oxidative stress and increased generation of ROS.
Both conditions of gluco- and lipotoxicity attenuate GSIS in addition to downregulation
of diverse groups of genes that are responsible for insulin biosynthesis and processing.
In addition to the above factors that have been established in the progression to
T2DM, several observations have suggested significant abnormalities in various
intracellular signals that contribute to defective insulin secretion in G-protein knockout
animal models. One example of this is the Rac1-null mice [βRac1-/- mice] were an
impaired glucose tolerance and hypoinsulinemia was noticed [234]. This observation
was in concordance with the in vitro studies in cultured beta-cells where GSIS was
attenuated when function of Rac1 was compromised. In addition to its positive
modulatory roles, Rac1 has been observed to negatively modulate metabolic
dysfunction of beta-cells by participating in the generation of ROS. Numerous
observations from our laboratory have demonstrated a role for Tiam1/Rac1/Nox
signaling in beta-cell dysregulation under the duress of glucolipotoxicity. Both the
activity and expression of Rac1 were increased in ZDF islets and in human islets
exposed to glucotoxicity.
Using the animal model Goto-Kakizaki [GK] rat, Metz et al reported that insulin
secretory defects were due to a defect late in the signal transduction leading to
exocytosis and not due to levels of insulin found in the cell. And the secretory defect
was corrected by the use of Mastoparan [Mas] proved that a G-protein involved in
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exocytosis was responsible for the abnormality [235]. Another group used galparan to
stimulate insulin secretion from islets derived from GK rat. They found galparan to
stimulate secretion of insulin at a distal in stimulus-secretion [236]. Systematic
approach to identify more G-proteins that are compromised during diabetic condtions
need to be identified.
Pancreatic beta-cell failure, starts early and progresses to T2DM, is a
phenomenon that determines the progression from impaired glucose tolerance to overt
diabetes. It has been demonstrated that a dysfunction in secretory process in ZDF islets
is a result of altered expression of wide variety of genes. It includes both key factors
involved in glucose-sensing and vesicle trafficking events. Data from G-protein knockout
animal models definitely are promising and encourage the idea that G-protein signaling
play an important role in insulin secretion and maintain optimal beta-cell mass.
Additionally, evaluation of post-translational modifications and their enzymes need to be
studied on the same importance as their substrate, small G-proteins. Posttranslational
modifications have been an indispensable feature to for translocation or for membrane
targeting. Roberts et al. provided sufficient evidence in favor of posttranslational
modifications such as CAAX motif and methyltransferase [237]. Future studies,
involving a systematic assessment of the above targets under diabetic conditions will be
necessary to delineate their contribution to the secretory phenotype.
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Chapter 7
Conclusions and Future directions
On a concluding note, the vast expanse of research to understand the regulatory
roles of small G-proteins has seen tremendous progress since early ‘90s. A review of
the presented data and published evidence from multiple laboratories indicates a
significant role for Arf6 in regulating GSIS from the pancreatic beta-cell. This is
confirmed in a wide variety of insulin-secreting cells including clonal beta-cells, rat,
mouse and human islets. As an added step, the regulatory factor GEF-ARNO for Arf6,
has been implicated in modulating its activity upon stimulation. Herein, based on all the
above evidences, I built a working model [Figure 7-1], for ARNO/Arf6 signaling cascade
in the events leading insulin secretion with the probable key molecules [PLD, ERK1/2,
Rac1, Nox, dynamin-1 and cofilin]. Apart from the regulatory factors for the small Gproteins, I have determined posttranslational modification i.e., carboxylmethylation, on
the activity of Rac1 and its role in insulin release and generation of ROS.
Future studies in light of the presented data will involve:
1. Identifying whether PLD is upstream/downstream to ERK1/2
2. What are the possible posttranslational modifications Arf6 undergoes in the event
of insulin secretion.
3. Does PLD regulate activity of dynamin-1?
4. Determine the molecular events after exocytosis and how nm23H1/Arf6/dynamin1 regulate the recycling of vesicles after secretion.
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Figure 7-1: Working model placing all the key players in the event leading to exoendocytosis of insulin-laden secretory granules.
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Glucose-stimulated insulin secretion [GSIS] involves interplay between small G-proteins and their
regulatory factors. Herein, we tested the hypothesis that Arf nucleotide binding site opener [ARNO], a
guanine nucleotide-exchange factor [GEF] for the small G-protein Arf6, mediates the functional
activation of Arf6, and that ARNO/Arf6 signaling axis, in turn, controls the activation of Cdc42 and Rac1,
which have been implicated in GSIS. Molecular biological [i.e., expression of inactive mutants or siRNA]
and pharmacological approaches were employed to assess the roles for ARNO/Arf6 signaling pathway in
insulin secretion in normal rat islets and INS 832/13 cells. Degrees of activation of Arf6 and Cdc42/Rac1
were quantitated by GST-GGA3 and PAK-1 kinase pull-down assays, respectively. ARNO is expressed in
INS 832/13 cells, rat islets and human islets. Expression of inactive mutants of Arf6 [Arf6-T27N] or ARNO
[ARNO-E156K] or siRNA-ARNO markedly reduced GSIS in isolated b-cells. SecinH3, a selective inhibitor
of ARNO/Arf6 signaling axis, also inhibited GSIS in INS 832/13 cells and rat islets. Stimulatory
concentrations of glucose promoted Arf6 activation, which was inhibited by secinH3 or siRNA-ARNO,
suggesting that ARNO/Arf6 signaling cascade is necessary for GSIS. SecinH3 or siRNA-ARNO also
inhibited glucose-induced activation of Cdc42 and Rac1 suggesting that ARNO/Arf6 might be upstream
to Cdc42 and Rac1 activation steps, which are necessary for GSIS. Lastly, co-immunoprecipitation and
confocal microscopic studies suggested increased association between Arf6 and ARNO in glucosestimulated b-cells. These ﬁndings provide the ﬁrst evidence to implicate ARNO in the sequential
activation of Arf6, Cdc42 and Rac1 culminating in GSIS.
Published by Elsevier Inc.
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1. Introduction
It is widely accepted that small G-proteins regulate various
cellular functions including proliferation, survival and demise. At
least four major classes of small G-proteins have been identiﬁed in
the pancreatic b-cell. These include the Ras, Rho, Rab and ADPribosylation factor [Arf] family of G-proteins [1], of which Arf
family of G-proteins is less studied in the islet. Though originally
identiﬁed as an ADP-ribosylator for cholera toxin, Arf has gained
much importance as a critical modulator of membrane trafﬁc in
eukaryotic cells. Among the six members of the Arf family, Arf6 is a
well-documented protein for its positive modulatory roles in

Abbreviations: Arf6, ADP-ribosylation factor 6; ARNO, Arf nucleotide binding site
opener; GAP, GTPase activating protein; GDI, GDP-dissociation inhibitor; GEF,
guanine nucleotide-exchange factor; GGA3, Golgi-localized c-ear homology domain
Arf-binding protein-3; GSIS, glucose-stimulated insulin secretion; PA, phosphatidic
acid; PIP2, phosphatidylinositol-4,5-bisphosphate; PLD, phospholipase-D.
* Corresponding author. Tel.: +1 313 576 4478; fax: +1 313 576 1112.
E-mail address: akowluru@med.wayne.edu (A. Kowluru).
0006-2952/$ – see front matter . Published by Elsevier Inc.
doi:10.1016/j.bcp.2011.01.006

multiple cell types including regulation of various effector proteins
[e.g., phospholipase-D; PLD] and trafﬁcking of secretory granules
to the plasma membrane for exocytosis [2]. Regazzi and coworkers
ﬁrst described localization and regulation of Arfs in insulinsecreting RINm5f cells [3,4]. More recently, Lawrence and
Birnbaum have demonstrated regulatory roles for Arf6 in insulin
secretion mediated by glucose, GTPgS and membrane depolarization. They further demonstrated that Arf6 regulates insulin
secretion by maintaining plasma membrane phosphatidylinositol-4,5-bisphosphate (PIP2; [5]). Existing evidence also supports a
potential role for PLD in physiological insulin secretion [6–8].
Arf6 cycles between the GDP-bound [inactive] and GTP-bound
[active] conﬁgurations; which are tightly regulated by two distinct
classes of regulatory factors namely the GTPase activating proteins
[GAPs] and the GTP/GDP exchange factors (GEFs; [9,10]). GAPs
inactivate Arf6 by promoting its conversion to the inactive GDPbound form, while GEFs facilitate its activation. The GEF activity is
a rate-deﬁning step and involves coordination of multiple
intracellular signals. In this context, many GEFs with distinct size
and structure have been identiﬁed for Arf6 [11–16]. However, in
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the majority of the signaling events, only one member belonging to
the cytohesin family has been closely linked to activate Arf6
[13,14,17,18]. Recently, Hafner et al. reported a small molecule
inhibitor, secinH3, which selectively blocks ARNO-mediated
activation of Arf6 [19]. Previous studies have utilized secinH3 to
determine the regulatory roles for ARNO/Arf6 signaling in cellular
signal transduction [20,21].
In an attempt to identify precise regulatory mechanisms
involved in glucose-mediated activation of Rac1 and insulin
secretion, we ﬁrst proposed [22] and subsequently conﬁrmed
experimentally [23] that certain biologically active lipid second
messengers [e.g., PA, PIP2] promote dissociation of Rac1 from Rac1/
GDI complex to facilitate activation of Rac1 in rodent islets and
clonal b-cells. Therein, we also proposed that Arf6 could represent
one of the upstream regulators of Rac1 activation by generating
relevant lipid second messengers via phospholipase activation to
dissociate the Rac1/GDI complex [22,23]. Studies from Thurmond’s
laboratory have demonstrated the requirement of Cdc42, a Rho
family GTPase in the Rac1 activation process for actin remodeling
and insulin exocytosis [24,25]. The current study is undertaken to
test the hypothesis that ARNO mediates sequential activation of
Arf6, Cdc42 and Rac1 leading to GSIS. Using molecular biological
and pharmacological approaches we provide below the ﬁrst
evidence to in support of this hypothesis in normal rodent islets
and insulin-secreting INS 832/13 cells.
2. Materials and methods
2.1. Materials
SecinH3 was from Tocris Biosciences [Ellisville, MO]. siRNAArf6 consisting of pools of three to ﬁve target-speciﬁc 19–25 nt
siRNAs were from Santa Cruz Biotechnology [Santa Cruz, CA].
siRNA-ARNO was from Dharmacon [Lafayette, IL]. The rat insulin
ELISA kit was from American Laboratory Products [Windham, NH].
Antisera directed against Arf6, ARNO and Dbl were from Santa Cruz
Biotechnology [Santa Cruz, CA]. Cdc42 and Rac1 antisera were from
BD Biosciences [San Jose, CA]. Cdc42 and Rac1 activation kits were
from Cytoskeleton Inc. [Denver, CO]. Arf6 activation assay kit and
the Classic Co-IP kit were from PIERCE [Rockford, IL]. Alexa-ﬂuor
secondary antibody was from Invitrogen Molecular Probes
[Carlsbad, CA]. All other reagents used in these studies were from
Sigma Aldrich Co. [St. Louis, MO] unless stated otherwise.
2.2. Insulin-secreting INS 832/13 cells, rat islets and human islets
INS 832/13 cells were kindly provided by Dr. Chris Newgard
(Duke University Medical Center, Durham, NC). The cells were
cultured in RPMI 1640 medium containing 10% heat-inactivated
fetal bovine serum supplemented with 100 IU/ml penicillin and
100 IU/ml streptomycin, 1 mM sodium pyruvate, 50 mM 2mercaptoethanol, 11 mM glucose, and 10 mM HEPES (pH 7.4).
Islets were isolated from pancreas of male Sprague–Dawley rats
(Harlan Laboratories, Oxford, MI), using collagenase digestion and
a ﬁcoll gradient as we described previously [22]. All experiments
were reviewed and approved by the Wayne State University
Institutional Animal Care and Use Committee. Human pancreatic
islet lysates were kindly provided by Dr. Karl Olson [Michigan State
University, Lansing, MI].
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Brieﬂy, about 400 mg of cell [INS 832/13 cell or islet] homogenate
protein, prepared in 400 ml of buffer (20 mM Tris–HCl, pH 7.5,
0.5 mM EGTA, 2 mM MgCl2, 10 mg/ml leupeptin, and 2 mg/ml
aprotinin), supplemented with 1% (w/v) Triton X-114 was overlaid
on 400 ml sucrose cushion 6% (w/v) prepared in 20 mM Tris–HCl
buffer (pH 7.4) containing 0.06% (w/v) Triton X-114. Following
brief incubation at 30 8C, samples were centrifuged at 300  g for
3 min and the aqueous phase was mixed with 0.5% (w/v) fresh
Triton X-114 at 4 8C. Following dissolution, the mixture was again
overlaid on the same sucrose cushion, incubated for 3 min at 30 8C
and centrifuged at 300  g for 3 min. The lower hydrophobic phase
was diluted to a ﬁnal volume of 400 ml with homogenization
buffer, while the aqueous phase was transferred into a separate
tube supplemented with 2% fresh Triton X-114, incubated for
3 min at 30 8C, and centrifuged at 300  g without sucrose cushion.
The supernatant obtained thereof served as total hydrophilic
phase. The relative abundance of ARNO in hydrophilic and
hydrophobic phases was determined by Western blotting.
2.4. Transfection of Arf6 or ARNO mutants and siRNAs
INS 832/13 cells were subcultured at 50–60% conﬂuency and
transfected using Effectene [Qiagen, Valencia, CA], with 0.2 mg of
plasmid DNA constructs against either dominant-negative of Arf6
[T27N] or ARNO [E156K] per well of a 24-well plate. Endogenous
Arf6 or ARNO expression was depleted by transfecting cells using
small interfering RNA [siRNA; 100 nM] using HiPerfect transfection reagent [Qiagen, Valencia, CA]. Efﬁciency of mutant expression or protein knockdown was determined by Western blotting.
2.5. Insulin release studies
Arf6 or ARNO mutant or siRNA-transfected or secinH3
inhibitor-treated cells were cultured overnight in low serum
and low glucose containing medium and then stimulated either
with high glucose, KCl or arginine in Krebs–Ringer bicarbonate
buffer [KRB, pH 7.4] for different time intervals as indicated in the
text. In studies involving KCl-induced insulin secretion, we noticed
that INS 832/13 cells were not responsive to 40 mM KCl in
releasing insulin. However, higher KCl concentrations [60 mM]
were found to elicit robust insulin release. Therefore, in KClstimulated insulin secretion studies, cells were incubated with
60 mM KCl in an osmolarity-balanced KRB medium [5]. For
arginine [L-Arg]-stimulated insulin release, a stock solution was
prepared in TrisHCl [pH 7.4], and diluted to desired concentration
with KRB. The insulin released into the medium was quantitated by
ELISA [22].
2.6. Quantitation of Arf6GTP in pancreatic b-cells
Active Arf6 was quantitated by a pull-down assay. Brieﬂy, the
incubation medium was aspirated and cells were washed with icecold PBS. Cells were lysed with 500 ml lysis buffer and the lysate
was clariﬁed by centrifugation at 16,000  g at 4 8C for 15 min and
incubated 400 mg protein with 100 ml of glutathione resin and
100 mg of GST-GGA3-PBD beads at 4 8C for 1 h with gentle rocking,
following which the reaction mixture was spun at 6000  g for
30 s. The GST-tagged beads were washed [3] and proteins were
separated by SDS-PAGE and activated Arf6 was identiﬁed by
Western blotting.

2.3. Hydrophilic and hydrophobic phase partitioning method using
Triton X-114

2.7. Quantitation of Cdc42 and Rac1 activation

Total hydrophobic and hydrophilic phases of lysates derived
from INS 832/13 cells and pancreatic islets were separated using
Triton X-114 according to method described earlier by us [22].

Relative degree of activated Cdc42 and Rac1 [i.e., GTP-bound
form] was determined by p21-activated kinase-p21-binding
domain pull-down assay as described in [22]. Brieﬂy, INS 832/
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13 cells treated with either diluent or secinH3 [50 mM] or cells
were either mock-transfected or transfected with ARNO-siRNA
were cultured overnight in low serum-low glucose media. Cells
were stimulated with either low [2.5 mM] or high [20 mM] glucose
for 3 or 30 min at 37 8C in the continued presence of either diluent
or secinH3 with respect to inhibitor studies. The GTP-bound forms
of Cdc42 and Rac1 in the pull-down samples were quantitated by
Western blotting and densitometry.
2.8. Co-immunoprecipitation studies
Immunoprecipitation studies were performed using the Classic
Co-IP kit as suggested by the manufacturer [26]. Brieﬂy, b-cell
lysates [500 mg protein] were incubated with anti-ARNO for 2 h at
4 8C followed by incubation with agarose resin for an additional 1 h
at 4 8C. Beads were washed; eluted using sample buffer and
proteins were resolved by SDS page to quantify Arf6.
2.9. Immunoﬂuorescence studies
INS 832/13 cells were plated onto coverslips and incubated
with [2.5 or 20 mM] glucose for 30 min at 37 8C followed by
washing in PBS and ﬁxed with 4% paraformaldehyde solution for
15 min at room temperature. They were then permeabilized with
0.2% Triton X-100 for 15 min at room temperature. After blocking
with 1% BSA for 1 h, the cells were further incubated with primary
antibodies Arf6 [1:150] and ARNO [1:150] in 0.1% BSA solution for
1 h. After extensive washes, the cells were further incubated with
secondary antibodies Alexa-ﬂuor 488 anti-mouse [1:1000] and
Alexa-ﬂuor anti-goat 546 [1:1000] in 0.1% BSA solution for 1 h at
37 8C. The coverslips were then mounted on glass slides containing
mounting media [DAKO Corporation, Carpinteria, CA] and visualized under a confocal LSM 510 microscope in the midplane using a
63 oil-immersion lens [26].
2.10. Statistical analyses
The statistical signiﬁcance of the difference between the
experimental conditions was determined by Student’s t-test
unless mentioned otherwise. p values <0.05 were considered
signiﬁcant.
3. Results
3.1. Distribution of ARNO in pancreatic b-cells
Data shown in Fig. 1A indicated that ARNO is expressed in
normal rat islets, human islets and INS 832/13 cells. The relative
abundance of ARNO in the total hydrophilic and hydrophobic
compartments [isolated from cell lysates using Triton X-114 phase
separation protocol; see Section 2] indicated that ARNO remains
associated with the hydrophilic compartment [Fig. 1B].
3.2. Molecular biological inhibition of Arf6 or ARNO attenuates insulin
release by various insulin secretagogues in INS 832/13 cells
We ﬁrst veriﬁed potential consequences of overexpression of
dominant negative mutants of Arf6 or ARNO on GSIS from INS 832/
13 cells. To examine this, INS 832/13 cells were either mocktransfected or transfected either with Arf6-T27N or ARNO-E156K
[see Section 2]. Transfection efﬁciency of mutants was veriﬁed by
Western blotting [Fig. 2A]. Insulin secretion was quantitated in
these cells in the presence of 2.5 or 20 mM glucose. Data in Fig. 2C
showed a marked reduction in GSIS in cells expressing Arf6-T27N.
Likewise, overexpression of ARNO-E156K, a mutant lacking the
GEF function, signiﬁcantly inhibited GSIS in these cells [Fig. 2D].

Fig. 1. Expression of ARNO in INS 832/13 cells, rat islets and human islets. Panel A:
lysates from rat islets, human islets and INS 832/13 cells were separated by SDSPAGE and probed for ARNO [48 kDa]. Panel B: hydrophilic [HPL] and hydrophobic
[HPB] phases of the homogenates from rat islets and INS 832/13 cells were isolated
using Triton X-114 partition technique [see Section 2 for additional details].
Proteins were separated by SDS-PAGE and probed for ARNO. A representative blot
from three independent experiments is shown here.

Together, these data suggested key roles for Arf6 and ARNO in
signaling events leading to GSIS. Next, we veriﬁed if knockdown of
endogenous Arf6 and ARNO by using siRNA affects insulin secretion
elicited by high glucose. We observed 50–60% reduction in the
expression of Arf6 or ARNO by Western blotting analysis [Fig. 2B].
Under these conditions, GSIS was signiﬁcantly inhibited in Arf6- and
ARNO-knocked-down cells [Fig. 2E and F]. Together, data in Fig. 2
[panels C–F] implicated Arf6/ARNO signaling axis in GSIS.
In the next series of studies, we determined potential roles of
Arf6 or ARNO in insulin secretion elicited by a membranedepolarizing concentration of KCl or arginine. To address this, INS
832/13 cells were transfected with either siRNA-Arf6 or siRNAARNO, and insulin secretion in the presence of KCl [60 mM; Fig. 2G]
or arginine [20 mM; Fig. 2H and I] was quantitated. Data depicted
in Fig. 2 [panels G–I] demonstrated that insulin secretion elicited
by KCl or arginine was inhibited in cells in which the endogenous
Arf6 or ARNO was knocked-down. Together, data described in Fig. 2
implicate regulatory roles for ARNO/Arf6 in insulin secretion
elicited by a variety of secretagogues.
3.3. Glucose activates Arf6 in pancreatic b-cells
To further understand the role of Arf6 in stimulus-coupled
secretion, we next examined whether insulinotropic concentrations of glucose activates Arf6 in the b-cell. This was accomplished
by using a recently developed GST-GGA3 pull-down assay, which
utilizes GGA proteins to capture activated forms of Arf6 by
interacting with the Arf-binding domain [27]. Efﬁciency and
speciﬁcity of the activation assay was conﬁrmed by the ability of
GTPgS to stimulate Arf6 activation in broken cell preparations
[additional data not shown]. A time-course study for Arf6
activation by glucose [Fig. 3A and B] suggested that glucoseinduced activation was seen as early as 1 min and reached
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Fig. 2. Overexpression of inactive mutants or siRNA-Arf6 or siRNA-ARNO markedly inhibits glucose-induced insulin secretion in INS 832/13 cells. Panel A: INS 832/13 cells
were either mock-transfected or transfected with dominant mutants of Arf6 [T27N] or ARNO (E156K; see Section 2). Relative degrees of expression of the mutants were
veriﬁed by Western blotting. A representative blot from three independent studies yielding similar results is provided here. Panel B: INS 832/13 cells were either mocktransfected or transfected with siRNA-Arf6 or siRNA-ARNO as described in Section 2. Relative degrees of knockdown of these proteins were veriﬁed by Western blotting. A
representative blot from three independent studies yielding similar results is shown here. Panel C: INS 832/13 cells were transfected with dominant negative Arf6 [T27N] at a
ﬁnal concentration of 0.2 mg of DNA and cultured for 48 h. Following this, cells were stimulated with either low [2.5 mM] or high [20 mM] glucose in KRB for 30 min at 37 8C.
Insulin released into the media was quantitated and expressed as ng/ml. Data are mean  SEM from three independent experiments. * represents p < 0.05 vs. mock low glucose;
**p < 0.05 vs. mock transfected cells treated with high glucose, and data points with similar symbol did not differ signiﬁcantly. Panel D: INS 832/13 cells were transfected with
dominant negative ARNO [E156K] at a ﬁnal concentration of 0.2 mg of DNA and cultured for 48 h following which cells were stimulated with either low [2.5 mM] or high [20 mM]
glucose for 30 min at 37 8C. Insulin released into the medium was quantitated and expressed as ng/ml. Data are mean  SEM from three independent experiments. * represents
p < 0.05 vs. mock transfected low glucose and **p < 0.05 vs. mock transfected high glucose, and data points with similar symbol do not differ signiﬁcantly. Panel E: INS 832/13 cells
were either mock-transfected or transfected with Arf6-siRNA at a ﬁnal concentration of 100 nM. After 48 h culture in regular medium, cells was stimulated with low [2.5 mM] or
high [20 mM] glucose for 30 min. Insulin released into the medium was quantitated and expressed as ng/ml. Data are mean  SEM from three independent experiments.
* represents p < 0.05 vs. mock low glucose; **p < 0.05 vs. mock transfected cells treated with high glucose, and data points with similar symbol did not differ signiﬁcantly. Panel F:
INS 832/13 cells were either mock-transfected or transfected with ARNO-siRNA at a ﬁnal concentration of 100 nM. After 48 h culture in regular medium, cells were stimulated with low
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Fig. 2. (Continued). [2.5 mM] or high [20 mM] glucose for 30 min. Insulin released into the medium was quantitated and expressed as ng/ml. Data are mean  SEM from ﬁve
independent experiments. * represents p < 0.05 vs. mock transfected low glucose; **p < 0.05 vs. mock transfected high glucose. Insulin release values between mock low glucose
and siRNA transfected low glucose did not differ signiﬁcantly. Panel G: INS 832/13 cells were either mock-transfected or transfected with ARNO-siRNA at a ﬁnal concentration of
100 nM. After 48 h culture in regular medium, cells were stimulated with low [2.5 mM] or KCl [60 mM; osmolarity adjusted] for 60 min. Insulin released into the medium was
quantitated and expressed as ng/ml. Data are mean  SEM from three independent experiments. * represents p < 0.05 vs. mock-transfected low glucose; **p < 0.05 vs. mock
transfected K+. Insulin release values between mock low glucose and siRNA transfected low glucose did not differ signiﬁcantly. Panels H and I: INS 832/13 cells were mocktransfected or transfected either with Arf6-siRNA/ARNO-siRNA at a ﬁnal concentration of 100 nM. After 48 h culture in regular medium, cells were stimulated with 1 mM glucose
[Glu] or 1 mM glucose + 20 mM arginine [L-Arg] for 15 min. Insulin released into the medium was quantitated and expressed as percent of control. Data are mean  SEM from
replicates. * represents p < 0.05 vs. mock-transfected 1 mM glucose; **p < 0.05 vs. mock-transfected 1 mM Glu + 20 mM L-Arg. Insulin release values between mock and siRNA
transfected under low glucose [1 mM] conditions did not differ signiﬁcantly.

optimum at 3 min time point. Even though, we noticed a reduction
in activated Arf6 at 5 min time point, Arf6 remained active
[Arf6GTP] above basal till 30 min [additional data not shown].
Together, these data suggest that Arf6 activation might represent
one of the early signaling steps leading to GSIS [see below].
3.4. siRNA-mediated knockdown of ARNO or pharmacological
inhibition of ARNO/Arf6 signaling results in attenuated glucoseinduced activation of Arf6
The conversion of the GDP-bound inactive forms of Gproteins to their GTP-bound active state is mediated by GEFs.
The above data prompted us to investigate if ARNO represents
one of the GEFs for glucose-mediated activation of Arf6. This was
veriﬁed by two complementary methods. In the ﬁrst, glucoseinduced activation of Arf6 was examined in cells in which ARNO
expression was reduced by siRNA-ARNO. Data in Fig. 4A and B
indicated complete inhibition of glucose-induced activation of
Arf6 under these conditions. This was further veriﬁed by a
second approach involving pharmacological inhibition of ARNO/
Arf6 signaling by secinH3 [19–21]. Data in Fig. 4C and D
suggested a complete inhibition of glucose-induced activation of
Arf6 by secinH3. Taken together, these data indicate that
glucose-induced activation of Arf6 requires the intermediacy of
ARNO.

3.5. SecinH3 markedly attenuates GSIS in INS 832/13 cells and rat
islets
As a logical extension to the above studies, we next investigated
potential impact of pharmacological inhibition of ARNO on GSIS in
INS 832/13 cells and normal rat islets. Data in Fig. 5 demonstrated
complete inhibition of GSIS by secinH3 in INS 832/13 cells [Fig. 5A]
and normal rat islets [Fig. 5B]. Under these conditions secinH3
failed to increase basal secretion in either INS 832/13 cells or rat
islets [Fig. 5A and B]. It should be noted that inhibitory effects of
secinH3 on Arf6 activation [Fig. 4] or GSIS [Fig. 5] were not due to
its cytotoxic effects since we noticed no signiﬁcant effects of this
inhibitor on the metabolic cell viability of b-cells under these
conditions [not shown]. Together, these pharmacological data
conﬁrm the above molecular biological data to support our
hypothesis that ARNO/Arf6 signaling cascade plays a positive
modulatory role in GSIS.
3.6. siRNA-mediated knockdown of ARNO or pharmacological
inhibition of ARNO leads to marked reduction in glucose-induced
activation of Rac1 and Cdc42
Several recent studies, including our own, have implicated Rho
subfamily of small G-proteins [e.g., Cdc42 and Rac1] in cytoskeletal
remodeling leading to the translocation of insulin-laden secretory
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reported glucose-induced activation of Cdc42 within 3 min of
exposure. They also demonstrated that Cdc42 activation is
upstream to Rac1 activation in the cascade of events leading to
GSIS [25]. Therefore, we examined if inhibition of ARNO/Arf6
signaling step affects Cdc42 activation. Our ﬁndings suggested
50% inhibition of glucose-induced activation of Cdc42 in INS 832/
13 cells following inhibition of ARNO/Arf6 by secinH3 [Fig. 6C].
Together, our ﬁndings are suggestive of sequential activation of
Arf6, Cdc42 and Rac1 by ARNO in glucose-stimulated b-cell
culminating in insulin secretion.
It should be noted that recent investigations from our
laboratory have described the roles for Tiam1, a GEF for Rac1 in
GSIS. For example, we have shown that siRNA-mediated knockdown of Tiam1 or pharmacological inhibition of Tiam1/Rac1
signaling axis [e.g., NSC23766] markedly attenuated GSIS in INS
832/13 cells [37]. Along these lines, Western blot data indicated
expression of Dbl, a known GEF for Cdc42 [38], in INS 832/13 cells,
normal rat islets and human islets [Fig. 6D]. Together, these data
are suggestive expression of at least three GEFs [i.e., ARNO, Tiam1
and Dbl] in the islet b-cell. Potential cross talk between these GEFs,
if any, in the context of GSIS, remains to be veriﬁed.
3.7. Glucose promotes association between Arf6 and ARNO in
pancreatic b-cells

Fig. 3. Time-dependent activation of Arf6 by glucose in pancreatic b-cells. Panel A:
INS 832/13 cells were incubated with KRB for 1 h and either left unstimulated
[diluent] or stimulated with high glucose [20 mM] for different time points as
indicated. Cell lysates were used for detecting activated Arf6 [Arf6GTP] by GSTGGA3-PBD pull down assay [see Section 2]. Total Arf6 was used as the loading
control and a representative blot from three independent experiments is shown.
Panel B: densitometric quantitation of Arf6 activation depicted in panel A is shown
here. * represents p < 0.05 vs. diluent. Statistical analysis was performed using oneway ANOVA, all pairwise multiple comparison method (Dunnetts’).

granules to the plasma membrane for fusion and exocytotic
secretion of insulin [28,29]. In this context, recent evidence
appears to suggest a signiﬁcant cross-talk between ARNO/Arf6 and
Rac1 in the regulation of cell function in multiple cell types [30–
35]. Therefore, we asked if ARNO/Arf6 signaling axis regulates
glucose-induced Rac1 activation in the pancreatic b-cell. We
addressed this question by quantitating glucose-induced Rac1
activation in INS 832/13 cells in which ARNO function is
compromised via pharmacological [e.g., secinH3] or molecular
biological [e.g., siRNA-ARNO] approaches. As expected, we noticed
a signiﬁcant Rac1 activation in control cells exposed to glucose
[Fig. 6A]. Interestingly, siRNA-mediated knockdown of ARNO
increased Rac1 activation under basal glucose conditions. However, glucose-induced activation of Rac1 was completely inhibited in
ARNO-depleted b-cells [Fig. 6A]. Likewise, pharmacological
inhibition of ARNO/Arf6 signaling axis with secinH3 abolished
glucose-induced activation in these cells [Fig. 6B] suggesting that
ARNO/Arf6 signaling step might be upstream to the Rac1 activation
step in the cascade of events leading to GSIS. These data, which are
compatible with our original proposal [22] also ﬁt into the timeframe for glucose-induced activation of these proteins. We noticed
in this study that Arf6 activation is seen as early as 1 min while
glucose-induced activation of Rac1 is maximal at 15–20 min
[28,29].
Along these lines, earlier studies from our laboratory have
suggested that the carboxylmethylation of Cdc42 is stimulated by
glucose within 1 min of exposure [36]. More recent and
comprehensive investigations by Thurmond’s group [24,25] have

In the last series of studies we utilized co-immunoprecipitation
and immunoﬂuorescence approaches to further determine if
exposure of isolated b-cells to an insulinotropic concentration
of glucose promotes association between Arf6 and ARNO. Data
shown in Fig. 7A indicate detectable levels of Arf6 in ARNO
immunoprecipitates suggesting that these two proteins stay
complexed under basal conditions. Moreover, incubation of these
cells with stimulatory glucose resulted in a signiﬁcant increase
[2-fold] in the amount of Arf6 in the ARNO immunoprecipitates
[Fig. 7B]. Together, these data suggest that glucose promotes
physical association between ARNO and Arf6 in insulin-secreting
cells. We veriﬁed these ﬁndings via a complementary immunoﬂuorescence approach. Data in Fig. 7C suggested that both Arf6
[green] and ARNO [red] remain diffused throughout the cell under
basal conditions [2.5 mM glucose]. Merged images of subpanels a
and b in Fig. 7 [i.e., subpanel c] further suggested that the two
proteins remain localized in the cytosolic compartment. However,
exposure of these cells to a stimulatory concentration of glucose
[20 mM] led to a signiﬁcant association of these proteins as
evidenced in the merged images of subpanels d and e of Fig. 7 [i.e.,
subpanel f]. Together, these ﬁndings [Fig. 7] provide evidence for
increased association of Arf6 and ARNO in the presence of glucose
leading to the activation of ARNO/Arf6 signaling pathway followed
by sequential activation of Cdc42/Rac1 culminating in insulin
secretion.
4. Discussion
It is widely accepted that the Arf family of G-proteins play a key
regulatory role in membrane trafﬁcking [9]. Among these, Arf6 is
well studied and has been shown to regulate several cellular events
including cell motility, vesicular transport, and cortical actin
rearrangements [17,32,39]. In addition, Arf6 has been shown to
activate several G-proteins and enzymes of lipid metabolism
including PLD to generate fusogenic lipids such as PA and PIP2
[40,41]. Such experimental evidence led to the postulation that
Arf6 might represent one of the G-proteins whose activation may
be necessary for the trafﬁcking of secretory vesicles to the plasma
membrane and fusion to lease their contents into the circulation.
The functions of Arf6 are regulated by factors such as GEFs.
Despite compelling evidence in many cell types, little is known
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Fig. 4. Molecular biological or pharmacological inhibition of ARNO attenuates glucose-induced activation of Arf6 in INS 832/13 pancreatic b-cells. Panel A: INS 832/13 cells
were either mock-transfected or transfected with siRNA-ARNO and cultured for 48 h following which cells were stimulated in the presence of either low glucose [LG, 2.5 mM]
or high glucose [HG, 20 mM] for 30 min at 37 8C. The relative amounts of activated Arf6 [i.e., Arf6GTP] were determined by pull down assay. Total Arf6 from cell lysates was
used as the loading control and a representative blot from three independent experiments is shown. Panel B: data shown in the panel A were analyzed densitometrically and
expressed as fold change in Arf6GTP over basal and are mean  SEM of three independent experiments. * represents p < 0.05 vs. mock transfected low glucose; **p < 0.05 vs.
mock transfected high glucose, and data points with similar symbol do not differ statistically. Panel C: INS 832/13 cells were incubated overnight in the presence or absence of
secinH3 [50 mM] and stimulated with either low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] in the continuous presence or absence of secinH3 [50 mM] for 30 min. Relative
degrees of Arf6 activation were quantitated as described in panel A. Total Arf6 from cell lysates was used as the loading control and a representative blot from three independent
experiments is shown. Panel D: data shown in the panel C are analyzed densitometrically and expressed as fold change in Arf6GTP over basal. Data are mean  SEM from three
independent experiments. * and # represent p < 0.05 vs. low glucose without secinH3; and **p < 0.05 vs. high glucose without secinH3.

Fig. 5. SecinH3, a selective inhibitor of ARNO attenuates GSIS in INS 832/13 cells and normal rat islets. Panel A: INS 832/13 cells were incubated in low serum-low glucose
overnight in the continuous presence of 50 mM secinH3 or diluent and stimulated with either low [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min in KRB. Insulin
released into the medium was quantitated by ELISA and expressed as ng/ml. Data are mean  SEM from four independent experiments. * represents p < 0.05 vs. low glucose
without secinH3; **p < 0.05 vs. high glucose without secinH3 and data points with similar symbol do not differ statistically. Panel B: normal rat islets were incubated in low serumlow glucose overnight in the continuous presence of either 50 mM secinH3 or diluent and stimulated with either low [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min in KRB.
Insulin released into the medium was quantitated by ELISA. Data are expressed as ng/ml insulin released and are mean  SEM from four independent experiments. * represents
p < 0.05 vs. low glucose with secinH3 and without secinH3; and **p < 0.05 vs. high glucose without secinH3. Data points with similar symbol do not differ signiﬁcantly.
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Fig. 6. Molecular biological or pharmacological inhibition of ARNO function attenuates glucose-induced Rac1 or Cdc42 activation in INS 832/13 cells. Panel A: INS 832/13 cells
were either mock-transfected or transfected with siRNA-ARNO at a ﬁnal concentration of 100 nM and after 48 h culture, cells were stimulated with either low glucose [LG,
2.5 mM] or high glucose [HG, 20 mM] for 30 min at 37 8C. The relative amounts of activated Rac1 [i.e., Rac1GTP] were quantitated by PAK-PBD pull down [see Section 2 for
additional details]. Total Rac1 from cell lysates was used as the loading control. Data were analyzed densitometrically and expressed as fold change in Rac1GTP over basal.
Data are mean  SEM of ﬁve independent experiments. * and # represent p < 0.05 vs. low glucose without siRNA-ARNO; and **p < 0.05 vs. high glucose without siRNA-ARNO. Panel
B: INS 832/13 cells were cultured overnight in the presence or absence of secinH3 [50 mM] and further stimulated with low glucose [LG, 2.5 mM] and high glucose [HG, 20 mM] for
30 min in the continuous presence or absence of secinH3. The relative amounts of activated Rac1 [i.e., Rac1GTP] were determined by PAK-PBD pull down assay as described in panel
A. Total Rac1 from cell lysates was used as the loading control. Data were analyzed densitometrically and expressed as fold change in Rac1GTP over basal and are mean  SEM of
three independent experiments. * represents p < 0.05 vs. low glucose without secinH3; **p < 0.05 vs. high glucose without secinH3, and data points with similar symbol do not differ
statistically. Panel C: INS 832/13 cells were starved overnight in the presence or absence of secinH3 [50 mM] and were stimulated with low glucose [LG, 2.5 mM] and high glucose
[HG, 20 mM] for 3 min in the continuous presence or absence of secinH3. The relative amounts of activated Cdc42 [i.e., Cdc42GTP] was determined by PAK-PBD pull down assay.
Total Cdc42 from cell lysates was used as the loading control. Data were densitometrically analyzed and is expressed as fold change in Cdc42GTP over basal and are mean  SEM of
three independent experiments yielding similar results. * and ** represent p < 0.05 vs. low glucose without secinH3 and #p < 0.05 vs. high glucose without secinH3. Panel D: lysates
from rat islets, human islets and INS 832/13 cells were separated by SDS-PAGE and probed for Dbl by Western blotting.

with regard to regulatory factors for Arf6 in b-cells. Therefore, in
the current study, we tested the hypothesis that ARNO mediates
the functional activation of Arf6, and that the ARNO/Arf6 signaling
cascade, in turn, controls the activation of downstream regulatory
proteins including Cdc42 and Rac1 leading to GSIS. In the present
study we demonstrated that ARNO might subserve the function of
a GEF for Arf6 in the islet b-cell. Salient features of our study are: [i]
ARNO is expressed in clonal b-cells, rodent islets and human islets;
[ii] overexpression of inactive mutants of ARNO or Arf6 or siRNAs
of Arf6 or ARNO reduces insulin secretion elicited by glucose,
arginine and KCl in insulin-secreting cells; [iii] secinH3, a selective
inhibitor of ARNO/Arf6 signaling pathway, also inhibits GSIS in INS
832/13 cells and rodent islets; [iv] insulinotropic concentration of
glucose stimulates Arf6 activation; [v] glucose-induced Arf6
activation is inhibited by secinH3 or siRNA-ARNO, suggesting a
critical involvement of ARNO/Arf6 in insulin secretion; [vi]
pharmacological or molecular biological inhibition of ARNO/Arf6
inhibits glucose-induced activation of Cdc42 and Rac1; and [vii]
glucose promotes association between ARNO and Arf6 as
evidenced by co-immunoprecipitation and confocal microscopic

studies. These ﬁndings provide the ﬁrst evidence to implicate novel
roles for ARNO in insulin secretion.
Regazzi et al. ﬁrst reported [3,4] that incubation of permeabilized RINm5F cells with non-hydrolyzable analogs of GTP
resulted in a signiﬁcant redistribution of otherwise cytosolic Arfs
to the Golgi and plasma membrane compartments. Based on these
and insulin secretion data, they concluded that Arf is subjected to
cycling between the membrane and soluble compartments and
this cycling is governed by regulatory factors to mediate insulin
secretion in clonal b-cells. And more recently Lawrence and
Birnbaum demonstrated regulatory roles for Arf6 in insulin
secretion from MIN6 cells [5]. Using adenoviral expression
protocols involving the wildtype, dominant negative and constitutively active Arf6 mutants, these investigators provided compelling evidence to implicate regulatory roles for Arf6 in glucose-, KCland GTPgS-induced insulin secretion. Along these lines, at least
two other recent studies have veriﬁed roles for Arf6 in islet
function and insulin secretion. Grodnitzky et al. have demonstrated a role for EFA6A, another GEF for Arf6 in somatostatin-mediated
activation of PLD in clonal b [HIT-T15] cells. Interestingly,
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Fig. 7. Glucose promotes association between Arf6 and ARNO in INS 832/13 cells. Panel A: co-immunoprecipitation studies: herein, INS 832/13 cells were incubated in the presence
of low glucose [LG, 2.5 mM] or high glucose [HG, 20 mM] for 30 min at 37 8C. ARNO was immunoprecipitated in the lysates using a speciﬁc antibody as described in Section 2. The
immunoprecipitates were separated by SDS-PAGE and probed for Arf6. A representative blot from three studies is shown. Panel B: data from multiple studies shown in panel A are
analyzed densitometrically and expressed as densitometric units and are mean  SEM. * represents p < 0.05 vs. low glucose. Panel C: immunoﬂuorescence studies using confocal
microscopy: INS 832/13 cells were cultured on coverslips and cultured overnight prior to the incubation with either 2.5 mM or 20 mM glucose for 30 min at 37 8C. The cells were ﬁxed in
4% paraformaldehyde solution in PBS for 15 min and permeabilized using 0.2% triton X-100 for 15 min. Fixed cells were examined for Arf6 [stained in green] and ARNO [stained in red] as
described under Section 2. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)

however, this pathway appears to be distinct from glucosemediated effects in INS 832/13 cells and normal rat islets [current
study] since overexpression of inactive ARNO mutant [E156K]
failed to affect somatostatin-induced PLD activation [42]. More
recent ﬁndings by Ma and coworkers further implicated Arf6 in
glucose-induced PLD activation in MIN6N8 cells, which suggested

binding of Arf6 to PLD. Furthermore, brefeldin A, a known inhibitor
of Arf6, decreased glucose-induced PLD activity and insulin
secretion [43].
What then is the potential connection between glucoseinduced ARNO/Arf6 signaling cascade and Rac1 activation that
we have demonstrated in the current study? We proposed earlier
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Fig. 8. A proposed mechanism for ARNO signaling axis in GSIS via sequential activation of Arf6, Cdc42 and Rac1 in pancreatic b-cells: based on the data described herein and
our previously published data [22,23], we propose a model for potential involvement of ARNO as a GEF for Arf6 in promoting GSIS in pancreatic b-cells. We propose that
glucose activates islet endogenous ARNO to facilitate the conversion of inactive GDP-bound Arf6 to its GTP-bound biologically active conformation. Essential nature for ARNO
in this signaling cascade was demonstrated via the use of molecular biological [E156K mutant and siRNA-ARNO] and pharmacological approaches [e.g., secinH3]. A role for
Arf6 in GSIS was conﬁrmed via molecular biological [i.e., Arf6-T27N mutant and siRNA-Arf6] approaches. These data conﬁrm the original observations of Lawrence and
Birnbaum [5]. We propose that the activation of ARNO/Arf6 signaling pathway leads to the activation of PLD [43] leading to the generation of fusogenic lipids [e.g., PA], which
in turn, promote dissociation of Rac1/GDI complexes leading to the activation and membrane association of Rac1 [22,23]. Our time course studies also suggest that ARNOmediated activation of Cdc42 [within 1 min] is upstream to Rac1 activation [15–20 min] together suggesting that ARNO facilitates sequential activation of Arf6, Cdc42 and
Rac1 to promote insulin secretion. Potential mechanisms underlying Arf6 mediated activation of Cdc42 remain to be determined. It might include dissociation of Cdc42/GDI
complex by biologically active lipids as in the case of Rac1 [21,22] or inhibition of GAP activity speciﬁc for Cdc42 by ARNO/Arf6 signaling pathway [see Section 4]. These
aspects are being investigated in our laboratory currently.

[22] that Rac1 activation might be downstream to Arf6 in the
signaling events leading to GSIS. More recently we have provided
further evidence to suggest that biologically active, fusogenic lipids
regulate Rac1 signaling in the b-cell [23]. For example, using
lysates derived from normal rat islets and INS 832/13 cells we have
demonstrated that these lipids promote the dissociation of Rac1/
GDI complex, which is necessary for the membrane translocation
and activation of Rac1 [23]. Earlier observations also demonstrated
potential involvement of PLD activation in the signaling mechanisms leading to GSIS [6,7,44–46]. Therefore, it is reasonable to

speculate that glucose-induced Arf6-mediated activation of PLD1
[43] results in biologically active, fusogenic lipids, which, in turn,
facilitate the dissociation of Rac1/GDI complex and leading to the
translocation, membrane association and activation of Rac1
culminating in the cytoskeletal remodeling and fusion of granules
with the plasma membrane. This remains to be veriﬁed
experimentally.
Our current ﬁndings from the time course studies suggested
that Cdc42 activation [3 min] step as an intermediate between
Arf6 [1 min] and Rac1 [20 min] activation. In support of
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sequential activation of Arf6, Cdc42 and Rac1, our current data
demonstrated that inhibition of ARNO/Arf6 signaling leads to
inhibition of Cdc42 and Rac1. Findings from Thurmond’s laboratory have clearly demonstrated that Cdc42 plays an upstream
regulatory role to Rac1 in GSIS [25]. Based on these ﬁndings, we
propose that GSIS involves sequential activation of ARNOmediated stimulation of Arf6, Cdc42 and Rac1 as shown below.

studies have clearly implicated non-regulatory roles for Cdc42/
Rac1 signaling pathways in KCl-induced insulin secretion ([28,29]
and references therein). To the best of our knowledge, very little is
known with regard to potential involvement of small G-proteins
[e.g., Rac1] in insulin secretion facilitated by amino acids, such as
arginine. These aspects, which are not included in the current
model [Fig. 8], are being investigated in our laboratory currently.

l

However, it remains to be veriﬁed if Cdc42 activation
mechanism by ARNO/Arf6 also involves the dissociation of
Cdc42/GDI complexes by biologically active lipids as in the case
of Rac1 [23]. Further, it is likely that ARNO/Arf6-mediated Cdc42
activation in the b-cell might involve a mechanism similar to the
one described in MCF7 cells by Dubois et al. [47]. These
investigators have demonstrated that active Arf proteins bind to
Cdc42. GTPase activating protein thereby preventing its GAP
function and retain Cdc42 in the GTP-bound active conformation.
Such a possibility remains to be veriﬁed for Arf6 in the islet.
Lastly, our current studies identify ARNO as one of the GEFs for
glucose-induced activation of Arf6. The list of G-protein regulatory
factors involved in GSIS continues to grow. Along these lines, we
have identiﬁed Tiam1 as one of the GEFs for Rac1 [37]. Rho-GDI
appears to subserve the roles of GDI for Cdc42 and Rac1 [29]. The
above described Western blot data are suggestive of localization of
Dbl, a known GEF for Cdc42, in INS 832/13 cells, normal rat islets
and human islets. Studies are underway to determine potential
cross-talk between various GEFs and their corresponding Gproteins in the cascade of events leading to insulin secretion.
In conclusion, based on the existing experimental data including
those described herein, we propose a mechanism [Fig. 8] involved in
GSIS in pancreatic b-cells involving ARNO/Arf6 signaling steps. We
propose that GSIS involves ARNO-mediated conversion of GDP-Arf6
[inactive] to GTP-Arf6 [active]. We veriﬁed this by overexpression of
dominant negative mutants of ARNO and Arf6 as well as siRNAmediated knockdown of these proteins in pancreatic b-cells. This
postulation was further supported by our ﬁndings of pharmacological inhibition of glucose-induced ARNO-mediated activation of Arf6
by secinH3. Based on the data described herein and our previously
published data [22,23], it is likely that glucose metabolic events lead
to the activation of endogenous phospholipases, including PLD
[44,45] and the subsequent generation of biologically active lipid
second messengers [e.g., PA and PIP2], which, in turn, facilitate the
dissociation of Rac1/GDI complex for attaining the GTP-bound active
conformation [23]. Potential involvement of ARNO/Arf6-mediated
activation of Cdc42 and Rac1 via PLD remains to be veriﬁed. Finally,
as we demonstrated previously [48], it is also likely that biologically
active lipids could exert direct effects on the functional activation of
speciﬁc GTPases by increasing their GTP binding function and
decreasing their GTPase activities thereby retaining putative Gproteins in their GTP-bound active conformation [29].
Lastly, it may be germane to point out that data described above
implicated regulatory roles for ARNO/Arf6 signaling axis in insulin
secretion elicited by KCl. Our current observations are compatible
with studies of Lawrence and Birnbaum implicating a role for Arf6
in KCl-induced insulin secretion [5]. However, it remains to be seen
if ARNO/Arf6 signaling cascade regulates additional pathways
which are independent of Cdc42/Rac1 activation in insulinsecreting cells. Such an examination is necessary since recent
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Isoprenylcysteine carboxyl methyltransferase (ICMT) catalyzes the post-translational methylation of C-terminal
cysteines of isoprenylated proteins, including small G-proteins and the γ-subunits of heterotrimeric G-proteins. It is
widely felt that carboxymethylation promotes efficient membrane association of the methylated proteins and specific
protein-protein interactions. In the current study, we tested the hypothesis that ICMT-mediated carboxymethylation of
specific proteins (e.g., Rac1) plays a regulatory role in glucose-stimulated insulin secretion (GSIS). Western-blot analysis
indicated that lCMT is expressed and predominantly membrane associated in INS 832/13 β-cells. siRNA-mediated
knockdown of endogenous expression of ICMT markedly attenuated glucose, but not KCl-induced insulin secretion.
These findings were further supported by pharmacological observations, which suggested a marked reduction in
glucose-, but not KCl-stimulated insulin secretion by acetyl farnesyl cysteine (AFC), a selective inhibitor of ICMT. In
addition, glucose-induced Rac1 activation, a hallmark signaling step involved in glucose-stimulated insulin secretion,
was markedly inhibited following pharmacological (AFC) or molecular biological (siRNA-ICMT) inhibition of ICMT. Lastly,
we also noticed a marked reduction in glucose-induced acute increase in the generation of reactive oxygen species in
INS 832/13 cells pre-treated with AFC or transfected with siRNA-ICMT. Together, these data suggest that ICMT regulates
glucose-induced Rac1 activation, generation of reactive oxygen species and insulin secretion in pancreatic β-cells.
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Introduction
It has been known for a long time that both monomeric G-proteins
(e.g., Rac1 and Cdc42) and the γ-subunits of heterotrimeric
G-proteins (Gγ subunits) undergo post-translational modifications, such as isoprenylation and methylation at their C-terminal
cysteine residues (often referred to as the CAAX motif).1,2 The
first of the four step modification sequence includes incorporation of mevalonic acid-derived farnesyl or geranylgeranyl isoprenoid moiety onto the C-terminal cysteine. This is followed by
the proteolytic cleavage of—AAX peptide by the Ras-converting
enzyme1 (Rce1) endoprotease of microsomal origin, which leads
to methylation of the prenylated cysteine by the carboxyl methyl
transferase (ICMT) in the presence of S-adenosyl methionine
serving as the methyl donor.3 It is widely accepted that the prenylation and carboxymethylation modification steps increase the

hydrophobicity of the candidate proteins for optimal targeting
to their relevant membranous sites for the regulation of effector
proteins.1-3
While a significant number of recent studies have focused
on putative roles of G-protein prenylation in glucose-stimulated
insulin secretion (GSIS), very little is known with regard to the
potential roles of carboxymethylation in islet function.3 Original
studies from our laboratory have attempted to address the roles
of carboxymethylation in islet function, including insulin secretion.4,5 Therein, using selective inhibitors of ICMT such as acetyl farnesyl cysteine (AFC), we have been able to demonstrate
that Cdc42 and Gγ subunits undergo carboxymethylation in
response to glucose in clonal β-cells, normal rat and human
islets.4,5 Follow-up studies by Li and coworkers characterized
ICMT in insulin-secreting cells for its subcellular localization
and regulation by known second messengers of insulin secretion.6
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Figure 1. Expression and subcellular distribution of ICMT in INS 832/13
cells. Total particulate and soluble fractions were isolated from INS
832/13 cells by a single step centrifugation method described in Materials and Methods. ICMT expression was determined in these fractions by
western blotting. A representative of three blots is shown here.

In the current study, we have revisited this area of islet biology
to precisely determine the role of carboxymethylation and the
identity of methylated proteins to further evaluate their roles in
the signaling events leading to insulin secretion.
Along these lines, emerging evidence implicates novel regulatory roles for phagocyte-like NADPH oxidases (Nox) in physiological insulin secretion. For example, using selective inhibitors
(e.g., DPI or apocynin) and molecular biological tools (e.g.,
antisense and siRNAs for Nox subunits), several recent studies have demonstrated “second messenger” roles for Nox-derived
reactive oxygen species in glucose-stimulated insulin secretion.7-9
Some of these aspects, including downstream targets for reactive
oxygen species signals, have been reviewed by Pi and Collins
recently in reference 10. Furthermore, recent studies from our
laboratory have also demonstrated a novel regulatory role for
Rac1 in Nox-derived generation of reactive oxygen species, thus
suggesting that glucose-induced Rac1 activation step might
be necessary for Nox-mediated generation of reactive oxygen

species and insulin secretion. For example, using selective inhibitors of prenylation (e.g., GGTI-2147), we have demonstrated
that post-translational prenylation of Rac1 is important for its
regulation of generation of reactive oxygen species.11 Therefore,
based on the above evidence and as a logical extension to studies
to suggest obligatory roles of ICMT-mediated carboxymethylation of Rac1 function for its subcellular localization and function,12,13 we undertook the current investigation to determine
the regulatory roles of ICMT in glucose-induced Rac1 activation, generation of reactive oxygen species and insulin secretion
in INS 832/13 cells. We have accomplished this goal by two distinct approaches to compromise the β-cell endogenous ICMT
function, via siRNA-mediated knockdown of ICMT expression
and pharmacological inhibition of ICMT by AFC. Indeed, data
accrued from the current studies underscores the importance of
carboxymethylation of Rac1 in glucose-induced Nox activation
and associated generation of reactive oxygen species and insulin
secretion.
Results
ICMT is expressed in INS 832/13 cells. At the outset we determined the immunological localization and subcellular distribution of ICMT in INS 832/13 cells. For this, total particulate and
soluble fractions were isolated from INS 832/13 cells by a single
step centrifugation method and relative abundance of ICMT
was determined in these fractions by western blotting. Data in
Figure 1 suggested a predominant membrane association of
ICMT in these cells. It should also be noted that we consistently
observed a doublet for ICMT on western blots, which might
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Figure 2. Localization of ICMT in INS 832/13 cells by immunofluorescence under basal and glucose-stimulated conditions. INS 832/13 cells were plated
on coverslips and cultured overnight in low serum low glucose media prior to incubation with either 2.5 mM (A) or 20 mM glucose (B) for 45 min at
37°C. The cells were fixed in 4% paraformaldehyde solution in PBS for 15 min and permeabilized using 0.2% triton X-100 for 15 min. Fixed cells were
examined for ICMT (stained in green) and nuclei (stained in blue) as described under Methods.
2
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Figure 3. Glucose-, but not KCl-stimulated insulin secretion, is attenuated in INS 832/13 cells following siRNA-mediated knockdown of ICMT.
INS 832/13 cells were either mock transfected or transfected with scrambled siRNA or siRNA-ICMT at a final concentration of 100 nM and cultured for
24 h. Transfection efficiency was determined by separating equal amounts of proteins on SDS-PAGE and probing with ICMT antibody [(A) representative of three transfections is shown here]. Data in (A) was densitometrically analyzed and expressed as fold change over basal (B). *p < 0.05 compared
with mock or scrambled siRNA transfected cells. Further, transfected cells were incubated either with low glucose (LG; 2.5 mM) or high glucose [(C) HG;
20 mM] or a membrane depolarizing concentration of KCl [(D) 60 mM; osmolaity adjusted by lowering NaCl] for 45 min at 37°C. Insulin released into
the medium was quantitated by ELISA. Data are expressed as percentage of basal and are mean ± SEM from three independent determinations.
*p < 0.05 vs. respective low glucose controls; **p < 0.05 vs. mock transfected cells.

represent a post-translationally modified form of this protein.
In the next series of studies we determined the distribution of
ICMT in INS 832/13 cells by immunofluorescence method.
Data in Figure 2 suggested that ICMT (green) remain diffused
throughout the cell under basal [(A) LG; 2.5 mM glucose] conditions. Further, we observed no clear effects of stimulatory glucose
[(B) HG; 20 mM glucose] on ICMT distribution in these cells.
siRNA-mediated knockdown of ICMT attenuates glucose-, but not KCl-induced insulin secretion in INS 832/13
cells. We next investigated potential regulatory roles of ICMT
in glucose-induced insulin secretion in these cells. To address
this, we knocked down the endogenous expression of ICMT by
siRNA methodology. Data in Figure 3A and B indicated more
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than ~70 % inhibition in the expression of ICMT following
siRNA-ICMT transfection. Data in Figure 3C suggested no
significant effects of scrambled siRNA transfection either on
basal or glucose-induced insulin secretion (bars 1 vs. 3 and 2
vs. 4). However, transfection of siRNA-ICMT in these cells led
to a modest increase in basal secretion (bars 1 or 2 vs. 5), but
insulin secretion elicited by stimulatory glucose was significantly
reduced in ICMT knocked down cells (bars 2 or 4 vs. 6). This
data suggested that activation of ICMT is necessary for glucosestimulated insulin secretion to occur. We then determined
potential requirement for ICMT in insulin secretion elicited by
a membrane depolarizing concentration of KCl. Data shown in
Figure 3D suggested no significant effects of ICMT knockdown
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Figure 5. Glucose-induced ROS generation was attenuated in INS
832/13 cells following siRNA-mediated knockdown of ICMT. INS 832/13
cells transfected with ICMT-siRNA (or mock transfected) following
which cells were stimulated with low glucose (2.5 mM) or high glucose
(20 mM) for 1 h and were incubated with DCHFDA (10 μM; 30 min) and
harvested for quantitation of DCF fluorescence. Data expressed as DCF
fluorescence and are mean ± SEM from three independent determinations. *p < 0.05 vs. respective low glucose; **p < 0.05 vs. high glucose in
mock transfected cells.
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Figure 4. Depletion of endogenous ICMT markedly attenuates glucoseinduced activation of Rac1 in INS 832/13 cells. INS 832/13 cells were
transfected with ICMT-siRNA or mock transfected and cultured for 24 h.
At confluence, cells were starved overnight and stimulated with either
low (2.5 mM) or high (20 mM) glucose for 30 min. The extent of Rac1 activation in these cells was quantitated by PAK-PBD pulldown assay. Total
and activated (Rac1.GTP) were determined by western blotting (A) and
quantitated by densitometry (B). Data are expressed as fold change in
Rac1 activation and are mean ± SEM from three independent determinations. *p < 0.05 vs. mock transfected low glucose; **p < 0.05 vs. mock
transfected high glucose.

on KCl-induced insulin secretion. Together, data in Figure 3C
and D suggest that glucose, but not KCl-evoked insulin secretion
is mediated via activation of ICMT.
siRNA-mediated knockdown of ICMT attenuates glucoseinduced Rac1 activation in INS 832/13 cells. Published evidence from several laboratories, including our own have suggested
that activation of Rac1, a small G-protein, is a requisite step in
the signaling events leading to glucose-insulin secretion.2,14,15
Furthermore, using inhibitors of post-translational geranylgeranylation (e.g., GGTI-2147) or a dominant negative mutant of the
α-subunit of geranylgeranyl transferase, we have demonstrated a

4
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requirement for post-translational geranylgeranylation in glucoseinduced Rac1 activation and insulin secretion.16 Since Rac1
undergoes carboxymethylation, we investigated if silencing of
ICMT affects glucose-induced Rac1 activation. Data shown in
Figure 4 demonstrated a significant increase in glucose-induced
Rac1 activation (lane 1 vs. 3). siRNA-mediated knockdown of
ICMT failed to exert any clear effects on basal Rac1 activation
(lane 1 vs. 2), but significantly attenuated glucose-induced Rac1
activation (lane 3 vs. 4). Pooled data from multiple experiments
are provided in Figure 4B. Together, these findings suggested a
requirement for carboxymethylation for glucose-induced activation of Rac1.
siRNA-mediated knockdown of ICMT markedly inhibits glucose-induced reactive oxygen species generation in INS
832/13 cells. Emerging evidence from multiple laboratories
appears to suggest novel second messenger roles for reactive
oxygen species in glucose-stimulated insulin secretion.10 It has
also been shown that reactive oxygen species generated via the
activation of phagocyte-like NADPH oxidase (Nox) plays such
regulatory roles in glucose-stimulated insulin secretion since
pharmacological (e.g., apocynin or DPI) or molecular biological (e.g., siRNA or antisense for p47phox) inhibition of Nox led
to inhibition of glucose-stimulated insulin secretion.8-10 Since
Rac1 represents one of the members of Nox holoenzyme,2,18 we
investigated if siRNA-mediated knockdown of ICMT exerts any
regulatory effects on glucose-induced generation of reactive oxygen species in INS 832/13 cells. Data in Figure 5 suggested no
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Figure 6. AFC, a competitive inhibitor of ICMT, attenuates glucose-induced ROS generation and insulin secretion in INS 832/13 cells. INS 832/13 cells
were cultured overnight with low-glucose and low-serum medium and then incubated in KRB in the presence of diluent or AFC (100 μM; 1 h) as indicated in the figure. Cells were further stimulated with either low glucose (LG; 2.5 mM) or high glucose (HG; 20 mM) for 1 h in continuous presence or
absence of diluent or inhibitor. At the end of stimulation, ROS generation was determined by quantitating DCF fluorescence (A) as described in Figure
5. In a separate set of studies glucose- and KCl-stimulated insulin secretion was quantitated (B and C) under conditions described in Materials and
Methods. Data in (B) are mean ± SEM from three independent determinations. *p < 0.05 vs. low glucose without AFC; **p < 0.05 vs. high glucose without AFC whereas data in (C) are mean ± SEM from 12 determinations in each case. *p < 0.05 vs. low glucose without AFC and low glucose with AFC.

significant effects of ICMT knockdown on basal levels of reactive oxygen species in these cells (bar 1 vs. 2). However, glucoseinduced generation of reactive oxygen species was markedly
attenuated in cells in which expression of ICMT was knocked
down (bar 3 vs. 4). Taken together, these data demonstrated that
glucose-induced Rac1 activation (Fig. 4), generation of reactive
oxygen species (Fig. 5) and insulin secretion (Fig. 3) are regulated by ICMT in INS 832/13 β-cells.

www.landesbioscience.com
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Acetyl farnesyl cysteine (AFC), a selective inhibitor of
ICMT, attenuates glucose-induced generation of reactive
oxygen species and insulin secretion in INS 832/13 cells.
We next confirmed the above data accrued through the use of
siRNA-ICMT by a pharmacological approach. In the following studies. we determined the effects of acetyl farnesyl cysteine (AFC), a selective inhibitor of ICMT,4,5 on glucose-induced
generation of reactive oxygen species and insulin secretion.
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Figure 7. ICMT inhibition does not affect cell viability. (A) INS 832/13 cells were mock transfected or transfected either with ICMT siRNA or scrambled
siRNA (100 nmol, 24h) or treated with AFC [(B) 100 µM, 1h]. Activated caspase 3 in the lysates was determined by western blot analysis using an
antiserum that identifies both the native procaspase and degradative product of caspase 3 using etoposide as a positive control as described under
Methods. A representative blot for [(A) n = 2 determinations] and for [(B) n = 3 determinations] is shown here. Actin was used as a loading control. (C)
INS 832/13 cells were mock transfected or transfected either with ICMT siRNA or scrambled siRNA (100 nmol, 24h). Cell viability in transfected cells
was determined by MTT reduction method as described above. Data are means ± SEM from two independent experiments yielding identical results
with n >12 in each group and expressed as percent change over control. * represents p< 0.05 compared with mock or scrambled siRNA transfected
cells. (D) INS 832/13 cells treated with AFC (100 µM, 1h) were incubated with MTT (5 mg/mL, 4h) as described in Materials and Methods. Cell viability
was determined by quantitating reduction of MTT by metabolically active cells at 570 nm. Data are means ± SEM from two independent experiments
yielding identical results with n >12 in each group and expressed as percent change over control. * represents p< 0.05 compared with control.

Data shown in Figure 6A indicated a modest, but significant
inhibition in basal level of reactive oxygen species in these cells
following exposure to AFC (Fig. 6; bar 1 vs. 2). However, increase
in the level of reactive oxygen species seen in the presence of stimulatory glucose was significantly inhibited by AFC (Fig. 6; bar 3
vs. 4). Furthermore, insulin secretion elicited by stimulatory
(Fig. 6B; bar 3 vs. 4), but not basal glucose (Fig. 6B; bar 1 vs. 2),
was markedly attenuated by AFC. In addition, in a manner akin
to siRNA-ICMT effects, we observed no significant effects of
AFC on KCl-induced insulin secretion (Fig. 6C). Together, our
above described findings confirm that glucose-, but not KClmediated effects on insulin secretion require activation of ICMT.
Furthermore, along these lines, we also noticed a significant
inhibition of glucose-induced activation of Rac1 by AFC under
the conditions it inhibited glucose-induced generation of reactive
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oxygen species (~41 ± 10% inhibition by AFC; mean ± SEM from
three pull down assays; p < 0.05 vs. diluent) and insulin secretion
(additional data not shown). Together, these data further confirm our siRNA-ICMT findings and support our hypothesis that
ICMT-mediated carboxymethylation of specific proteins (e.g.,
Rac1) plays a positive modulatory role in the cascade of events
leading to glucose-induced generation of reactive oxygen species
and insulin secretion in INS 832/13 cells.
Inhibition of ICMT does not affect cell viability. We next
investigated potential cytotoxic effects, if any, of ICMT knockdown (via siRNA-ICMT) or inhibition of ICMT activity
(by AFC) on INS 832/13 cells. We asked this question to be sure
that either inhibition in Rac1 activation, reactive oxygen species
generation or insulin secretion seen under these conditions are
not due to potential loss in cell viability or cell demise following
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Figure 8. Expression of ICMT in lysates of INS 832/13 cells
under the duress of gluco-, lipo-, glucolipotoxicity
and endoplasmic reticulum stress. INS 832/13 cells were
plated in six-well plates, grown to 70% confluence and
treated with low glucose (LG, 2.5 mM, 48 h), high glucose
(HG, 50 mM, 48 h), palmitic acid (PA, 300 μM; 48 h), HG
plus PA (48 h) and thapsigargin (TH, 0.5 μM, 9 h). ICMT
expression was determined by western blotting. A representative of two blots is shown here. Actin was used as a
loading control.

inhibition of ICMT expression and/or activity. We addressed this
by two independent experimental approaches. In the first, we
quantitated activation of caspase-3, a hallmark of cellular apoptosis, in both siRNA-ICMT transfected cells and AFC-treated cells.
In the second approach, we quantitated the metabolic viability of
siRNA-ICMT transfected or AFC-treated cells using the MTT
assay. Data shown in Figure 7A and B indicated no caspase 3
activation following siRNA-ICMT transfection or AFC treatment. However, a significant activation of caspase 3 was seen in
INS 832/13 cells treated with etoposide, which causes apoptosis
in cells via caspase 3 activation. Together, these data in Figure 7A
and B suggest no cell death in INS 832/13 cells following inhibition of expression and activity of ICMT. In addition, we observed
only a modest inhibition in cell viability as assessed by the MTT
in cells following ICMT knockdown via siRNA-ICMT (Fig. 7C)
or AFC treatment (Fig. 7D). Together, these findings suggest that
the observed inhibition of glucose-induced Rac1 activation, generation of reactive oxygen species and insulin secretion following
inactivation of ICMT are specific and do not involve cytotoxic
mechanisms.
Alterations in ICMT expression in in vitro models of gluco-,
lipo-, glucolipotoxicity and endoplasmic reticulum stress. A
growing body of evidence implicates that long-term exposure of
β-cells to saturated fatty acids (i.e., lipotoxicity), glucose (i.e., glucotoxicity) or both (i.e., glucolipotoxicity) leads to severe metabolic
dysfunction and eventual demise of the β-cell.19 Furthermore,
exposure of these cells to thapsigargin, leads to endoplasmic reticular stress via depletion of calcium pools culminating in cellular
dysfunction.20,21 Therefore, in the last series of these studies we
investigated potential alterations in the expression of ICMT in
INS 832/13 cells following exposure to palmitate, glucose or thapsigargin. Data shown in Figure 8 indicated a significant increase
in the expression of ICMT in cells exposed to gluco-, lipo- or glucolipotoxic conditions. However, no detectable changes were seen
in the expression of ICMT protein in thapsigargin-treated cells.

signaling cascade leading to glucose-induced ROS generation
and insulin secretion. We have presented supporting evidence via
two distinct approaches, namely siRNA-mediated knockdown or
selective pharmacological inhibition of ICMT, which mediates
the carboxymethylation of these signaling proteins.
At least two distinct carboxylmethyl transferases have been
identified in insulin secreting cells. The first one is involved in
methylating the carboxy terminal leucine (Leu-309) of the catalytic subunit of protein phosphatase 2A; such a signaling step has
been implicated in subunit interaction and catalytic activation of
the enzyme.22 The second enzyme, which is the focus of the current study, is the ICMT. In a previous study, Li and associates
characterized the ICMT in insulin-secreting cells and normal rat
islets.6 Such an activity was monitored by quantitating the degree
of methylation of AFC by the islet ICMT in the presence of [3H]
S-adenosylmethionine as the methyl donor. Subcellular fraction
assays revealed that this enzyme activity is enriched in the endoplasmic reticulum.6 Along these lines, using the pharmacological
approaches, we have demonstrated that glucose promotes the carboxymethylation of Cdc42, another small G-protein involved in
cytoskeletal remodeling and glucose-stimulated insulin secretion.4
It was also demonstrated that the Gγ-subunits also undergo carboxymethylation in a glucose-sensitive manner in clonal β-cells,
normal rat islets and human islets.5 Not much has been reported
since then with regard to potential functional consequences of carboxymethylation in islet function primarily due to lack of experimental tools (e.g., siRNA) to selectively deplete the expression of
ICMT in isolated β-cells. Indeed, data from the current investigation further reinforce our original hypothesis that in addition
to prenylation, carboxymethylation of specific G-proteins (e.g.,
Rac1) plays regulatory roles in physiological insulin secretion.
Such regulatory effects may, in part, be due to the ability of methylated Rac1 to increase the activation of Nox and associated generation of reactive oxygen species.
Data accrued in the current studies implicate carboxymethylation as one of the requisite signaling steps for glucose-induced
activation by Rac1 in a stimulated β-cell. Moreover, the carboxymethylation of Rac1 appears to be necessary for glucose-induced
Nox activation and generation of reactive oxygen species. In this
context, using reconstituted systems and the C-terminal Rac1 peptides, Kreck and coworkers have provided experimental support to
implicate participatory roles for Rac1 in cell-free activation and
assembly of NADPH-oxidase.23 Compatible with these findings
are our recent data to implicate inhibition of glucose- or mitochondrial-fuel-induced Nox activation and generation of reactive oxygen species in INS 832/13 cells and normal rat islets by inhibitors
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Discussion
Several earlier studies have implicated activation of small
G-proteins (e.g., Arf6, Cdc42 and Rac1) in physiological insulin
secretion. Such conclusions were drawn from studies involving
the use of Clostridial toxins, dominant negative mutants, siRNAs and inhibitors of post-translational modifications, including
prenylation, carboxymethylation and palmitoylation (reviewed in
ref. 2). To the best of our knowledge, the current study provides
the first evidence to implicate carboxymethylation of Rac1 in the
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of protein prenylation. These studies thus provided evidence for
requisite roles for prenylation in the functional regulation of Nox
in the islet β-cell.11 Data from the current investigation indicate
that in addition to prenylation, the carboxymethylation of specific G-proteins may be necessary for optimal regulation of Nox
by glucose. More importantly, our current findings also suggest
that carboxymethylation is necessary for glucose-induced activation of Rac1, since pretreatment of isolated β-cells with AFC
or selective depletion of ICMT by siRNA markedly attenuated
glucose-induced Rac1 activation. These findings are in agreement with recent findings of Cushman and Casey demonstrating inhibition of EGF-induced Rho A and Rac1 activation by
cysmethynil, a selective inhibitor of ICMT, in MDA-MD-231
cells.24 Together, based on the above discussion it is concluded
that both prenylation and carboxymethylation of Rac1 are necessary for glucose-induced Nox-mediated ROS generation and
insulin secretion. It is important to note that palmitoylation of
cysteine residues upstream to prenylated and carboxylmethylated
Rac1 may not be involved in this signaling cascade at least based
on recent studies from Roberts and associates who reported no
known consensus palmitoylation motifs for Rac1,25 although this
remains to verified experimentally in the islet β-cell.
Emerging evidence appears to implicate a significant contributory role for Nox in the generation of oxidative stress and the
onset of mitochondrial dysfunction in multiple cell types, including the islet β-cell. For example, it has been shown that chronic
exposure of isolated β-cells to high concentrations of saturated
fatty acids (e.g., palmitate; lipotoxicity), glucose (i.e., glucotoxicity) or both (i.e., glucolipotoxicity) or a mixture of cytokines
(e.g., IL-1β, TNFα and IFNγ) culminates in increased oxidative
stress, mitochondrial dysfunction and apoptosis in these cells.2628
Inhibition of protein prenylation of Rac1 by pharmacological approaches (e.g., GGTI-2147) or Rac1 activation by Tiam1,
a known guanine nucleotide exchange factor for Rac1 (using
NSC23766) markedly attenuated metabolic dysfunction of the
β-cell.27,28 Along these lines, data described herein suggest a significant increase in the expression of ICMT under glucolipotoxic
conditions. Whether such an increase in the expression translates
into increased ICMT activity remains to be verified. Nonetheless,
it may be likely that use of selective inhibitors of carboxymethylation might prove to be valuable in preventing oxidative stress
induced under the duress of glucolipotoxicity and/or cytokines.
These are being studied in our laboratory currently. Based on
the data accrued in the current studies we conclude that ICMT
regulates glucose-induced Rac1 activation, generation of reactive
oxygen species and insulin secretion in pancreatic β-cells.

Cytoskeleton (Cat # BK035). ICMT antiserum was from
Santa Cruz Biotechnology, Inc., (Cat # Sc-130150). DCHFDA
(Cat # 35845), thapsigargin (Cat # T9033) and etoposide
(Cat # E1383) were from Sigma Aldrich. Alexa-fluor 488 antirabbit secondary antibody (Cat # A11008) and Hoechst dye
(Cat# 3570) was from Invitrogen molecular probes. Cell proliferation kit (MTT, Cat # 11465007001) was purchased from
Roche diagnostics.
Insulin-secreting cells. INS 832/13 cells were provided by Dr.
Chris Newgard (Duke University Medical Center, Durham, NC)
and were cultured in RPMI 1640 medium containing 10% heatinactivated fetal bovine serum supplemented with 100 IU/ml
penicillin and 100 IU/ml streptomycin, 1 mM sodium pyruvate,
2-mercaptoethanol (50 μM) and 10 mM HEPES (pH 7.4). The
medium was changed twice weekly and cells were trypsinized
and subcloned weekly.
Isolation of total particulate and soluble fractions from INS
832/13 cells. INS 832/13 cells were homogenized in RIPA buffer
(50 mm Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mm NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM
Na3VO4, 1 mM NaF and protease inhibitor cocktail) and were
centrifuged at 105,000x g for 1 h to separate total particulate and
soluble fractions. Proteins from individual fraction were resolved
by SDS-PAGE and transferred to a nitrocellulose membrane.
The blots were then probed with antibody raised against ICMT
(1:500 dilution) and with rabbit secondary antibody conjugated
to horseradish peroxidase. Immune complexes were then detected
using the enhanced chemiluminescence kit.
Immunofluorescence studies. INS 832/13 cells were plated
onto coverslips and incubated with (2.5 or 20 mM) glucose for
45 min at 37°C followed by washing in PBS and fixed with 4%
paraformaldehyde solution for 15 min at room temperature.
They were then permeabilized with 0.2% Triton X-100 for
15 min at room temperature. After blocking with 1% BSA for
1 h, the cells were further incubated with primary antibody
ICMT (1:150) in 0.1% BSA solution for 1 h. After extensive
washes, the cells were further incubated with secondary antibody Alexa-fluor 488 anti-rabbit (1:1,000) in 0.1% BSA solution
for 1 hr at 37°C. Hoechst dye was used to stain for nuclei. The
coverslips were then mounted on glass slides containing mounting media (DAKO corporation; Carpinteria, CA) and visualized
under an Olympus IX71 inverted fluorescence microscope using
a x100 oil-immersion lens.17
siRNA-mediated knockdown of ICMT. Endogenous expression of ICMT was knocked down by transfecting INS 832/13
cells with ICMT-siRNA. In brief, INS 832/13 cells were plated
on 24-well plates and transfection with ICMT-siRNA was
performed at 50–60% confluence at a final concentration of
100 nM using HiPerFect transfection reagent. Further, to assess
specificity of siRNA, cells were transfected in parallel with nontargeting siRNA (scrambled siRNA; 100 nM). Transfected cells
were cultured in complete growth medium for 24 h and efficiency of ICMT knockdown was determined by western blot
analysis.
Caspase 3 activity. Activation of caspase-3 was assessed in
cells either transfected with ICMT siRNA or in cells treated
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Materials and Methods
Materials. siRNA-ICMT (Cat # 43907710) and scrambled
siRNA (negative control; Cat # 4390843) were from Ambion.
AFC was from Cayman Chemical (Cat # 63270). ECL reagent
was from GE Healthcare (Cat # RPN2132). HiPerFect transfection reagent was obtained from Qiagen (Cat # 301705). The
rat insulin ELISA kit was from American Laboratory Products
(Cat # 80-INSRTH-E01). Rac1 activation assay kit was from
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with AFC. Cells were harvested and homogenized in sample
buffer (0.5% Nonidet P-40, 20 mM HEPES, pH 7.4, 100 mM
NaCl and 20 mM DTT and PIC). And ~30 μg of proteins were
resolved by SDS-PAGE (12%) and immunoprobed for caspase-3.
Activation of caspase-3 is evidenced by the presence of a hydrolytic product (~17 kDa). Etoposide (60 μM, 6 h) was used as a
standard for apoptotic cell death.
Cell viability assay. INS 832/13 cells were either treated with
AFC (100 μM, 1 h) or transfected with ICMT-specific or scrambled siRNA as described above. Cell viability was determined by
incubating AFC treated or ICMT-siRNA transfected cells with
10 μL of stock MTT [4(5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide] for 4 h at 37°C. Following dissolution of
formazan crystals in solubilization solution, the absorbance was
measured at 570 nm using ELISA plate reader.
Insulin release studies. siRNA-ICMT or scrambled siRNA
ransfected cells or AFC-treated cells were cultured overnight in
low serum-low glucose-containing media. They were stimulated
further either with low or high glucose or potassium chloride
in Krebs-Ringer bicarbonate (KRB) buffer, pH 7.4 for periods
of time indicated in the text. In studies involving KCl-induced
insulin secretion, we noticed that INS 832/13 cells were not
responsive to 40 mM KCl in releasing insulin. However, higher
KCl concentrations [60 mM] were found to elicit robust insulin
release. Therefore, in KCl-stimulated insulin secretion studies,
cells were incubated with 60 mM KCl in an osmolarity balanced
KRB medium.17
Rac1 activation assay. The extent of Rac1 activation
(i.e., GTP-bound form) was determined using a commercially
available kit (Cytoskeleton, Denver, CO).16,27,28 ICMT-siRNA
transfected or AFC (100 μM) treated INS 832/13 cells were
incubated with low (2.5 mM) or high glucose (20 mM) for 30
min at 37°C. Cell lysates were clarified by centrifugation and
p21-activated kinase binding domain (PAK-PBD)-beads were
added to the supernatant and mixed gently at 4°C for 1 h. The
beads were then centrifuged at x4,000 g for 5 min, rinsed with
wash buffer (25 mM Tris, pH 7.5, 30 mM MgCl2, 40 mM NaCl
and 150 mM EDTA), and then reconstituted in Laemmli buffer.

Proteins were separated on 12% SDS-PAGE and immunoblotted
for activated Rac1.
NADPH oxidase activity assay. This was carried according
the method we described recently in reference 27 and 28. In brief,
INS 832/13 cells were plated in six-well plates, grown to subconfluence and then either transfected with ICMT-siRNA or treated
with AFC (100 μM; 1 h). The cells were washed with PBS and
further incubated with 2',7'-dichloro-dihydrofluorescein diacetate (DCHFDA, 10 μM) for 30 min at 37°C. Cells were then
harvested and centrifuged. The pellet was resuspended in PBS
and protein concentration was determined using Bradford’s assay.
Equal amount of proteins were taken and fluorescence was measured at excitation and emission wavelengths of 485 and 530 nm
respectively (using Perkin Elmer fluorimeter, Waltham, MA).
ICMT expression profile. INS 832/13 cells were plated
in six-well plates, grown to 70% confluence and treated with
low glucose (2.5 mM), high glucose (50 mM), palmitic acid
(300 μM), palmitic acid plus high glucose for 48 h or thapsigargin (0.5 μM) for 9 h. Cells were then harvested and centrifuged.
The pellet was resuspended in buffer solution (0.5% Nonidet
P-40, 20 mM HEPES, pH 7.4, 100 mM NaCl, 20 mM DTT
and protease inhibitor cocktail). Equal amount of proteins were
resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The blots were then probed with antibody raised against
ICMT (1:500 dilution) and with rabbit secondary antibody conjugated to horseradish peroxidase. Immune complexes were then
detected using the enhanced chemiluminescence kit.
Statistical analysis. Data are presented as mean ± SEM.
Statistical significance differences between values were evaluated
by Student’s t-test or ANOVA where appropriate. p < 0.05 was
considered to be statistically significant.
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Type 2 diabetes mellitus is marked by a substantial beta-cell failure which is
characterized by defective insulin secretion and resistance to insulin. Understanding the
molecular events leading to Glucose-stimulated insulin secretion [GSIS] might serve as
therapeutic potential towards diabetes. GSIS involves interplay between small Gproteins and their regulatory factors. Herein, I tested the hypothesis that Arf nucleotide
binding site opener [ARNO], a guanine nucleotide exchange factor [GEF] for the small
G-protein Arf6, mediates the activation of Arf6, and that ARNO/Arf6 signaling axis, in
turn, controls the activation of downstream effectors. Salient features of my study are: [i]
ARNO/Arf6 is expressed in clonal β-cells, rodent islets and human islets; [ii]
overexpression of inactive mutants of ARNO or Arf6 or siRNAs of Arf6 or ARNO
reduces both GSIS and membrane depolarization induced insulin release in clonal βcell line; [iii] secinH3, a selective inhibitor of ARNO/Arf6 signaling pathway, also inhibits
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GSIS in INS 832/13 cells and rodent islets; [iv] insulinotropic concentration of glucose
stimulates Arf6 activation; [v] glucose-induced Arf6 activation is inhibited by secinH3 or
siRNA-ARNO, suggesting a critical involvement of ARNO/Arf6 in insulin secretion; and
[vi] glucose promotes association between ARNO and Arf6 as evidenced by coimmunoprecipitation and confocal microscopic studies. These findings provide the first
evidence to implicate novel roles for ARNO/Arf6 in insulin secretion.
There are many factors that contribute to GSIS including various enzymes, small
G-proteins and actin remodelers. As a step towards elucidating the ARNO/Arf6
signaling cascade, I identified potential downstream effectors that were regulated by
ARNO/Arf6 upon glucose stimulation. I identified potential effectors using an ARNOselective inhibitor [e.g., secinH3] and determined regulatory roles for Arf6/ARNO in
promoting

phospholipase

D

[PLD],

extracellular-regulated

kinases

[ERK

1/2],

Rac1/Cdc42, NADPH oxidase [Nox], reactive oxygen species [ROS], dynamin-1 and
cofilin [actin-severing protein] signaling steps in isolated beta-cells.
Lastly, this work demonstrates dysfunction of Arf6 and Rac1 in beta-cells
exposed to glucotoxicity and their abnormal response to physiological concentrations of
glucose. This evidence indicates that defective insulin secretion seen in progressive
beta-cell failure even after normalization might be at the level of abnormal functioning of
small G-proteins. Together my data suggest Arf6/ARNO → PLD →Rac1 → Nox →
cofilin signaling cascade regulate the exo-endocytotic pathway leading to GSIS.
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